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Cardiovascular disease and inflammation 
 
In the last decade evidence is accumulating that inflammation plays a pivotal role in the 
development of atherosclerosis and subsequent cardiovascular disease (CVD). Some authors state 
that atherosclerosis should be seen as an inflammatory disease.[1-3] 
The significance of inflammation in the development of CVD is demonstrated by several studies 
showing associations between future cardiovascular events and previous elevated C-reactive 
protein levels.[4-6] 
Underlying pathophysiological pathways in the relationship between inflammation and 
atherosclerosis have not yet been completely elucidated. One prevailing hypothesis is that 
inflammation might cause deterioration of fatty streaks into (unstable) plaques and ultimately 
lead to plaque ruptures.[6] Furthermore, it might cause complement activation[7] or facilitate 
deterioration of the lipid profile.[8] 
 
 
Rheumatic diseases and cardiovascular disease 
 
Two of the most common inflammatory rheumatic diseases are rheumatoid arthritis (RA) and 
ankylosing spondylitis (AS). RA, a chronic inflammatory joint disease of unknown etiology, 
affects approximately one percent of the general population.[9,10] The standardised mortality 
ratio of RA is elevated and ranges from 1.3 to 3.0.[11,12] Several reports attribute the increased 
mortality to CVD and particularly to coronary atherosclerotic disease.[13,14]  
AS is also a chronic inflammatory rheumatic disease and affects predominantly males, starting in 
young adulthood and resulting in immobility of the spine and sacroiliac joints. The reported 
prevalence of AS varies from 0.2-0.9 percent in the general population. Although the number of 
studies investigating mortality in AS is limited, the majority of these studies suggests an 
increased total mortality compared to the general population.[15-18] Furthermore, the increased 
mortality appears to be predominantly caused by CVD with a doubled cardiovascular 
standardised mortality ratio.[19] 
A clear explanation for the increased cardiovascular risk in rheumatic diseases is lacking, 
although several causes have been postulated. Firstly, an increased prevalence of new or 
established cardiovascular risk factors, as hypertension, diabetes, dyslipidemia, higher body mass 
index, higher waist to hip-ratio or impaired physical fitness, might play a role. A second 
possibility is undertreatment of cardiovascular co-morbidity.[20,21] Thirdly, the rheumatic 
disease itself could be responsible for the excess in cardiovascular morbidity and mortality, either 
by a decreased functional capacity[22], or by the underlying inflammatory process. 
A complex element in the association between rheumatic diseases and cardiovascular risk is the 
use of antirheumatic drugs. Patients with persisting disease activity require treatment with 
disease-modifying antirheumatic drugs (DMARDs).[23] There are some studies indicating that 
DMARDs can alter cardiovascular risk either by influencing atherosclerotic processes directly by 
effects on the inflammatory process or indirectly by influencing cardiovascular risk 
factors.[24,25] However, reports on the relationship between DMARDs and CVD are 
contradictory and limited in number and content.[26,27] 
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Aims of this thesis 
 
1) To assess the risk for CVD in the chronic inflammatory disease RA. 
2) To study several risk factors for CVD in association with inflammation in RA and AS. 
3) To investigate the effect of anti-rheumatic treatment on the cardiovascular risk. 
4) To increase the awareness of the enhanced cardiovascular risk in RA and AS. 
 
 
Outline of this thesis 
 
In chapter 2 the question is addressed whether or not there is an enhanced risk for CVD in RA. 
In this chapter the cardiovascular risk in RA is compared to that of healthy individuals and to two 
groups with a well known increased cardiovascular risk, i.e. individuals with an impaired glucose 
metabolism and diabetes mellitus type 2 patients. 
A well established risk factor for CVD that could explain an increase in cardiovascular risk is 
dyslipidemia. In chapters 3 and 4 we investigated a possible effect of the most prominent 
characteristic of rheumatic diseases, i.e. inflammation, on the lipid profile. If inflammation 
deteriorates the lipid profile and makes it more atherogenic, the risk for CVD increases. 
It is known that inflammation starts many years before the clinical onset of RA. Whether or not 
inflammation already alters the lipid profile at this stage is investigated in the pre-clinical phase 
of RA. The results of this study are shown in chapter 5. 
Another traditional risk factor for CVD is hypothyroidism. Whether RA is associated with an 
elevated prevalence of thyroid disorders, especially hypothyroidism, and subsequently with an 
amplified cardiovascular risk is assessed in chapter 6. 
In chapter 7 the association between prevalent CVD and the formation of antibodies against 
human 60-kDa Heat-Shock Protein (HSP60) is discussed. HSP60 is an intracellular protein 
protecting endothelial cells, smooth muscle cells and macrophages against denaturation caused 
by harmful influences, as oxidising agents, dyslipidemia, hypertension and certain agents in 
cigarette smoke. Patients with rheumatic disorders are known to form more antibodies than 
healthy individuals, for example, against citrinullated peptides. Moreover, in the general the 
formation of antibodies against HSP60 is associated with a higher prevalence of CVD, 
population. The antibodies against HSP60 are thought to counteract or even be cytotoxic to 
HSP60, thereby jeopardizing the ability of HSP60 to protect the endothelial cells. 
Antirheumatic drug treatment might affect the cardiovascular risk by several pathways, for 
instance, biologic agents by influencing the inflammatory processes and non-steroidal anti-
inflammatory drugs by interacting with the cyclo-oxygenase metabolism. In chapter 8 an 
overview is shown of the cardiovascular risk profile of agents commonly administered in 
osteoarthritis and rheumatoid arthritis. Chapter 9 further elaborates on this topic and shows the 
influence of treatment with conventional DMARDs on the cardiovascular risk in RA-patients. 
In view of the increased cardiovascular risk in rheumatic diseases screening and possibly 
treatment seems the logical next step. Reducing the risk for CVD can, subsequently, be done by 
lipid lowering therapy, for example with statins. Moreover, it is increasingly acknowledged that 
statins are pleiotropic drugs and in addition to their lipid lowering properties have anti-
inflammatory effects. Hence, the use of statins in rheumatic diseases to decrease the 
cardiovascular risk could be 'a double edged sword', i.e. by lowering lipid levels as well as by 
through inflammation modulation (chapter 10). 
Chapter 1 
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ABSTRACT 
 
Objectives 
Patients with rheumatoid arthritis (RA) have an increased cardiovascular risk, but the magnitude 
of this risk is not precisely known. We therefore investigated the associations between RA and 
type 2 diabetes (DM2), a well-established cardiovascular risk factor, on the one hand and 
cardiovascular disease (CVD) on the other. 
Methods 
We determined the prevalences of CVD, (i.e. coronary, cerebral and peripheral arterial disease), 
in 343 randomly selected outpatients with RA (diagnosed between 1989 and 2001, aged between 
50 and 75 years; the CARRÉ study), and in participants of a population-based cohort study on 
diabetes and CVD (the Hoorn study). RA-patients with normal fasting glucose levels from the 
CARRÉ study (RA, n = 294) were compared to individuals from the Hoorn study with a normal 
glucose metabolism (non-diabetic, n = 258) and individuals with DM2 (DM2, n = 194). 
Results 
The prevalence of CVD was 5.0% (95%-CI: 2.3-7.7%) in non-diabetic, 12.4% (95%-CI: 7.5-
17.3%) in DM2, and 12.9% (95%-CI: 8.8-17.0%) in RA individuals. With non-diabetic 
individuals as reference category, the age- and gender-adjusted prevalence odds ratio (ORs) for 
CVD was 2.3 (95%-CI: 1.1-4.7) for individuals with DM2 and 3.1 (95%-CI: 1.6-6.1) for RA-
patients. There was an attenuation of the prevalences after adjustment for conventional 
cardiovascular risk factors (ORs: 2.0 (95%-CI: 0.9-4.5) and 2.7 (95%-CI: 1.2-5.9), respectively. 
Conclusions 
The prevalence of CVD in RA is increased to an extent that is at least comparable to that of 
DM2. This should have implications for primary cardiovascular prevention strategies in RA. 
 
 
 
 
 
INTRODUCTION 
 
Rheumatoid arthritis (RA) is a chronic inflammatory joint disease of unknown etiology affecting 
approximately one percent of the general population.[1] The standardized mortality ratios are 
markedly elevated in RA, which seems largely attributable to cardiovascular disease (CVD).[2] 
The increased cardiovascular risk in RA-patients could have several causes. First, the prevalence 
of cardiovascular risk factors, such as dyslipidemia, diabetes, hypertension, higher body mass 
index (BMI), higher waist to hip-ratio (WHR) or impaired physical fitness, may be increased.[3] 
Second, in chronic diseases as RA, unrelated conditions such as cardiovascular risk factors are 
frequently undertreated.[4] Third, the chronic inflammatory process in RA may increase CVD 
risk.[5] 
The purpose of this study is to more precisely determine the magnitude of cardiovascular risk 
associated with RA. Better knowledge of this risk is relevant for determining optimal primary 
cardiovascular prevention strategies. A relevant comparator to RA is type 2 diabetes (DM2), 
which by many is regarded as a CVD risk equivalent, implicating that preventive strategies in 
these patients should be equal to those with established CVD.[6] 
RA resembles DM2 as cardiovascular risk factor 
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METHODS 
 
The CARRÉ study 
'CARRÉ' is a Dutch acronym of CARdiovascular research and RhEumatoid arthritis. The 
CARRÉ study is a cohort study investigating CVD and its risk factors in RA-patients who will be 
followed prospectively for at least five years. For the present study the cross-sectional baseline 
data were used. In 2000, a random sample of RA-patients registered at the Jan van Breemen 
Institute in Amsterdam, the Netherlands, was drawn. Patients were eligible for participation if 
they fulfilled the 1987 American College of Rheumatology classification criteria, were diagnosed 
between 1989 and 2001, and were aged between 50 and 75 years.[7] Patients were enrolled 
between January 2001 and January 2002. A total of 353 RA-patients participated. For the present 
study we excluded patients with known type 1 diabetes (n = 6) or patients of whom fasting blood 
samples were missing (n = 4). 
 
The Hoorn study 
The Hoorn Study is a Dutch cohort study of glucose metabolism and other cardiovascular risk 
factors. In 1989, a random sample of all men and women aged 50 to 75 years was drawn from the 
municipal population registry office of Hoorn. A total of 2484 individuals participated giving a 
response rate of 71%. An extensive cardiovascular investigation was performed in an age-, 
gender-, and glucose tolerance-stratified random sub sample of 631 participants (response rate of 
89%).[8] 
The local ethics committees approved both study protocols and all participants gave their written 
informed consent for the studies. 
 
RA-related data in the CARRÉ study 
All RA-patients attended the outpatient clinic at the Jan van Breemen Institute, where they were 
seen by a research physician, and completed a questionnaire recording demographic data, 
medical and medication history. A physical examination was performed also including the 28 
joint disease activity index score (DAS-28).[9] Furthermore, fasting blood samples were taken to 
measure inflammatory parameters, i.e. erythrocyte sedimentation rate (ESR) and (CRP), 
serological markers, i.e. IgM-rheumatoid factor (IgM-RF) and anti-cyclic-citrullinated-peptides 
(anti-CCP) antibodies and (possible) cardiovascular risk factors such as lipid levels. IgM-RF and 
anti-CCP antibodies were measured using in-house enzyme-linked immunosorbent assays as 
described previously.[10] In addition, to assess the functional (disability) status the Health 
Assessment Questionnaire (HAQ) was used. The HAQ is a generic measure used in various 
chronic diseases, using a self-reported patient-oriented questionnaire.[11] 
 
Assessment of diabetes and cardiovascular disease in both study protocols 
The diagnosis of diabetes was assessed using the 1999 World Health Organisation criteria.[12] In 
the Hoorn study, the mean of two oral glucose tolerance tests (OGTT) and the mean of two 
fasting plasma glucose levels were used. Cohort participants with a mean fasting plasma glucose 
level < 6.1 mmol/l and a mean OGTT < 7.8 mmol/l were classified as normal glucose metabolism 
(controls, n = 258) and those with a fasting plasma glucose level ≥ 7.0 mmol/l, OGTT ≥ 11.1 
mmol/l, or already treated with glucose lowering agents were classified as type 2 diabetes (DM2, 
n = 194). In the CARRÉ study, fasting plasma glucose levels were used and those with glucose 
levels < 6.1 mmol/l and not treated with glucose lowering agents were classified as patients 
having normal fasting glucose (RA, n = 294).  
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Prevalences of subjects already using insulin, glucose-lowering agents, or a diet for diabetes 
(classified as ‘known diabetes’), and newly detected diabetes were 5.4 and 2.6% in the CARRÉ 
study, and 3.6 and 5.0% in the total Hoorn study, respectively.[13] 
CVD was defined as a history of coronary, cerebral or peripheral arterial disease verified by the 
research physician as described elsewhere.[14] In brief, coronary diseases were defined as having 
a history of myocardial infarction confirmed by a cardiologist or a percutaneous transluminal 
coronary angioplasty or surgery for ischemic heart disease. Cerebral arterial disease was defined 
as having a history of a stroke or a transient ischemic attack confirmed by a neurologist or a 
carotid endarterectomy. Peripheral arterial disease was defined as a peripheral arterial 
reconstructive surgery, limb amputation or an ankle brachial pressure index (ABPI) less than 
0.50. ABPI was obtained with the use of a handheld Doppler, measuring the maximum systolic 
pressure of either the dorsalis pedis artery or posterior tibial artery divided by the maximum 
systolic blood pressure in the brachial artery after a 5 minute resting period in a supine position in 
the CARRÉ study and by means of Doppler-assisted systolic blood pressure measurement taken 
form the brachial and the three crural arteries on both sides as previously described in the Hoorn 
study.[15] The lowest ABPI of either limb was used for statistical analyses. 
 
Cardiovascular risk factors in both study protocols 
Cardiovascular risk factors assessed during physical examination were blood pressure, BMI and 
WHR. Height and weight were measured barefoot wearing light clothes only. The BMI was 
calculated as the ratio of weight and squared height. Double readings of the systolic and diastolic 
blood pressure were obtained on the right arm with the subject in sitting position after a 5 minute 
rest. Hypertension was defined as a systolic blood pressure over 140 mmHg and/or a diastolic 
blood pressure over 90 mmHg and/or the current use of antihypertensive medication. The waist 
circumference and hip circumference were measured at the level midway between the lowest rib 
margin and the iliac crest and at the widest level over the greater trochanters, respectively. The 
mean value of 2 measurements was used. Measurements in both study protocols were performed 
by different physicians.  
For each patient fasting blood samples were collected for assessment of glucose, CRP, creatinine 
and lipid levels. Renal function was assessed by using the Cockcroft-Gault formula in ml/min: 
[(140-age)*body weight / creatinine *71) * 0.85 if female]. The formula is given in traditional 
units and to convert it to International System units in mg/dl, creatinine is multiplied by 88.4. 
Serum total cholesterol (TC) and triglyceride levels were analysed by enzymatic techniques. LDL 
cholesterol levels were calculated by means of the Friedewald formula (except when triglycerides 
were > 8.0 mmol/l) and the TC/HDLc ratio was calculated dividing total cholesterol levels by 
HDL cholesterol levels. Finally, patients were classified as never, former or current smoker. 
 
Statistical analyses 
Characteristics of both study populations, i.e. CARRÉ study and Hoorn Study, with a normal 
distribution were presented as means with standard deviations or as absolute numbers with 
percentages of the total. Non-normally distributed variables were presented as medians with 
interquartile ranges. Baseline characteristics of the control group were compared to DM2 and 
RA-patients, using Students’ T-tests, Mann-Whitney’s U-tests and Pearson’s Chi Square tests, 
when appropriate.  
Prevalence odds ratios (ORs) for CVD were calculated for DM2 and RA-patients relative to the 
control group. Logistic regression analysis was done with three separate models: a) univariate 
RA resembles DM2 as cardiovascular risk factor 
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analyses, (Model I), b) age- and gender-adjusted analyses (Model II) and c) analyses adjusting for 
cardiovascular risk factors: systolic blood pressure, antihypertensive agents, TC/HDL ratio, lipid-
lowering drugs, waist circumference, creatinine and smoking (Model III). In order to investigate 
the influence of inflammation on CVD risk, CRP was separately introduced as an independent 
variable. Analyses were carried out using SPSS 14.0 software and p-values less than 0.05 were 
considered statistically significant. 
 
 
 
RESULTS 
 
Characteristics of the RA-patients 
A total of 343 RA-patients were included in this study, 49 had either known diabetes or fasting 
plasma glucose levels above 6.1 mmol/l, and were thus excluded, leaving 294 RA-patients with 
normal fasting glucose levels in the study (Table 1). The vast majority of the participants were 
IgM-rheumatoid factor positive and had erosions on radiographs. The average disease duration 
was more than seven years and disease activity was moderate with a mean DAS-28 of almost 4. 
 
Cardiovascular diseases 
The prevalence of CVD based on a history of at least one confirmed cardiovascular event was 
5.0% (95%-CI: 2.3-7.7%) in controls, 12.4% (95%-CI: 7.5-17.3%) in DM2, and 12.9% (95%-CI: 
8.8-17.0%) in RA patients (Table 1). Compared to the control group, cerebral and peripheral 
arterial disease were more frequently observed in DM2, and coronary and cerebral arterial 
disease more often in RA-patients. 
 
Cardiovascular risk factors 
Table 1 summarizes cardiovascular risk factors of participants from the Hoorn study and of 
patients from the CARRÉ study. Compared to controls, RA-patients were more often female, had 
a lower mean WHR and lower total, and LDL cholesterol, and higher HDL cholesterol levels. 
RA-patients also had higher rates of smoking, hypertension, and use of lipid-lowering drugs. No 
significant differences were observed for serum creatinine levels, renal function, waist 
circumference, weight, and BMI. CRP levels were higher in RA-patients. 
 
Prevalence of cardiovascular disease in controls, DM2 and RA 
Compared to healthy controls, the OR for CVD in RA was 3 times higher, and in DM2 
approximately 2.5 times higher (Model I and Model II, Table 2). Similar to diabetes, adjustment 
for cardiovascular risk factors (systolic blood pressure, antihypertensive agents, TC/HDL 
cholesterol, lipid-lowering drugs, waist circumference, creatinine, and smoking) moderately 
attenuated the OR in RA, but RA remained independently associated with CVD (Model III, Table 
2). Adding CRP to model II resulted in a slightly decreased RA versus controls ratio for CVD. 
For example, introduction of CRP into model II reduced the OR by approximately 5%. As in 
some studies an ABPI-cut-off value of 0.9 is used to define PAD, regression analyses were also 
done with this latter cut-off value. Then, in comparison with control individuals, the age- and 
gender-adjusted OR for CVD in DM2 was almost 2.5 times higher and in RA 2 times higher.
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Table 1   Comparison of RA patients with normal fasting glucose (from the CARRÉ study) and 
non-RA patients with normal glucose metabolism or type 2 diabetes (from the Hoorn Study) 
 
  Hoorn study CARRÉ study 
Groups NDC DM2 RA-NFG 
   Number 258 194 294 
Demographic variables    
   Age, years  63 (7) 66 (7)* 63 (7) 
   Female, % 49 45 65* 
Cardiovascular disease, N (%) 13 (5.0%) 24 (12.4%)* 38 (12.9%)* 
   Coronary artery disease, n 10 (3.9%) 11 (5.7%) 23 (7.8%)* 
   Cerebral arterial disease, n 2 (0.8%) 7 (3.6%)* 13 (4.4%)* 
   Peripheral arterial disease, n 2 (0.8%) 10 (5.2%)* 4 (1.4%) 
Cardiovascular risk factors    
   Systolic blood pressure (mmHg) 133 (18) 144 (19)* 141 (20)* 
   Diastolic blood pressure (mmHg) 81 (10) 83 (10)* 81 (9) 
   Anti-hypertensive drugs, % 17 41* 24 
   Hypertension, % 38 76* 57* 
   Creatinine, (micromol/ml) 92 (15) 92 (26) 88 (16)* 
   Cockcroft-Gault (mg/dl) 71 (16) 76 (18)* 74 (19) 
   Waist circumference (cm) 90 (10) 99 (11)* 92 (13) 
   Hip circumference (cm) 101 (7) 104 (8)* 104 (10)* 
   Waist hip ratio  0.89 (0.08) 0.95 (0.08)* 0.88 (0.08) 
   Weight (kg) 74 (11) 80 (12)* 75 (14) 
   Height (cm) 169 (9) 167 (9) 168 (9) 
   Body mass index  26 (3) 29 (4)* 26 (5) 
   Total cholesterol (mmol/l) 6.6 (1.2) 6.5 (1.3) 5.8 (1.1)* 
   HDL cholesterol (mmol/l) 1.4 (0.4) 1.1 (0.3)* 1.5 (0.5)* 
   LDL cholesterol (mmol/l) 4.6 (1.0) 4.3 (1.1)* 3.7 (1.0)* 
   Triglycerides (mmol/l) 1.5 (1.0-1.8) 2.0 (1.4-2.8)* 1.3 (1.0-1.8) 
   Lipid lowering drugs users, % 1 2 11* 
   Smoking    
      Never, % 35 39 21* 
      Former smoker, % 35 36 47* 
      Current smoker, % 30 25 32* 
   CRP (mg/L)   1 (1-3) 2 (1-4)* 6 (3-18)* 
RA variables    
   Age at onset RA, years   55 (8) 
   RA-duration, years   7 (4-10) 
   IgM-RF > 30 IU/m, %  70 
   Anti-CCP > 50 AU/ml, %  54 
   Erosions on radiographs, %  83 
   DAS-28   3.8 (1.4) 
   HAQ   0.8 (0-3) 
   Current methotrexate-users, %  60 
   Current sulfasalazine-users, %  15 
   Current hydroxychloroquine-users, %  7 
   Current prednison-users, %  15 
   Current biological-users, %   10 
Variables significantly different from the NDC-group are marked with an asterisk. NDC = non-
diabetic controls; DM2 = diabetes mellitus type 2; RA-NFG = rheumatoid arthritis and normal fasting 
glucose; CRP = C-reactive protein; RF = rheumatoid factor, CCP = cyclic citrinulated peptide; DAS-
28 = 28 joint disease activity index score, HAQ = health assessment questionnaire 
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Table 2   Prevalence Odds Ratios for cardiovascular disease using individuals without 
rheumatoid arthritis and with normal glucose metabolism as a reference 
 
 OR 95% CI p-value 
Model I    
   Non-diabetic controls 1.00 Reference  
   DM2 2.62 1.29-5.32 0.008 
   RA 2.81 1.46-5.42 0.002 
Model II    
   Non-diabetic controls 1.00 Reference  
   DM2 2.31 1.13-4.72 0.022 
   RA 3.11 1.59-6.08 0.001 
Model III    
   Non-diabetic controls 1.00 Reference  
   DM2 2.01 0.90-4.51 0.090 
   RA 2.70 1.24-5.86 0.012 
OR = odds ratio; CI = confidence interval;  
DM2 = diabetes mellitus type 2; RA = rheumatoid arthritis 
Model I: crude associations;  
Model II: corrected for age and gender; 
Model III corrected for cardiovascular risk factors (= age and gender, systolic blood pressure, 
antihypertensive agents, TC/HDL ratio, lipid lowering drugs, creatinine, waist circumference, 
and smoking) 
 
 
 
 
DISCUSSION 
 
The CVD risk associated with RA equals that of DM2. This excess cardiovascular risk in 
comparison to the general population is explained only partly by conventional cardiovascular risk 
factors. Hence RA itself should be regarded as a strong, independent cardiovascular risk factor, 
for which cardiovascular risk management, as in DM2, should be considered.  
In the present study we observed a prevalence of CVD of 12.9% in RA-patients (without 
diabetes) resulting in a 2 to 3-fold higher risk of prevalent CVD than in healthy controls, which is 
similar as in DM2. The pattern of CVD manifestations was different, however, with a 
predominance of coronary artery disease in RA, as opposed to peripheral arterial disease in DM2. 
The increased CVD risk in RA could be entirely due to traditional cardiovascular risk factors, but 
this is unlikely.[16] In our RA-patients some traditional risk factors were increased, some 
decreased, and many were similar to controls, and these findings correspond with other 
studies.[17] Moreover, the chance of having CVD was attenuated, but still significantly increased 
after adjustment for traditional cardiovascular risk factors. Undertreatment of cardiovascular co-
morbidity might be another reason why RA-patients have elevated CVD risk.[18] This is also 
unlikely as, for instance, the ratio of subjects receiving antihypertensive agents and those who 
qualified for antihypertensive treatment according to national guidelines was comparable in RA-
patients and controls (data not shown). 
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Epidemiologic, clinical and laboratory investigations have shown that the immune system and 
inflammation play a major role in all stages of atherosclerosis and contribute considerably to the 
increased cardiovascular risk.[19] Inflammation is known to cause deterioration of fatty streaks 
into (unstable) plaques, plaque ruptures, and complement activation.[20,21] Inflammation may 
also act synergistically with conventional cardiovascular risk factors in the pathogenesis of 
atherosclerosis. For example, inflammation is associated with a higher systolic blood pressure and 
an adverse lipid profile.[22,23] Hence, it can be expected that CVD occurs more frequently in 
diseases with a high inflammatory burden such as RA. This is supported by observations that 
disease severity is associated with an increased mortality ratio, and that powerful anti-
inflammatory treatment, e.g. tumour necrosis factor α blocking agents, reduces the cardiovascular 
risk in RA.[24,25] However, within the RA-group as well as in the glucose-stratified participants 
of the Hoorn study, we were unable to demonstrate a significant relation between inflammatory 
markers and CVD. This might be due to a type II error, as the study was not designed to study 
CVD risk at different levels of inflammation. Also, it may well be that the cumulative 
inflammatory burden (e.g. areas under the curve for CRP) over the last years would need to be 
assessed in order to show an association between disease activity and CVD risk in RA-patients.  
Non-steroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 (COX-2) inhibitors and 
disease modifying anti-rheumatic drugs (DMARDs) are other drugs that influence the 
cardiovascular risk in RA-patients. Indeed it was demonstrated that the use of DMARDs was 
associated with a lower cardiovascular risk mediated by inflammation suppression.[26] The net 
effects of NSAIDs and COXIBs on cardiovascular risk are more difficult to ascertain, as on one 
hand most of them, but not all, have prothrombotic effects, and on the other hand these agents 
improve inflammation and mobility of RA-patients, which might counterbalance the 
prothrombotic effects.[27] 
Our findings have important clinical implications. DM2 is regarded as a cardiovascular disease 
risk equivalent [28], which implicates that preventive strategies should be equal to patients with 
established CVD. Our findings reveal that RA resembles DM2 as a cardiovascular risk factor, 
implicating that preventive strategies are equally warranted for RA. 
Our study has several limitations. First, causality can only be investigated to a limited extent in 
cross-sectional epidemiological studies. Second, there may be differences between the Hoorn 
study and the CARRÉ study as cardiovascular risk measurements were done by different 
physicians and some by different techniques. In particular, the different definition of diabetes in 
both studies is important. In the Hoorn study, controls and DM2 were classified according to the 
mean of two fasting plasma glucose levels and the mean of two OGTTs, whereas one single 
fasting plasma glucose level was used in the CARRÉ study. Hence, the number of true non-
diabetic patients in the RA-group might actually be lower. Such non-exclusion of diabetic 
patients would inflate the OR for RA. When, however, participants of the Hoorn study were 
stratified according to fasting plasma glucose levels alone, the age- and gender-matched ORs for 
RA slightly decreased but remained more than twofold increased compared to controls of the 
Hoorn study (data not shown). Hence, a significant underestimation of diabetes in RA is not 
likely. Finally, the Hoorn study was conducted about a decade earlier than the CARRE study. 
Hospital admission rates for CVD showed a marked decline during the second half of the 1990s 
in the Netherlands, which indicates that the CVD prevalence in the CARRÉ study, relative to the 
CVD prevalence of the controls assessed one decade before, are more probably more under- than 
overestimated.[29] 
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In conclusion, the prevalence of CVD in RA is greatly elevated compared to healthy individuals 
and is comparable to that in DM2. A higher prevalence of traditional CV risk factors only partly 
explains this increased risk of having CVD in RA. Hence, RA should be considered as high CVD 
risk condition, equivalent to that in DM2 emphasizing the need for preventive cardiovascular 
strategies in RA.  
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ABSTRACT 
 
Objectives 
Cardiovascular mortality is increased in patients with ankylosing spondylitis (AS). A possible 
explanation might be a more prevalent atherogenic lipid profile in AS compared to the general 
population. It has been postulated that inflammation deteriorates the lipid profile, thereby 
increasing cardiovascular risk. The present study explores the association between disease 
activity and the lipid profile in patients with AS. 
Methods 
AS disease activity parameters and lipid levels (total cholesterol (TC), HDL-cholesterol (HDLc) 
and triglycerides) were measured in 45 AS patients during 6 months after starting leflunomide or 
placebo treatment. Findings in this treatment group were compared to 10 AS patients treated with 
etanercept. A specialised regression model, adjusting for repeated measurements, age and gender 
was used to assess the influence of the disease activity variables on the lipid levels. 
Results 
Multilevel regression analyses revealed significant associations between disease activity 
parameters and lipid levels, for instance an increase of 30 mm/hr in erythrocyte sedimentation 
rate was associated with decrease of approximately 6% in TC level and a decrease in HDLc 
levels of approximately 11%. Similar significant associations were found between other disease 
activity parameters and lipid levels. 
Conclusion 
Increases in disease activity were associated with decreases in lipid levels. The decrease in HDLc 
levels tended to be almost twice as large as the decrease in TC levels, resulting in a more 
atherogenic lipid profile. Hence, effective treatment of disease activity in AS might lower the 
cardiovascular risk by improving the lipid profile. 
 
 
 
INTRODUCTION 
 
Ankylosing spondylitis (AS) is a chronic inflammatory disease which affects predominantly 
males, starts in young adulthood and results in immobility of the spine and sacroiliac joints. 
Although the number of studies investigating mortality in AS is limited, the majority of these 
studies show an increased total mortality compared to the general population.[1-4] Furthermore, 
this increased mortality appears to be predominantly caused by cardiovascular disease (CVD) 
with a twofold enhanced cardiovascular standard mortality ratio.[5] 
A possible explanation for this increased cardiovascular risk is a higher prevalence of 
conventional cardiovascular risk factors, such as a more atherogenic lipid profile.[6] An 
atherogenic lipid profile is characterised by a reduced high density lipoprotein cholesterol 
(HDLc) level and an increased levels of total cholesterol (TC), low density lipoprotein 
cholesterol (LDLc) and triglycerides. An important prognostic indicator for (future) CVD is the 
atherogenic index which is the TC/HDLc ratio.[7-10] 
Whether or not an atherogenic lipid profile is present in AS is presently unclear.[11-13] 
Moreover, there is growing evidence that inflammation is associated with deterioration of the 
lipid profile,[14,15] but so far data for AS patients are lacking. Hence, we hypothesise that 
disease activity in inflammatory diseases, such as AS, worsens the lipid profile, thereby 
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increasing the risk for (future) cardiovascular disease. As a consequence, lowering the disease 
activity in AS patients could have a beneficial effect on the lipid profile.  
Two recent studies, investigating the safety and efficacy of leflunomide and etanercept treatment 
in patients with AS, gave us the opportunity to asses the relationship between disease activity and 
the lipid profile in a total of 55 AS patients, treated with either leflunomide, etanercept or 
placebo. 
 
 
 
METHODS 
 
Patients 
All studied patients, aged 18 to 70 years, fulfilled the 1984 modified New-York criteria for 
AS.[16] The first population consisted of forty-five consecutive AS patients participating in a 
monocentre, randomised, double blind, placebo-controlled, phase II trial in which the safety and 
efficacy of leflunomide was assessed.[17] Thirty patients were treated with the active compound 
in a dose of 20 mg daily and fifteen patients received placebo, for duration of 24 weeks. During 
this period other pharmacological treatments had to remain stable. 
The findings of the above-mentioned AS patients were compared to a second population, 
consisting of 10 consecutive AS patients who were treated for six months with etanercept (25 mg 
twice weekly).[18] 
 
Disease activity parameters 
The Bath Ankylosing Spondylitis Global score (BASG)[19], the Bath Ankylosing Spondylitis 
Functional Index (BASFI)[20] and Bath Ankylosing Spondylitis Disease Activity Index 
(BASDAI)[21], all with a scale from 0 to 10, were determined by an experienced rheumatologist 
at baseline, week 4, 12 and 24. Furthermore, the erythrocyte sedimentation rate (ESR) and C-
reactive protein (CRP) level were measured at baseline and weeks 2, 4, 6, 9, 12, 16, 20 and 24. 
ESR was determined with local measurement techniques and expressed in millimetres per hour 
(N men < 20 mm/hr, women < 30 mm/hr). CRP was measured using a turbidimetric assay 
supplied by Biomedical Diagnostics (N < 10 mg/L). 
 
Lipids 
Blood samples for lipid measurements were taken after an overnight fast at baseline, week 2, 4, 6, 
9, 12, 16, 20 and 24. Serum TC (N < 5.0 mmol/L) and triglycerides (N < 2.2 mmol/L) were 
analysed by an enzymatic method using the appropriate assays supplied by Roche Diagnostics, 
The Netherlands, on a Hitachi 911 analyser (Roche) according to the instructions of the 
manufacturer. PEG-modified enzymes were used for assessing the HDLc levels (N men > 0.9 
mmol/L, women > 1.1 mmol/L). The atherogenic index was calculated as the TC level divided by 
the HDLc level. 
 
Statistics 
Measuring lipid levels and disease activity parameters in a particular population at several time 
points, with variable time intervals, causes an important statistical problem, i.e. ‘repeated 
measurements within subjects’. To adjust for ‘repeated measurements within subjects’ a 
multilevel linear regression analysis was used. This regression technique allows for both starting 
levels and progression over time to differ between patients. It calculates the regression coefficient 
Chapter 3 
 28 
over time for various variables and it looks for associations between two of these variables, and 
tests it for statistical significance. Furthermore, the found associations between two variables, in 
our case lipid levels and disease activity parameters, was also corrected for age and gender. 
One advantage of combining the cross-sectional data of the various time points into one 
association is that this increases the statistical power. Another important advantage of this 
method is that it holds into account and corrects for the possibility that one or a few subjects with 
aberrant values distort the association between lipid levels and disease activity, i.e. the above 
mentioned 'repeated measurements within subjects'. If one or a few patients have for example an 
abnormally high level of a certain lipid this will not distort the relationship this lipid has with 
disease activity because the multilevel regression analysis will only look at this relationship and 
corrects for the aberrant starting points. 
As the primary goal of this investigation was to study the relationship between disease activity 
and lipid levels it was of no importance whether or not the anti-rheumatic treatment alters disease 
activity, so the data of placebo- and leflunomide-treated patients were lumped together. The 
findings were compared to a group of 10 AS patients, treated with etanercept, for whom similar 
analyses were conducted. 
As the HDLc levels, the atherogenic index and triglyceride levels were not normally distributed, 
the analyses were done with the natural logarithms of these values. For reasons of clarity, the 
regression coefficients for these lipids were retransformed to geometric means. The multilevel 
analyses were performed with the statistical program MLwiN.[22,23] A p-value of ≤ 0.05 was 
considered statistically significant. 
 
 
 
RESULTS 
 
Patients 
The first group consisted of 45 AS patients (13 women, 32 men), with a mean age of 42 years 
(SD: 11) ranging from 21 to 66 years, were followed for 24 weeks. Nine patients suffered from 
hypertension, eight of them used antihypertensive agents. Two patients were treated for 
hypercholesterolemia. Non steroidal anti-inflammatory drugs (NSAIDs) were used by 39 patients 
and prednisone was given to one. 
Ten AS patients (1 woman, 9 men), with a mean age of 41 years (SD: 10) ranging from 28 to 60 
years, starting etanercept-treatment were used to compare the findings with the first population. 
One patient was treated for type II diabetes mellitus, one for hypertension and one patient 
received treatment for hypercholesterolemia. Nine patients used NSAIDs.  
All pharmacological treatments remained unchanged during the entire observation period. The 
baseline characteristics, including demographic and clinical data, are shown in table 1. 
 
Lipid levels and disease activity parameters 
The lipid levels and the disease activity parameters in the AS patients treated with placebo or 
leflunomide (N=45) are shown in figure 1. No significant changes of these variables during the 
24-weeks observation period were seen. The multilevel regression analyses yielded several 
significant associations between lipid level progression over time and disease activity parameters, 
the height of the disease activity had a statistical significant influence on the height of the lipid 
levels. Higher ESR and CRP levels were significantly (p<0.001) associated with lower TC levels, 
with regression coefficients of –0.01 and –0.01, respectively. The ln-triglyceride levels also had 
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an inverse relationship with ESR and CRP, with regression coefficients of -0.005 and –0.004, 
respectively. A similar relationship was observed for ln-HDLc with ESR and CRP levels 
(regression coefficients of –0.004 and –0.002, respectively). Moreover, the disease activity 
parameters tended to have a linear relationship with the atherogenic index (p=0.09).  
The relationship between disease activity parameters and lipid levels, with other words the 
influence of disease activity on the lipid levels, is shown in Table 2 as absolute values and 
percentages. The influence of ESR and CRP on TC levels was almost twice as large as the effect 
on HDLc levels, resulting in a higher atherogenic index (p< 0.001). 
The multilevel analyses of etanercept-treated patients showed that an increased ESR, CRP, 
BASG, BASFI or BASDAI was significantly (p<0.02) decreased TC levels ( regression 
coefficients of –0.01, -0.02, -0.07, -0.12 and –0.13, respectively). Higher ESR and CRP levels 
were associated with lower HDLc levels and TC levels, albeit that the decrease of HDLc was 
(again) twice as large as the decrease of TC levels, resulting in a higher atherogenic index. 
Moreover, increase in other disease activity parameters was also associated with an increase of 
the atherogenic index, this association did not reach statistical significance (p>0.08).  
 
Table 1   Baseline characteristics 
 
 Leflunomide or Placebo (n=45) 
Etanercept 
(n=10) 
Demographic features  
Age, years  42 (± 11) 41 (± 10) 
Gender, male / female 32 / 13 9 / 1 
Disease activity parameters  
BASG 6.4 (± 1.8) 6.7 (± 1.6) 
BASFI 5.3 (± 1.8) 4.4 (± 1.9) 
BASDAI 5.5 (± 1.4) 4.9 (± 1.2) 
ESR, mm/hr 15 (10 - 31)* 37 (13 - 49)* 
CRP, mg/l 13 (4 - 40)* 11 (4.4 - 29.4)* 
Lipids  
TC, mmol/l 4.9 (± 1.2) 4.4 (± 0.8) 
HDLc, mmol/l  1.1 (0.9 - 1.4)* 1.3 (± 0.3) 
Atherogenic index 4.3 (3.1 - 5.5)* 3.7 (± 1.1) 
Triglycerides, mmol/l 1.2 (0.8 - 1.8)* 1.1 (0.7 - 1.6)* 
 
Values are means with standard deviation or median with interquartile range (indicated by 
asterisk), where applicable. 
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Figure 1   Mean lipid levels and disease activity during the 24 weeks of treatment. 
 
TC = total cholesterol, atherogenic index = TC / HDLc, HDLc = high density lipoprotein 
cholesterol, BASG = Bath Ankylosing Spondylitis Global score, BASFI = Bath 
Ankylosing Spondylitis Functional Index, BASDAI = Bath Ankylosing Spondylitis 
Disease Activity Index, CRP = C-reactive protein, ESR = erythrocyte sedimentation rate. 
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Table 2   Influence of disease activity on the lipid levels 
 
increase of 
disease activity 
parameter 
lipids 
 
absolute 
change 
(mmol/L) 
relative 
decrease 
(%) 
p-value 
     
TC -0.29 -6.0 0.001* 
HDLc -0.13 -11.4 0.01* 
Atherogenic index 0.29 6.8 0.09 30 mm/hr ESR 
Triglycerides -0.15 -12.6 0.04* 
     
TC -0.18 -3.8 0.001* 
HDLc -0.06 -5.7 0.001* 
Atherogenic index 0.10 2.4 0.16 30 mg/L CRP 
Triglycerides -0.13 -10.9 0.001* 
     
TC 0.01 0.1 0.79 
HDLc -0.01 -0.7 0.44 
Atherogenic index 0.03 0.6 0.47 1 point BASG 
Triglycerides -0.05 -4.4 0.01* 
     
TC 0.02 0.4 0.62 
HDLc -0.02 -1.7 0.25 
Atherogenic index 0.08 2.0 0.19 1 point BASFI 
Triglycerides -0.06 -4.5 0.01* 
     
TC -0.01 -0.3 0.66 
HDLc -0.00 -0.4 0.71 
Atherogenic index 0.01 0.2 0.87 1 point BASDAI 
Triglycerides -0.07 -5.8 0.01* 
     
 
Influence of disease activity parameters on lipids levels, calculated using multilevel 
regression analyses correcting for age, gender and repeated measurements within 
subjects. Significant associations are indicated with an asterisk. 
ESR = erythrocyte sedimentation rate, CRP = C-reactive protein, BASG = Bath 
Ankylosing Spondylitis Global score, BASFI = Bath Ankylosing Spondylitis Functional 
Index, BASDAI = Bath Ankylosing Spondylitis Disease Activity Index,  
TC = total cholesterol, HDLc = high density lipoprotein cholesterol, Atherogenic index 
= TC / HDLc. 
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DISCUSSION 
 
Our investigations in AS patients demonstrate that higher disease activity (parameters) are 
associated with lower lipid levels, and vice versa. This was observed for TC, HDLc and 
triglyceride levels, which were significantly associated with disease activity parameters as the 
ESR, CRP and BASDAI. Moreover, an increase disease activity was associated with a decrease 
of TC levels and a more pronounced decrease in HDLc levels, subsequently resulting in a more 
atherogenic lipid profile. 
The magnitude in which disease activity influences the lipid levels was limited, which raises the 
question of its clinical relevance. Even though the found influence is small one has to keep in 
mind that AS is a chronic inflammatory disease what means that this small influence is there for 
years and years. One can imagine that the total load of inflammatory burden on the AS-patients 
of even a small worsening in lipid levels caused by disease activity could have a major impact on 
the total cardiovascular risk. The importance of small differences in lipid levels over a long 
period of time is best illustrated by a couple of studies in which cardiovascular risk reduction was 
found by lowering lipid levels slightly but over a long period of time. First, the follow up of the 
Framingham cohort demonstrated that a lower HDLc level of just one quarter of a millimolar was 
associated with a 50 % higher risk for future vascular events.[24] Second, a landmark study on 
fibrates showed a 22 % reduction of the risk for CVD in the group receiving the active compound 
versus placebo. The group receiving the active compound showed only small changes in lipid 
levels, i.e. 4 % decrease in TC, 6 % increase in HDLc and 31 % decrease in triglyceride 
levels.[25] Although these figures can not be directly extrapolated to the present study, it does 
indicate the clinical significance small alterations in lipid levels. 
There is growing evidence that inflammation plays an important role in the pathogenesis of 
cardiovascular disease particularly in atherosclerosis.[26] In addition to a postulated direct effect 
of inflammation on endothelial cells, there is mounting evidence that inflammation can also 
increase the cardiovascular risk by deterioration of the lipid profile. The latter is supported by the 
findings of one study demonstrating a decrease in HDLc and apo A-1 levels and an increase in 
triglycerides and apo B levels during an acute phase response.[27] Other investigators found an 
association between elevation of lipids as oxidised LDLc and proinflammatory cytokines as CRP, 
interleukin-6 and tumour necrosis factor-α.[28] The findings of the present study confirm these 
effects of inflammation on the various lipid concentrations. 
High disease activity is characterised by elevated cytokine expression and this could directly lead 
to altered lipid levels through effects on the liver or adipose tissue. Moreover, there might also be 
an indirect way through various intermediate factors, for example metabolic or dietary factors. 
AS patients with high disease activity might be in a metabolic state comparable to rheumatoid 
cachexia.[29] Decreasing disease activity would improve their general well being and physical 
function with subsequent changes in lipid levels. The results of the present study support this 
hypothesis, as lower disease activity (parameters) were associated with a more favourable lipid 
profile. 
The present investigation is in line with the accumulating evidence of the intriguing interactions 
between dyslipidemia, atherosclerosis and inflammation, showing a worsening of the lipid profile 
during increased disease activity. Obviously, more prospective investigations with cardiovascular 
endpoints are needed to further unravel these relationships. 
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ABSTRACT 
 
Objective 
Rheumatoid arthritis (RA) is characterized by inflammation and an increased cardiovascular risk. 
It was recently shown that active early RA is associated with dyslipidemia which could be a 
partial explanation for the enhanced cardiovascular risk. However, it is unknown when this 
dyslipidemia starts. Our objective was to investigate the progression over time of the lipid profile 
and the influence of inflammatory parameters on this lipid profile, in individuals who later 
developed RA. 
Methods 
Total cholesterol (TC), HDL cholesterol (HDLc), triglycerides, apolipoprotein A-1 (apo A-1), 
apolipoprotein B (apo B) and lipoprotein (a) (Lp(a)) levels were determined in 1078 stored, deep-
frozen, serial blood bank samples, collected between 1984 and 1999, of 79 blood donors who 
later developed RA. These samples were compared with 1071 control samples of unselected 
blood donors, matched for age, sex and storage time.  
Results 
The samples of future RA patients displayed, on average, 4% higher TC, 9% lower HDLc, 17% 
higher triglyceride and 6% higher apo B levels compared to matched controls (P≤0.05). 
The magnitude of the differences in lipid levels between groups, explained by CRP was limited. 
For example, only 3.6% of the difference in HDLc levels between the groups was explained by 
the CRP concentrations.  
Conclusion 
Future RA patients have a significantly more atherogenic lipid profile in comparison to matched 
blood donors, at least ten years before onset of symptoms. As inflammation only marginally 
explains the differences between the two groups a modulating effect of lipids on inflammatory 
processes is hypothesized. 
 
 
 
INTRODUCTION 
 
Rheumatoid arthritis (RA), an inflammatory joint disease, is associated with an excess 
cardiovascular morbidity and mortality as demonstrated by several inception cohort studies.[1-6] 
The cause of this enhanced cardiovascular risk is unknown but inflammation is thought to play an 
important part,[7] which is in line with the accumulating evidence that inflammation has a 
prominent role in the development of atherosclerosis.[8,9] The significance of inflammation in 
the development of cardiovascular disease is demonstrated by several observations showing 
associations between future cardiovascular events and elevated C-reactive protein (CRP)-
levels.[10-13] The underlying pathophysiological mechanism has not yet been completely 
elucidated and several possibilities have been suggested; acute phase proteins might: 1) 
deteriorate ‘fatty streaks’ into (instable) plaques,(9) 2) destabilize plaques and cause plaque 
ruptures,[12] 3) give complement activation,[13] or 4) facilitate deterioration of the lipid 
profile.[14] 
Dyslipidemia might be responsible for the increased cardiovascular risk in RA patients and 
several investigators demonstrated that active RA is associated with an unfavorable lipid profile, 
i.e. decreased total cholesterol and relatively more depressed high density lipoprotein cholesterol 
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(HDLc) levels.[14-16] The result is a less favorable atherogenic index, suggesting a relation 
between inflammation and dyslipidemia. 
Other lipoproteins have been suggested to play an important role in the development of 
atherosclerosis, i.e. lipoprotein(a) (Lp(a)), apolipoprotein A-1 (apo A-1) and apolipoprotein B 
(apo B). A few studies have investigated Lp(a) levels in patients with RA and the results are 
contradictory. Several earlier studies showed significantly lower Lp(a) levels in RA patients and 
a significant association with acute phase response.[17] A later study found no significant 
elevated levels of Lp(a) in RA patients, nor a significant relationship between Lp(a) and the acute 
phase response.[18] Evidence is growing that both apolipoprotein A-1 (apo A-1) and B (apo B) 
are useful predictors for future cardiovascular risk. Apo A-1 might protect against cardiovascular 
disease whereas apo B might increase the cardiovascular risk.[19-21] Apo A-1 is the major 
apolipoprotein in HDLc and has various structural and functional roles in HDLc metabolism. 
Apo B is the main apolipoprotein of chylomicrons, very low density, low density and 
intermediate density lipoproteins and seems to be a better predictor for cardiovascular disease 
(CVD) than LDLc.[22] So far, data regarding apolipoproteins in RA are sparse and contradictory. 
Recently, we demonstrated in a large group of blood donors, the presence of a preclinical phase 
preceding the actual clinical phase of RA, characterized by serological changes, i.e. elevated 
levels of IgM rheumatoid factor (IgM-RF) and anti cyclic citrullinated peptides (anti-CCP).[23] 
In addition, we also found elevated CRP levels in the samples of the blood donors who later 
developed RA compared to random control donors.[24] Furthermore, the presence of 
dyslipidemia in early active RA raises the question whether or not this phenomenon starts in the 
preclinical phase of RA. 
The present study was undertaken to investigate the lipid profile over time and its relationship 
with inflammation and serological markers, in subjects who later developed RA. 
 
 
 
METHODS 
 
Participants 
The Sanquin Blood Bank Northwest Region, formerly Red Cross Blood Bank, in Amsterdam, 
The Netherlands serves an area with approximately 2 million inhabitants. The blood bank stores 
one-milliliter aliquots of serum at -30°C, from each donation since 1984. On average the donors 
donate 2-4 times a year over a long-term period. Their maximum age is 70 years. Within the area 
in which the blood bank collects blood from donors, most of the RA patients are registered in the 
Jan van Breemen Institute, a regional network of rheumatology outpatient clinics. After receiving 
approval by the local Institutional Review Board, all registered RA patients were sent a letter 
asking them if they had been a blood donor before the RA symptoms started. When the patients’ 
reply was positive, they were asked to sign informed consent giving permission to use the stored 
blood samples for the present study. Ultimately, we identified 79 non-related patients with RA 
satisfying the 1987 American College of Rheumatology criteria for RA.[25] Chart review yielded 
the following data: time of the start of the symptoms, time of the diagnosis of rheumatoid 
arthritis, IgM-RF at time of the diagnosis and during follow-up and the presence of bony erosions 
on radiographs.  
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Procedures 
From 1984 to 1999 patient samples were collected longitudinally from each consecutive blood 
donation. This was done during the entire time frame in which the patients were blood donors. 
For each RA sample, one control sample from a random blood donor matched for gender, age (± 
3 years) and time of the blood donation, was selected as described earlier.[23,24] This method of 
control selection was chosen to ensure identical storage conditions for the materials from patients 
and controls. 
 
 
Laboratory Measurements 
Serum total cholesterol (N < 5.0 mmol/L) and triglycerides (N < 2.2 mmol/L) were analyzed by 
an enzymatic method using the appropriate assays supplied by Roche Diagnostics (Almere, The 
Netherlands), on a Hitachi 911 analyzer (Roche Diagnostics) according to the instructions of the 
manufacturer. PEG-modified enzymes were used for assessing the HDLc levels (N men > 0.9 
mmol/L, women >1.1 mmol/L). Apo A-I (N men 1.04-2.02 g/L, women 1.08-2.25 g/L), apo B (N 
men 0.66-1.33 g/L, women 0.60-1.17 g/L) and Lp(a) (N <30 mg/dl) were analyzed by an 
immunoturbidimetric method, using the appropriate assays supplied by Roche Diagnostics 
(Almere, The Netherlands). CRP (N < 10 mg/L) was measured using a latex enhanced highly 
sensitive assay also supplied by Roche Diagnostics (Almere, The Netherlands). Secretory 
phospholipase A2 (sPL-A2, N < 5 ng/ml) was measured by means of a highly sensitive ELISA 
provided by the Sanquin research at CLB, Amsterdam, The Netherlands. 
IgM-RF and anti-CCP antibodies were measured using in-house enzyme-linked immunosorbent 
assays on an ES 300 analyzer (Roche Diagnostics).[23,24] IgM-RF was calibrated with a national 
reference serum containing 200 IU/ml. No reference serum is available for anti-CCP. The applied 
criteria for positive tests were ≥ 30 IU/ml for IgM-RF and ≥ 50 AU/ml for anti-CCP. 
 
 
Statistics 
We divided the data into one-year periods before the start of the symptoms and we used the 
samples from ten to zero years before the start of the symptoms to estimate the time course of the 
different lipids. The samples from 15 to 10 years before the start of the symptoms were omitted 
because of the small number of available samples. The time course estimation was done using a 
random coefficient multilevel regression analysis, i.e. a longitudinal regression technique which 
allows both starting levels and progression over time to differ between subjects.[26] Multilevel 
regression analysis can be seen as a longitudinal linear regression analysis. It combines many 
cross-sectional linear regression models into one model of one variable over time. In the present 
study we looked the lipid levels over time and investigated the influence of being a future patient 
or a control and we investigated the influence of inflammation parameters on the progression 
over time of the various lipid levels. Multilevel regression analysis quantifies these influences, or 
rather associations between the lipid levels and these two sets of variables, and tests it for 
statistical significance.  
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Besides increasing the statistical power by combining the cross-sectional data of the various time 
points into one association, the multilevel method enables the user to correct for confounding 
caused by multiple testing within subjects. This technique holds into account the possibility that 
one or a few subjects with aberrant values distort the associations between lipid levels and being 
a patient or a control and between lipid levels and disease activity. If one or a few patients have 
for example an abnormally high level of a certain lipid this will not distort the relationship this 
lipid has with disease activity because the multilevel regression analysis will only look at this 
relationship and corrects for the aberrant starting points. 
The differences between patient and control groups in triglyceride and Lp(a) levels were reported 
as the differences in geometric means, as these variables were non-normally distributed. 
Subsequently, for the analyses the natural logarithms of these levels were used. 
Preceding the time course analysis it was investigated whether the various lipid levels were 
constant over time or if there were elevations or decreases in certain one-year periods. 
The first step of modelling the data was done to determine differences between patients and 
controls in the lipid levels over time. These differences were reported as absolute values and as 
percentages of the mean lipid levels as measured in the control groups. The possibility of 
interaction between time and group was also investigated in this model. In the second step of this 
analysis CRP, IgM-RF and anti-CCP were added to the model in order to investigate whether the 
difference between patients and controls could be explained by either CRP, IgM-RF or anti-CCP. 
The differences in the various lipid concentrations between patient and control groups that could 
be explained by CRP, IgM-RF or anti-CCP, were reported as percentages of the observed total 
differences between the two groups. We also added another acute phase reactant to the model, i.e. 
sPL-A2, to investigate whether this would have additional value. 
In another analysis, the longitudinal relationships between the lipids and respectively CRP, IgM-
RF and anti-CCP were analyzed for patients and controls combined as one group. First, a model 
investigating variables measured at the same time was used and secondly a ‘time-lag’-model in 
which the relationship between the lipid concentrations of a particular one-year period with 
inflammation or serological markers of a previous one-year period was investigated.[26] 
The random coefficient analyses were performed using the statistical program MLwiN.[27] A p-
value of less than 0.05 was considered statistically significant. 
 
 
RESULTS 
 
Patient characteristics 
We included seventy-nine RA patients, 61% were women, with a mean age of 51 years at the 
onset of symptoms. The range of available serum samples was 1 to 51 with a median of 13 
samples per patient. The first sample was taken at a median of 7.5 years (range 0.1 – 14.5) before 
the onset of symptoms. For 7 patient sera, no matched control sera were available, resulting in a 
total of 1078 patient and 1071 control sera. 
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Lipid Levels 
The development over time of lipid levels as measured in blood samples of the patients and 
controls is shown in figure 1. Investigation of the TC, HDLc, triglycerides, apo A-1, apo B and 
Lp(a) levels, using the one-year periods separately, yielded no trend breach in the progression of 
lipid levels over time, i.e. a possible increase or decrease in lipid levels was constant over time. 
This justified time course estimations in which the one-year periods were investigated as one 
whole time period. 
The first step modelling the data yielded significant differences in lipid levels between patients 
and controls. Mean TC levels were higher in the patient group compared to the control group, on 
average 0.21 mmol/L (p=0.05). Triglyceride and Apo B levels were also higher for patients 
compared to controls, on average 0.26 mmol/L (<0.001) and 0.06 mg/L (p=0.02), respectively. 
The HDLc levels were lower in the patient group, on average 0.08 mmol/L (p<0.001). Expressed 
as percentages of the calculated mean of the controls we found for the patients that the TC levels 
were on average 3.8 % higher, triglyceride levels 16.8 % higher, apo B levels 5.8 % higher and 
HDLc levels 9.0 % lower. No significant effect modification between time and the division into 
groups was found, indicating that the differences between patients and controls were mainly 
constant over time. 
The magnitude of the observed difference in lipids between patients and controls, explained by 
CRP, was for TC 4.0 %, for triglyceride 0.4 %, for HDLc 3.6 % and for apo B 2.0 %, 
respectively. The influence of IgM-RF and anti-CCP on the differences in TC, triglyceride, 
HDLc and apo B levels was also minor, ranging from less than one to a few percent. In addition, 
the other inflammation marker sPL-A2 had a similar effect on the differences in lipids between 
the two groups and it had no additional value above CRP (data not shown). The differences in 
lipid levels between the patient and control groups, including the data after adjustment for the 
influence of CRP, IgM-RF and anti-CCP, are shown in table 1. 
To investigate the longitudinal relationship of inflammation and serological markers with the 
various lipid levels, the patient and control groups were combined into one group. It was 
demonstrated that CRP had a statistically significant influence on the levels of TC, HDLc and 
apo A-1. An increase of 10 mg/L in CRP level was associated with decreases of 0.1 mmol/L in 
TC (p=0.01), 0.04 mmol/L in HDLc (p<0.001) and 0.05 mg/L in apo A-1 levels (p<0.001), 
respectively. No significant associations were found for the other lipids. Looking at the 
serological markers we could only find a small significant influence of IgM-RF on apo A-1 
(p=0.02), i.e. an elevation of 10 AU/ml in IgM-RF was associated with decrease in apo A-1 of 
0.005 g/L. The final analysis using this time course model yielded no evidence for a ‘time lag’ 
between the lipids and CRP, sPL-A2 or the serological markers. Although the here reported 
associations were found in the pooled population, it did not matter if you were a future RA-
patient or a control, because the same statistically significant relationship of inflammation and 
serological marker with the lipid levels was found in the separate groups. 
Lipids and Inflammation; lipid profile in pre-clinical phase of RA 
 
 41
 
Table 1 Results of the multilevel regression analyses of total cholesterol (TC), high density 
lipoprotein cholesterol (HDLc), apolipoprotein A-1 (apo A-1), apolipoprotein B (apo B) and 
lipoprotein (a) (Lp(a)) levels in future RA-patients and controls 
 
Lipid 
crude data 
 
absolute difference 
(95%-CI) 
CRP adjusted 
 
absolute difference 
(95%-CI) 
IgM-RF adjusted 
 
absolute difference 
(95%-CI) 
anti-CCP adjusted
 
absolute difference 
(95%-CI) 
TC 0.21 (-0.00  0.42)† 0.22 (0.00  0.43)† 0.21 (-0.00  0.43)† 0.19 (-0.02  0.41) 
HDLc -0.08 (-0.12  -0.03)‡ -0.07 (-0.11  -0.04)‡ -0.08 (-0.12  -0.04)‡ -0.07 (-0.11  -0.03)‡ 
Triglycerides§ 0.53 (0.48  0.58)‡ 0.53 (0.48  0.58)‡ 0.53 (0.48  0.59)‡ 0.53 (0.48  0.58)‡ 
apo A-1 -0.02 (-0.08  0.04) -0.02 (-0.08  0.04) -0.01 (-0.07  0.05) -0.02 (-0.08  0.04) 
apo B 0.06 (0.01  0.11)† 0.06 (0.01  0.11)† 0.06 (0.01  0.11)† 0.06 (0.01  0.11)† 
Lp(a)§ 3.16 (0.27  0.41) 0.33 (0.30  0.41) 0.34 (0.28  0.41) 0.33 (0.27  0.40) 
Values are absolute differences between future RA-patients and controls, in mmol/L, g/L and 
mg/L, with 95% confidence interval (95%-CI). No effect modification was found between time 
and division in patients or controls, so the differences remained constant over time. 
§ For Triglycerides and Lp(a) the differences of the geometric means were reported because these 
variables were non-normally distributed and the natural logarithm was used in the analyses. 
† P < 0.05 
‡ P < 0.001 
 
 
DISCUSSION 
 
The present study demonstrates that the lipid profile of blood donors who later developed RA is 
more atherogenic than that of matched controls. This lipid profile is characterized by higher TC, 
triglyceride and apo B levels and lower HDLc levels. Even after adjusting for IgM-RF, anti-CCP 
and CRP levels the lipid profile remained more atherogenic in the patient group. This 
phenomenon starts more than 10 years before the clinical onset of RA. 
The differences in the various lipid values are small but may have clinical relevance, in the light 
of results from other studies.[28-30] For instance, in a placebo controlled study with fibrates, the 
differences of the lipid values between the active treatment and the placebo group were similar to 
the found differences in the present study and the individuals treated with fibrates had ultimately 
a more than 20 % risk reduction for CVD.[31] 
Contrary to the expectations, CRP had only a marginal influence on the differences in lipid levels 
between patients and controls. Another acute phase reactant, sPL-A2, showed a comparable, 
marginal influence on the differences in lipids between patients and controls. The influence of 
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CRP on the lipid concentrations was equal for both groups, i.e. elevation of CRP was associated 
with a decrease of TC, HDLc, apo A-1 and Lp(a) and with an increase in triglycerides and apo B 
resulting in a higher atherogenic index (i.e. TC/HDLc ratio). 
There is growing evidence that inflammation plays an important role in the pathogenesis of 
cardiovascular disease particularly in atherosclerosis.[10] In addition to a postulated direct effect 
of inflammation on endothelial cells, there is mounting evidence that inflammation can also 
increase the cardiovascular risk by deterioration of the lipid profile. This latter is supported by the 
findings of one study demonstrating a decrease in HDLc and apo A-1 levels and an increase in 
triglycerides and apo B levels during an acute phase response.[32] Other investigators found an 
association between elevation of lipids as oxidized LDLc and proinflammatory cytokines as CRP, 
interleukin-6 and tumor necrosis factor-α.[33] The findings of the present study confirm these 
effects of inflammation on the various lipid concentrations. As the changes in CRP only 
explained a small part of the observed differences in lipid levels which remained after adjusting 
for CRP, an alternative explanation is required for the observed differences. 
Two possible explanations are plausible. First, in view of the association between the 
development of RA and a less favorable lipid profile, a (marginally) deteriorated lipid profile 
might render a subject more susceptible to inflammation or inflammatory diseases. In other 
words, one or more of the examined lipids could have a regulatory effect on inflammation. 
Several reports demonstrate anti-inflammatory effects of HDLc and particularly apo A-1. It is 
suggested that apo A-1 is able to inhibit interactions between T-lymphocytes and monocytes, 
thereby modulating the inflammatory response.[34] Moreover, an other study demonstrated the 
ability of apo A-1 to inhibit interleukin-1 and tumor necrosis factor-α, which further supports the 
theory of an active modulating role of lipids in inflammation.[35] 
A second explanation might be that a less favorable lipid profile is related to the development of 
RA by a common or linked background. This could be a socio-economic (including dietary) or a 
genetic background. Indeed, there are a few studies indicating a genetic predisposition for 
dyslipidemia in patients with RA.[36] Further unravelling of the human genome will probably 
elucidate this predisposition. Meanwhile further investigations into genetic markers that could 
single out the population at risk, should be undertaken. 
In summary, our study supports the observation that RA patients have a more atherogenic lipid 
profile even in the preclinical phase of RA, which ultimately could explain the increased 
cardiovascular risk in RA. Furthermore, we demonstrate that inflammation is associated with a 
(further) deterioration of the lipid profile. However, contrary to expectations, inflammation could 
explain only a small part of the observed differences in lipids between the persons who later 
develop RA and the controls. Whether lipids modulate the susceptibility to the development of 
inflammatory diseases such as RA remains to be elucidated. 
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ABSTRACT 
 
Objective 
Rheumatoid arthritis (RA) patients have an increased risk of developing cardiovascular diseases 
(CVD). Other autoimmune diseases like hypothyroidism are also associated with an enhanced 
risk for CVD. Our objective was to determine, firstly, the prevalence of hypothyroid disorders in 
RA patients and, secondly, the risk of CVD in RA patients with hypothyroid abnormalities. 
Methods 
Subjects were RA patients who participated in an ongoing prospective cohort study of 
cardiovascular mortality and morbidity (n = 358) in which hypothyroid abnormalities were 
assessed. CVD was defined as a verified medical history of coronary, cerebral or peripheral 
arterial disease. 
Results 
Clinical hypothyroidism was observed in 16/236 female RA patients (6.8%), which is 
significantly higher than in the general population of the Netherlands. Subclinical 
hypothyroidism was detected in 6/236 RA women (2.5%). 
In female RA patients, CVD was present in 6/16 (37.5%) of all hypothyroid women. The odds 
ratio for CVD comparing female hypothyroid RA patients with female euthyroid RA patients was 
4.1 (95%-CI: 1.2-14.3) after adjustment for sex, age, diabetes, smoking ever, hypertension and 
statin use. 
Conclusions 
Clinical hypothyroidism was observed three times more often in female RA patients than in 
females of the general population. In female RA patients, clinical hypothyroidism was associated 
with a fourfold higher risk of CVD in comparison with euthyroid female RA patients 
independently of the traditional risk factors. 
 
 
 
INTRODUCTION 
 
Several investigators have reported similarities between atherosclerosis and inflammatory 
autoimmune diseases such as rheumatoid arthritis (RA).[1-3] There is increasing evidence for the 
important role of inflammation in the development and progression of atherosclerosis. 
Inflammation may change a stable plaque into an unstable plaque and can cause thrombosis, 
which will frequently precipitate acute vascular events. Furthermore, it has been demonstrated 
that RA is associated with an excess of cardiovascular mortality.[4] Moreover there is a high 
prevalence of preclinical carotid atherosclerosis in patients with rheumatoid arthritis.[5] Hence, 
generalised autoimmune diseases can be an additional risk factor for the development of CVD.[4]  
Hypothyroidism can cause dyslipidemia characterized by an elevated LDL cholesterol (LDLc) 
and a total cholesterol (TC) by the induction of a decreased uptake of LDLc by liver cells.[6] 
Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial 
infarction in elderly women and it is associated with an insulin resistance related dyslipidemia in 
RA patients.[7-8] Therefore, clinical and subclinical hypothyroidism are generally considered to 
be risk factors for CVD. However, in a very recent, population-based investigation, subclinical 
hypothyroidism was found not to be associated with incident cardiovascular diseases.[9] 
There are scarce data available about the prevalence of CVD in patients with thyroid disorders. In 
the first systematic controlled autopsy study a higher prevalence of myocardial infarction in 
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myxedema patients was found in comparison with euthyroid controls.[10] Another autopsy study 
demonstrated a higher incidence of severe coronary artery diseases in hypothyroid patients 
independent of hypertension, diabetes mellitus, or obesity.[11] Both autopsy studies have 
methodological limitations and conclusions of these autopsy studies are therefore difficult to 
interpret.[12] 
The present study was undertaken to investigate the question whether hypothyroidism occurs 
more frequently in RA patients and to investigate the association of hypothyroidism with 
prevalent CVD in RA. 
 
 
 
METHODS 
 
Patients 
For this study three hundred fifty eight RA patients, participating in an ongoing prospective 
cohort study of cardiovascular mortality and morbidity in RA patients performed in the Jan van 
Breemen Institute (JBI), Amsterdam, were included. All RA patients registered at the JBI were 
eligible for participation; the study-population was randomly selected and subsequently recruited 
during regular outpatient visits. The participants were enrolled between January 2001 and 
January 2002. The patients’ ages ranged from 50 to 75 and RA was diagnosed according to the 
1987 ACR criteria.[13] At the inclusion visit patients’ demographic, clinical and laboratory data 
(including the assessment of thyroid function) were collected. The data and blood sera were 
obtained by systematic chart reviews of the medical notes. 
 
Thyroid abnormalities 
This study focused on hypothyroidism, hence we excluded hyperthyroid patients, resulting in 
three subgroups: i.e. subclinical hypothyroidism, clinical hypothyroidism and euthyroidism. 
Clinical hypothyroidism was defined by a documented medical history of hypothyroidism or by 
the criteria for thyroid abnormalities as defined by the Dutch national healthcare consensus 
committee. Subclinical hypothyroidism was defined by an increased (> 4.0 mU/l) serum thyroid 
stimulating hormone (TSH) in the presence of a normal (11-25 pmol/l) serum free thyroxine 
(fT4) assessed from blood samples. 
As reference for thyroid abnormalities the age adjusted prevalence in the general population data 
of the Dutch national healthcare consensus committee was used.[14-15] 
 
RA related data 
The 28 joints’ disease activity score (DAS 28) was assessed to measure the disease activity.[16] 
 
CVD related data 
CVD was defined as verified history of coronary, cerebral or peripheral arterial diseases. 
Coronary artery disease included a myocardial infarction, a coronary artery bypass graft 
procedure, percutaneous transluminal coronary angioplasty or Minnesota codes 1-1 or 1-2 on the 
ECG. Cerebral arterial disease was defined as a cerebral vascular accident, a transient ischaemic 
attack or carotid endarterectomy. Peripheral arterial disease included an aneurysm of the 
abdominal aorta, a peripheral arterial bypass, an ankle/brachial blood pressure index (ABPI) of 
less than 90% (independent of symptoms) and an amputation of the leg. The (traditional) risk 
factors for CVD were assessed: male gender, age, smoking, body mass index (BMI), waist 
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circumference, the presence of hypertension (defined as a blood pressure > 140 mm Hg systolic, 
> 90 mm Hg diastolic or the use of antihypertensive medication), diabetes mellitus (defined as 
fasting glucose > 7.0 mmol/L, or the use of antidiabetics), hypercholesterolemia (defined as a 
total cholesterol of more than 6.5 mmol/L or statin use) and the presence of renal insufficiency 
(defined as an increased serum creatinine level (for men > 114 μmol/l and for women > 88 
μmol/l)). Body mass index (BMI) was defined as weight (in kilograms) divided by length in 
square meters and a BMI ≥ 25 was defined abnormal. An abnormal waist circumference was 
defined according to the International Diabetes Foundation (IDF), for men a circumference ≥ 94 
cm and for women a circumference ≥ 80 cm. During the visit to the research physician the ABPI 
was measured and an ECG was made and assessed using Minnesota codes for myocardial 
infarction.  
 
 
Laboratory tests 
TSH and fT4 were assessed in all patients by the Elecsys test. IgM rheumatoid factor (IgM-RF) 
and anti cyclic citrullinated peptides (anti-CCP) antibodies were measured using in-house 
enzyme linked immunosorbent assays on an ES 300 analyser (Roche Diagnostics). 
 
 
Statistical analyses 
The prevalence of the hypothyroid subgroups was compared with the general population by 
means of a binomial test. The population-based prevalence was adjusted for age and gender. All 
patients suffering from (sub)clinical hypothyroidism were compared with the euthyroid patients 
for RA and CVD related parameters. The RA and CVD related data of the subgroups of thyroid 
dysfunction were compared, using Pearson’s Chi square test for dichotomous variables and using 
Mann-Whitney test for continuous variables. Logistic regression analysis was used to calculate 
the odds ratio (OR) with 95% confidence interval (CI) for thyroid disorders as risk factors for 
CVD. This OR was adjusted for possible confounders: i.e. age, gender, diabetes, smoking, 
hypertension, statin use, renal insufficiency, rheumatoid factor and disease duration. A P-value 
below 0.05 was considered to be statistically significant. For all analyses SPSS 13.0 for Windows 
(SPSS, Inc., Chicago, Illinois) was used. 
 
 
 
 
 
RESULTS 
 
Patients 
The main characteristics of our population are shown in table 1. In this study 358 patients with 
RA were evaluated, 236 of which were women (66%). All patients with clinical hypothyroidism 
(n=16) were women, which is significantly higher than in the other subgroups (subclinical 
hypothyroidism and euthyroidism), of which respectively 6/10 and 194/308 (approximately 60% 
in all the other subgroups) were women (p=0.001). Cardiovascular risk factors did not differ 
(significantly) between (sub)clinical hypothyroid and euthyroid RA patients. 
 
High prevalence hypothyroidism in RA emplifies CVD risk 
 51
 
Table 1   Main characteristics 
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N = 10 N = 16 N = 308 P-value P-value 
Demographic features    
Female sex, % 60 100 63 1.00 0.001 
Age, years 61 (57-65) 68 (63-74) 62 (56-68) 0.43 0.02 
RA related variables    
RA duration, years 5.9 (3.2-7.0) 6.2 (3.9-10.5) 7.1 (4.2-10.5) 0.12 0.60 
IgM-RF positive, % 70 81 71 1.00 0.57 
Anti-CCP, AU/ml 20 (6-2088) 40 (9-2120) 62 (10-450) 0.64 0.67 
DAS-28 4.4 (3.2-5.6) 4.2 (3.0-4.8) 3.9 (2.9-4.9) 0.30 0.57 
Prednison use, % 30 13 16 0.38 1.00 
CVD related variables    
CVD history, % 10 38 17 1.00 0.05 
Smoking ever, % 60 63 79 0.23 0.13 
DM, % 0 6 6 1.00 0.61 
Waist circumference, cm 90 (88-99) 94 (83-106) 92 (82-101) 1.00 0.53 
BMI, kg/m2 25 (24-30) 28 (25- 30) 26 (23-29) 0.80 0.11 
Statin use, % 0 13 11 0.39 1.00 
TC, mmol/l 5.4 (4.5-7.4) 5.5 (4.9-6.3) 5.7 (5.0-6.5) 0.72 0.48 
HDLc, mmol/l 1.4 (1.2-1.6) 1.2 (1.1-1.7) 1.4 (1.1-1.7) 0.81 0.49 
LDLc, mmol/l 3.5 (3.3-5.3) 3.6 (2.5-4.4) 3.6 (3.0-4.4) 0.53 0.47 
Creatinine, μmol/l 94 (85-103) 86 (71-93) 86 (78-97) 0.15 0.27 
Thyroid related variable    
TSH, mU/l 4.9 (4.3-9.0) 1.1 (0.3-3.8) 1.3 (0.9-1.8) <0.001 0.44 
Continues variables are presented as medians with inter-quartile ranges (between brackets). 
N = number; % = percentage; RF = rheumatoid factor; CCP = cyclic citrinulated peptide; DAS-28 = 28 
joint disease activity score; CVD = cardiovascular disease; DM = diabetes mellitus; TC = total 
cholesterol; HDLc = high density lipoprotein cholesterol; LDLc = low density lipoprotein cholesterol; 
TSH = thyroid stimulating hormone 
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Thyroid abnormalities 
In the RA population under study clinical hypothyroidism was more frequently present in women 
than in men; 6.8% (95%-CI: 5.1-8.4) of the women had clinically manifest hypothyroidism in 
comparison with the 2.7% observed in the Dutch population (P < 0.001) (table 2). In female RA 
patients subclinical hypothyroidism was less prevalent than in the general female population, 
2.5% (95%-CI: 1.5-3.6) versus 18%, respectively (P < 0.001). 
 
 
 
Thyroid subgroups 
Differences between the thyroid subgroups are shown in table 1. Hypothyroid disorders were not 
more prevalent in male RA patients than in men of the general population. The median age in 
euthyroid women (62) was significantly lower (P = 0.02) than that in hypothyroid women (68).  
 
Risk of CVD 
Table 3 shows that female RA patients with clinically manifest hypothyroidism had significantly 
more CVD in comparison with euthyroid RA patients, 37.5% and 13.0% (p = 0.05), respectively 
(OR 3.1 95%-CI: 1.1-8.9). After adjustments for the possible confounders age and gender the OR 
for CVD in hypothyroid RA patients was 3.2 (95%-CI: 1.0-10.1). After adjustments for the 
possible confounders age, gender, diabetes, smoking, hypertension, statin use and renal 
insufficiency, the OR was 4.6 (95%-CI: 1.3-16.7). 
The possible confounders rheumatoid factor and disease duration had no influence on any of the 
models. 
Table 2   Prevalence of hypothyroid status in RA patients 
Thyroid function Sex N % Population-based prevalence* P-value 
Euthyroidism(1) men women 
114 
194 
93.4 
82.2   
Hypothyroidism(2) men women 
0 
16 
0 
6.8 
0.3 
2.7 
0.29 
< 0.001 
Subclinical hypothyroidism(3) men women 
4 
6 
3.3 
2.5 
3.0 
18 
0.50 
< 0.001 
Other thyroid status men women 
4 
20 
3.3 
8.5   
Total men women 
122 
236 
100 
100   
(1) = TSH: 0.40 – 4.0 mU/l                                                                    * = age adjusted prevalence
(2) = TSH > 4.0 mU/l and fT4 < 11 pmol/l                                                                    N = number 
(3) = TSH > 4.0 mU/l and fT4: 11 – 25 pmol/l                                                         % = percentage
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Table 3   Odds ratios for cardiovascular disease per hypothyroid subgroups 
 Clinical hypo- thyroidism 
Subclinical hypo- 
thyroidism 
Subclinical and 
clinical hypo- 
thyroidism 
Eu- 
thyroidism 
Model 1 
OR 
(95%-CI) 
 
3.1 
(1.1-8.9) 
 
0.65 
(0.08-5.3) 
 
2.0 
(0.80-5.1) 
 
1.0 
 
Model 2 
OR 
(95%-CI) 
 
3.2 
(1.0-10.1) 
 
0.87 
(0.10-7.4) 
 
2.2 
(0.82-5.9) 
 
1.0 
 
Model 3 
OR 
(95%-CI) 
 
4.1 
(1.2-14.3) 
 
1.9 
(0.21-17.0) 
 
3.2 
(1.1-9.2) 
 
1.0 
 
Model 4 
OR 
(95%-CI) 
 
4.6 
(1.3-16.7) 
 
1.9 
(0.22-17.5) 
 
3.4 
(1.2-10.2) 
 
1.0 
 
Model 1   =   crude, uncorrected data 
Model 2   =   adjustment for sex and age 
Model 3   =   like model 2 plus adjustment for diabetes, smoking ever, hypertension and statin use 
Model 4   =   like model 3 plus adjustment for renal insufficiency 
OR = Odds Ratio, CI = confidence interval 
 
 
 
DISCUSSION 
 
The main conclusion of the present study is an almost threefold enhanced prevalence of clinical 
hypothyroidism in secondary care female RA patients in comparison with the general population. 
In female RA patients, clinical hypothyroidism was associated with a fourfold higher risk of 
CVD in comparison with euthyroid female RA patients independently of the traditional risk 
factors. No clinically manifest hypothyroidism was found in men, which is in accordance with 
previous observations which proved that thyroid abnormalities are sex related, albeit that the 
number of studied males was relatively small in our investigation.[18] 
The present study shows a prevalence of subclinical hypothyroidism in female RA patients which 
is lower than in a sex and age matched general population. This finding might be explained by 
the pyramid hypothesis. This hypothesis is based on the observation that subclinical 
hypothyroidism will develop into clinically manifest hypothyroidism in approximately one 
quarter of the cases. Facilitating factors for this development are old age, female gender and 
higher titers of antibodies for thyroid peroxidase (TPOab).[19-23] This progression into a clinical 
hypothyroidism is also called the “disease pyramid” theory. Autoimmune diseases such as RA 
may accelerate this progression of subclinical disease into a clinical disease, which might explain 
the lower prevalence of subclinical hypothyroidism in RA and the higher prevalence of 
hypothyroidism in female RA patients in comparison with women of the general population.[23]  
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It is known that (clinical) hypothyroidism is associated with an increased rate of CVD and an 
epidemiological study in patients with hypothyroidism showed an OR of 2.8 for early 
atherosclerosis.[24] The present study yielded an OR of 4.6 for the presence of CVD in 
hypothyroid female RA patients when comparing them to euthyroid female RA patients. This 
might indicate a synergistic detrimental effect of RA as well as hypothyroidism for the 
development of CVD. 
In a recent study the relative risk of CVD in Hashimoto’s thyroiditis was 1.8 in comparison with 
healthy controls.[25] This recent investigation also showed that restoration of thyroid status does 
not influence the occurrence of CVD. Hence, the excess of CVD in thyroid disorders is not 
necessarily due to thyroid hormone abnormalities and the accompanying dyslipidaemia, but may 
be mediated by chronic inflammation, i.e. autoimmunity which might amplify the cardiovascular 
risk in RA. Literature on inflammation and hypothyroidism is scarce. Some investigations found 
higher inflammation markers (ESR, CRP or hsCRP) in (sub)clinical hypothyroid patients, [26-27] 
other studies showed no difference in inflammation markers between (sub)clinical hypothyroid 
and euthyroid patients.[28-29] Another study revealed that hypothyroidism was associated with 
endothelium dysfunction, which was only partially dependent on the altered lipid profile.[30] 
Recently, these investigators found that low grade systemic inflammation causes endothelial 
dysfunction in Hashimoto thyroiditis patients.[31] 
Hence, our finding of the threefold enhanced prevalence of hypothyroidism in female RA 
patients, who are at increased risk of CVD (particularly, ischemic heart disease and congestive 
heart failure which both are not fully explained by traditional Framingham risk factors),[32] is 
important, as in hypothyroid patients endothelium dysfunction is found which is related to 
dyslipidaemia as well as systemic inflammation, which might accelerate the development of 
CVD in the already high risk RA patients. 
The cross sectional design of this study can be perceived as a limitation because it is difficult to 
establish the direction of the observed association. However, as most patients first developed 
hypothyroidism before clinically apparent cardiovascular disease, it appears that hypothyroidism 
contributes to the amplification of the cardiovascular risk in RA.  
To summarize, this is the first study demonstrating that hypothyroidism in female RA patients is 
associated with a higher risk of CVD in comparison with euthyroid female RA patients who have 
an already established increased cardiovascular risk.[33-34] Hence, we should be aware of this 
amplified cardiovascular risk in hypothyroid female RA patients and consider screening for 
hypothyroidism in female RA patients.  
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ABSTRACT 
 
Objectives 
Rheumatoid arthritis (RA) is associated with an unexplained increased risk of cardiovascular 
disease (CVD). Antibodies against human 60 kDa Heat-Shock Protein (anti-HSP60) are 
associated with the presence and severity of CVD. Therefore, we investigated whether anti-
HSP60 antibodies are associated with prevalent CVD in patients with RA.  
 
Methods 
In a nested case control design anti-HSP60 antibody levels were measured in the serum samples 
of 192 RA patients. In a regression analysis we examined the association between prevalent CVD 
and anti-HSP60 antibodies and in addition the possible influence on this association of several 
demographic, RA and CVD related variables. 
 
Results 
In a random sample of 326 RA patients, we identified 48 cases who also suffered from CVD. Per 
case we found 3 controls having RA but without CVD (n=144), matched for sex, age, disease 
duration and smoking habits. A regression analysis showed no significant association between 
prevalent CVD and anti-HSP60 antibodies, odds ratio 1.00 (95%-CI: 0.997 – 1.004). After 
correcting for possible confounders, still no association was found. 
 
Conclusions 
In contrast to the general population, anti-HSP60 antibody titres are not associated with prevalent 
CVD in patients with RA. We postulate that these findings are the result of an altered immune 
response in RA to HSP60. 
 
 
 
INTRODUCTION 
 
Heat-shock protein 60 (HSP60) is involved in intracellular transport and in the folding of 
intracellular proteins. It is produced by endothelial cells, smooth muscle cells and macrophages. 
HSP60 protects the cell against denaturation by associating with other intracellular proteins (i.e. 
chaperonins), when the cell is under stress due to inflammation, oxidising agents, 
hypercholesterolemia, hypertension and certain agents in cigarette smoke.[1] Human HSP60 has 
a similarity of approximately 55 % in amino acid sequence with mycobacterial HSP65 to which 
both the humoral and cellular immune system reacts by activating T-cells and producing 
antibodies. It is postulated that a cross-reaction may occur, causing the immune system to attack 
human HSP60.[2] Immune reactivity against HSP60 is thought to be pro-atherogenic. Antibodies 
may bind to HSP60 expressed on endothelial cells and may have a cytotoxic effect which 
subsequently leads to endothelial lesions and ultimately to the formation of atherosclerotic 
plaques.[3,4] HSP60 is detected on endothelial cells in atherosclerotic lesions of blood vessels, 
whereas no expression of HSP60 is observed in disease free control vessels.[5] In line with this 
hypothesis, it has been demonstrated in some epidemiological studies that antibodies against 
HSP60 (anti-HSP60) are associated with cardiovascular disease (CVD), although some studies 
fail to show this.[6,7] 
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Rheumatoid arthritis (RA) is an inflammatory joint disease associated with an increased 
cardiovascular risk for which a clear explanation is lacking.[8,9] It has been demonstrated that 
RA patients have increased HSP60 levels.[10] It is thought that chronic inflammation in RA is 
responsible for this elevated expression of HSP60. In addition, increased levels of anti-HSP60 
have been reported [11] but the relation with an increased cardiovascular risk has not yet been 
studied. In the present study, we hypothesise that increased anti-HSP60 levels are associated with 
CVD in RA. In addition, we assessed whether anti-HSP60 antibody levels in RA-patients were 
associated with demographic-, clinical- or laboratory variables.  
 
 
 
METHODS 
 
Patients 
Patients demographic, clinical and laboratory data were collected cross-sectionally as part of an 
ongoing prospective cohort study assessing CVD in RA. The patients’ age ranged from 50 to 75 
years at time of inclusion and RA was diagnosed in accordance with the 1987 American College 
of Rheumatology criteria.[12] The various data and sera were obtained by systematic chart 
review and during a visit to our outpatient clinic. 
A nested case-control study was performed comparing RA patients with prevalent CVD to those 
without CVD. Each case was compared to 3 controls, i.e. RA patients without CVD, matched for 
sex, age (±5 years), disease duration (longer or shorter than the median of 4 years) and current 
smoking habits. To establish a frame of reference the anti-HSP60 antibody levels were also 
determined in healthy donors. Furthermore, the longitudinal stability of the antibody levels was 
tested in serial samples of 10 RA-patients at time points 0, 12 and 24 months. 
 
CVD and risk factors to CVD 
CVD was defined as a objectified medical history of coronary, cerebral or peripheral arterial 
disease.[13] Coronary artery disease included a myocardial infarction, a coronary artery by-pass 
graft procedure, a percutaneous transluminal coronary angioplasty or ischemic abnormalities on 
the ECG (i.e. Minnesota codes 1-1 and 1-2). Cerebral arterial disease was defined as a cerebral 
vascular accident, a transient ischemic attack or a carotid endarterectomy. Peripheral arterial 
disease included an aneurysm of the aorta abdominalis, a peripheral arterial by-pass operation, an 
ankle/brachial blood pressure index of less than 90 % (independent of symptoms) and an 
amputation of the (lower) leg. 
Risk factors for CVD assessed were age, male sex, hypertension, hypercholesterolemia, diabetes, 
C-reactive protein levels (CRP) and smoking habits. Diabetes and hypercholesterolemia were 
considered to be present if patients received treatment for these conditions, or needed treatment 
according to the recommendations of the Dutch national consensus committee, at the time of 
inclusion of this study.[14] Hypertension was defined as receiving blood pressure lowering 
treatment or as a measured systolic blood pressure of more than 155 mmHg or a diastolic blood 
pressure of more than 95 mmHg. Smoking was assessed by questionnaire at time of inclusion in 
the study. Current and past smoking habits were recorded and as a cumulative measure we 
calculated the amount of packyears, i.e. the amount of years the patient smoked a pack of 20 
cigarettes a day.  
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ELISA for the detection of antibodies against human HSP60 
Recombinant human HSP60 (Stressgen, Victoria, Canada) was diluted to 2 μg/mL in coating 
buffer containing 0.1M NaHCO3- (pH 9.6), and 50 μL/well (i.e., 0.1 μg/well) was incubated in 
wells of microplates (Nunc MaxiSorp™) overnight at 4ºC. Control wells were incubated with 
coating buffer alone. Wells were then incubated overnight at 4ºC with 100 μL/well coating buffer 
containing 1% grade V bovine serum albumin (BSA, Sigma) to block nonspecific binding. Plates 
were then washed 3 times with PBS containing 0.05% Tween 20 (PBS-T). Plates were 
preincubated at room temperature with 200 μL/well of preincubation buffer, containing 0.05% 
Tween 20 and 1% BSA in PBS, for 1 hour. After washing 2 times with PBS-T, wells were 
incubated in triplicates with patient serum in a previously established optimum dilution of 1:50, 
50 µL/well, in incubation buffer and kept overnight at 4ºC. The next day, plates were washed 5 
times with PBS-T and incubated with goat F(ab’)2 anti-human IgG (Fc)-horseradish peroxidase 
conjugate (Cappel-ICN Immunobiologicals, Costa Mesa, CA), diluted 1:2000 in incubation 
buffer, for 2 hours at room temperature. After washing 5 times with PBS-T, 100 μL of freshly 
made substrate (containing 0.5 mg/mL o-Phenylenediamine, Sigma, and 0.03% H2O2 in 
citrate/phosphate buffer, pH 4.9) was added to each well. After 10 minutes, reaction was stopped 
with 50 μL 4N H2SO4 and plates were read at 490 nm. A standard positive serum sample with 
anti-HSP60 activity was run in every assay at 7 serial dilutions from 1:10 to 1:640. OD values 
were derived from triplicate determinations corrected for non-specific binding by subtraction of 
OD in uncoated wells. A standard curve was created with the seven OD values, and the undiluted 
serum sample was arbitrarily assigned 100 units/mL of activity. The OD readings of each test 
serum were then read off the standard curve to determine the number of units of anti-HSP60 
antibody activity. Results are expressed as anti-HSP60 antibody levels in arbitrary units 
(AU)/mL.  
 
Other laboratory variables 
Fasting serum total cholesterol (TC, N < 5.0 mmol/L) and triglycerides (N < 1.90 mmol/L) were 
analysed by an enzymatic method (Roche Diagnostics) in accordance with the instructions of the 
manufacturer. PEG-modified enzymes were used for assessing the high density lipoprotein levels 
(HDLc, N > 0.9 mmol/L). The low density lipoprotein cholesterol (LDLc) levels were calculated 
using the Friedewald-formula. In addition, we calculated the atherogenic index, i.e. TC / HDLc 
ratio, an important prognostic indicator for future cardiovascular disease. CRP (N < 10 mg/L) 
was measured using a latex enhanced highly sensitive assay (Roche Diagnostics). 
IgM rheumatoid factor (IgM-RF) and anti cyclic citrullinated peptides (anti-CCP) antibodies were 
measured using in-house enzyme-linked immunosorbent assays on an ES 300 analyser (Roche 
Diagnostics) as described previously.[15] 
 
Statistics 
We compared the group of patients with RA and prevalent CVD with the group of RA patients 
without CVD. Comparison of continuous variables between the two groups was conducted with 
the use of a Students’ t-test for variables with a normal distribution and with use of a Mann-
Whitney U test for variables with a non normal distribution. Dichotomous variables were 
compared with the use of a Pearson’s Chi-square tests. 
To estimate the cut-off value of anti-HSP60 the receiver operator characteristics (ROC) curve 
was determined.  
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In a logistic regression analysis we examined the association between having CVD or not and 
anti-HSP60 antibody levels and we adjusted for possible influence of demographic, clinical and 
laboratory variables.  
Furthermore, a linear regression model was used to examine whether the anti-HSP60 antibody 
levels were associated with any of the demographic, clinical or laboratory variables. 
A p-value of 0.05 or smaller was considered statically significant and all tests were performed 
using the SPSS 11.5 software package for windows. 
 
 
 
RESULTS 
 
Patient characteristics 
We identified 48 RA-patients with prevalent CVD, i.e. the cases, and matched these with 3 RA-
patients without CVD per case, amounting to a total of 192 subjects. The characteristics and 
comparison of demographic, RA related and CVD related variables between the two groups are 
shown in table 1. There were no significant differences between the two groups in demographic 
and RA related variables. As expected, statins were used more frequently in the RA-CVD group 
(p<0.000) and subsequently the TC and the (calculated) LDLc levels were significantly lower in 
this group (p=0.03, p=0.002, respectively), compared to RA patients without CVD. Furthermore, 
a significantly higher number of RA-patients with CVD received treatment for hypertension and 
their median packyears was higher compared to the group of RA-patients without CVD (p=0.000, 
p=0.004, respectively).  
The mean age of the healthy donors was 39 years (±9.0) and 56 % was male. The healthy donors 
did not suffer from known cardiovascular or any other disease and did not receive treatment for 
cardiovascular risk factors. 
 
 
Figure 1   Boxplot of the anti-HSP60 antibody titres for RA patients without and with CVD. 
P-values calculated using a Mann-Whitney U test for non-normal distributed variables. 
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Anti-HSP60 antibody levels 
The median anti-HSP60 antibody levels of RA-patients with CVD (31.1 AU/L) and RA-patients 
without CVD (34.8 AU/L) were not significantly different (Mann-Whitney U test: p=0.87, Figure 
1). Using a ROC-curve, no cut-off value could be determined (Figure 2). Subsequently, the mean 
titre + 2 x SD (=80 AU/L) of healthy donors was taken as the cut-off point. This resulted in 27 % 
of RA-patients with CVD and 22 % in of RA-patients without CVD being positive for anti-
HSP60, which was not significantly different (Pearson’s Chi-square test: p=0.43). 
 
Figure 2   Receiver operating characteristic curve. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The comparison between all three the groups separately is shown in figure 1. Moreover, the 
percentage of healthy donors exceeding the cut-off point of 80 AU/L was 13 which was not 
significantly lower compared to all RA-patients, RA-patients with CVD and RA-patients without 
CVD (p=0.16, p=0.10 and p=0.23, respectively).  
The logistic regression analysis revealed no association between the presence of CVD and anti-
HSP60 antibody levels (odds ratio (OR)= 1.00; 95%-CI= 0.997 – 1.004). When adjusting for 
potential confounders, such as age, sex, IgM-RF titre, the presence of bony erosions on 
radiographs, RA disease duration, erythrocyte sedimentation rate, CRP-levels, 28-joint disease 
activity score [16], TC-levels, HDLc-levels, LDLc-levels, triglyceride-levels, atherogenic index, 
smoking habits, hypertension, diabetes and prednisone or statin use, separately or all together the 
OR remained 1.00 (95%-CI = 0.994 – 1.003). 
With univariate linear regression analyses no significant associations between anti-HSP60 and 
any of the other variables were found, except for the IgM-RF titre (b=0.044 p=0.05). However, 
this association disappeared in a multivariate analysis.  
Testing the stability of the anti-HSP60 antibody levels in serial samples of 10 RA-patients 
showed a drop in the antibody level in one patient at one of the time points. This patient suffered 
from multiple co-morbidity amongst others diabetes mellitus and severe nephropathy providing 
possible explanation for the drop in antibody titre. The levels of the nine other RA-patients at the 
various time points remained stable (data not shown). 
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Table 1   Characteristics and comparison of RA-patients with and without CVD. 
 
 RA with CVD  (n=48) 
RA without CVD  
(n=144) p-value 
demographic variables    
mean age, years (SD) 66.2 (7.0) 64.6 (7.0) 0.17 
% males 46 44 0.80 
RA related variables    
mean disease duration, years 7.2 (3.5) 7.7 (4.1) 0.41 
% erosive patients 80 85 0.43 
% IgM-RF 72 71 0.96 
median IgM-RF titre, IU/L (IQ-range) 71 (14-200) 32 (10-150) 0.33 
median anti-CCP titre, AU/L (IQ-range) 50 (10-262) 62 (10-450) 0.57 
median ESR, mm/hr (IQ-range) 16 (9-29) 19 (8-34) 0.49 
median CRP, mg/dl (IQ-range) 6 (2-16) 8 (4-25) 0.12 
disease activity score 28 (SD) 3.9 (1.2) 4.0 (1.5) 0.74 
median number of used DMARDs, (IQ-range) 2 (2-4) 3 (2-3) 0.40 
% DMARD naive patients 13 9 0.49 
% current Methotrexate users 69 57 0.15 
% current Sulfasalazine users 15 20 0.39 
% current Prednison users 19 21 0.83 
CVD related variables    
% current smokers 36 31 0.53 
% history of smoking 89 82 0.23 
median packyears (IQ-range) 38 (18-50) 22 (6-37) 0.004* 
% hypertension, measured 19 25 0.41 
% hypertension, medication 49 22 0.000* 
% diabetes 6 4 0.39 
% current Statin users  46 6 0.000* 
mean bodymass index (SD) 25.9 (5.5) 26.8 (4.7) 0.33 
mean waist / hip –ratio (SD) 0.9 (0.08) 0.9 (0.09) 0.15 
mean TC, mmol/L (SD) 5.5 (1.3) 5.9 (1.0) 0.03* 
mean HDLc, mmol/L (SD) 1.4 (0.6) 1.4 (0.4) 0.77 
mean atherogenic index (SD) 4.4 (1.6) 4.7 (1.5) 0.37 
mean LDLc, mmol/L (SD) 3.4 (1.2) 3.9 (0.9) 0.002* 
median triglycerides, mmol/L (IQ-range) 1.3 (0.9-2.0) 1.8 (1.0-1.8) 0.83 
HSP    
median anti-HSP60, AU/ml (IQ-range) 31.1 (13-98) 34.8 (15-69) 0.87 
% anti-HSP60 titres ≥ 80 AU/L 27 22 0.43 
 
A Students’ t-test or Mann-Whitney test was used for comparison of continues variables and a 
Pearson’s Chi-square tests for dichotomic variables. 
TC=total cholesterol, HDLc=high density lipoprotein cholesterol,  
apo A-1=apolipoprotein A-1, apo B=apolipoprotein B, Lp(a)=lipoprotein (a), DMARD=disease 
modifying anti-rheumatic drug, SD=standard deviation,  
IQ-range=inter-quartile-range, %=percentage, no=number, *=significant 
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DISCUSSION 
 
To our knowledge, this is the first study in which the relationship between the occurrence of 
antibodies against HSP60 and CVD is investigated in patients with RA. Anti-HSP60 antibody 
levels in RA patients were increased compared to healthy donors, but the mean level was not 
significantly different between RA patients with and RA patients without CVD. An association 
was found between the anti-HSP60 antibody levels and IgM-RF titres. Contrary to earlier 
findings in healthy controls and patients with CVD there was no association found with age, 
diabetes and acute phase proteins.[17] 
The mean anti-HSP60 antibody levels found in our RA population appears to be higher than that 
in a group of healthy controls. This is consistent with findings of others [18], although it has also 
been reported that there was no difference between RA patients and healthy donors.[19] RA is 
known the be associated with the development of several auto-antibodies such as antibodies 
against rheumatoid factor and cyclic citrullinated peptides.[20] It can be hypothesised that the 
development of auto antibodies against HSP60 are part of the rheumatic disease per se and should 
subsequently not be seen as a marker for CVD. Hence, we suggest that the formation of anti-
HSP60 antibodies in RA-patients is part of the autoimmune response or the result of 
inflammation, both intricate elements of RA. The fact that we found a significant association 
between anti-HSP60 antibody levels and IgM-RF could give support to this hypothesis.  
There are a number of alternative hypotheses for the explanation of the absence of an association 
between anti-HSP60 antibody levels and CVD in RA. First, there may be a difference in 
functionality between anti-HSP60 antibodies formed in RA-patients compared to those formed in 
non-RA-patients, different epitopes of anti-HSP60 antibodies. The ‘RA-anti-HSP60 antibodies’ 
may be less cytotoxic to the endothelial cells to which these antibodies are directed and therefore 
they may be less atherogenic. Whether this is the case remains to be determined by further 
investigation into the functionality of anti-HSP60 in ‘RA-patients’ compared to ‘non-RA-
patients’. These investigations could show that there are several epitopes of anti-HSP60 
antibodies, some being more atherogenic, whereas other could be more artherogenic. 
Secondly, not only endothelial cells but also macrophages can bring HSP60 to expression on 
there cell membrane. As RA is characterised by proliferation of macrophages in synovial tissue, 
it can be hypothesised that this may result in an increased ‘load’ of the potential antigen, HSP60, 
and this can subsequently lead to elevated antibody formation. This could explain the higher 
levels of anti-HSP60 antibodies that were found in our RA population compared to healthy 
donors, as well as the lack association with CVD. 
Associations on anti-HSP antibodies and CVD, in non-RA populations, reported previously were 
obtained from incident cases of CVD. Whether the design of the present study in which prevalent 
cases of CVD in RA patients were investigated could explain the absence of such an association 
is unclear. Furthermore, it has been shown that statins have pleiotropic effects on endothelial 
function, inflammation and immunomodulation [21,22], therefore one may suggest that the more 
prevalent use of particular lipid lowering agents in the group of patients with RA and CVD may 
have an effect on anti-HSP60 levels. However, we were not able to find any effect of statins on 
anti-HSP levels in our RA patients (data not shown). Finally, some have debated the association 
of coronary heart disease with human HSP60 antibody levels and showed an association with 
antibodies to chlamydial heat shock protein 60, suggesting that bacterial heat shock proteins may 
be more important than human heat shock protein in the pathogenesis of coronary heart 
disease.[23] 
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In summary, anti-HSP60 antibodies are not associated with prevalent CVD in RA-patients and 
can therefore not be used as a marker for cardiovascular risk in these patients.  
 
 
 
ACKNOWLEDGEMENTS 
 
We gratefully acknowledge Margret de Koning and Ruud Theunissen for their technical 
assistance. 
 
 
 
REFERENCES 
 
1 Buchner J. Supervising the fold: functional principles of molecular chaperones. FASEB J 
1996; 10(1):10-19 
2 Ranford JC, Henderson B. Chaperonins in disease: mechanisms, models, and treatments. 
Mol Pathol 2002; 55(4):209-213 
3 Mayr M, Metzler B, Kiechl S, Willeit J, Schett G, Xu Q et al. Endothelial cytotoxicity 
mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia 
pneumoniae: immune reactions to heat shock proteins as a possible link between infection 
and atherosclerosis. Circulation 1999; 99(12):1560-1566 
4 Wick G, Knoflach M, Xu Q. Autoimmune and inflammatory mechanisms in 
atherosclerosis. Annu Rev Immunol 2004; 22:361-403 
5 Kleindienst R, Xu Q, Willeit J, Waldenberger FR, Weimann S, Wick G. Immunology of 
atherosclerosis. Demonstration of heat shock protein 60 expression and T lymphocytes 
bearing alpha/beta or gamma/delta receptor in human atherosclerotic lesions. Am J Pathol 
1993; 142(6):1927-1937 
6 Zhu J, Quyyumi AA, Rott D, Csako G, Wu H, Halcox J et al. Antibodies to human heat-
shock protein 60 are associated with the presence and severity of coronary artery disease: 
evidence for an autoimmune component of atherogenesis. Circulation 2001; 103(8):1071-
1075 
7 Xu Q, Willeit J, Marosi M, Kleindienst R, Oberhollenzer F, Kiechl S et al. Association of 
serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet 1993; 
341(8840):255-259 
8 Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE et al. 
Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. 
Circulation 2003; 107(9):1303-1307 
9 Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Symmons DP. Mortality in early 
inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. 
Arthritis Rheum 2002; 46(8):2010-2019 
10 Sato H, Miyata M, Kasukawa R. Expression of heat shock protein on lymphocytes in 
peripheral blood and synovial fluid from patients with rheumatoid arthritis. J Rheumatol 
1996; 23(12):2027-2032 
11 Yokota SI, Hirata D, Minota S, Higashiyama T, Kurimoto M, Yanagi H et al. 
Autoantibodies against chaperonin CCT in human sera with rheumatic autoimmune 
Chapter 6 
 66 
diseases: comparison with antibodies against other Hsp60 family proteins. Cell Stress 
Chaperones 2000; 5(4):337-346 
12 Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al. The 
American Rheumatism Association 1987 revised criteria for the classification of 
rheumatoid arthritis. Arthritis Rheum 1988; 31(3):315-324 
13 Hoogeveen EK, Kostense PJ, Beks PJ, Mackaay AJ, Jakobs C, Bouter LM et al. 
Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, 
especially in non-insulin-dependent diabetes mellitus: a population-based study. 
Arterioscler Thromb Vasc Biol 1998; 18(1):133-138 
14 Utrecht: Consensus Working Group. CBO. Therapy and prevention of coronary heart 
diseases through lowering of the serum cholesterol levels; third consensus 'cholesterol'. 
1998 
15 Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-
Bruinsma IE, de Koning MH et al. Specific autoantibodies precede the symptoms of 
rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 
2004; 50(2):380-386 
16 Prevoo ML, 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. 
Modified disease activity scores that include twenty-eight-joint counts. Development and 
validation in a prospective longitudinal study of patients with rheumatoid arthritis. 
Arthritis Rheum 1995; 38(1):44-48 
17 Zhu J, Quyyumi AA, Rott D, Csako G, Wu H, Halcox J et al. Antibodies to human heat-
shock protein 60 are associated with the presence and severity of coronary artery disease: 
evidence for an autoimmune component of atherogenesis. Circulation 2001; 103(8):1071-
1075 
18 Yokota SI, Hirata D, Minota S, Higashiyama T, Kurimoto M, Yanagi H et al. 
Autoantibodies against chaperonin CCT in human sera with rheumatic autoimmune 
diseases: comparison with antibodies against other Hsp60 family proteins. Cell Stress 
Chaperones 2000; 5(4):337-346 
19 Horvath L, Czirjak L, Fekete B, Jakab L, Prohaszka Z, Cervenak L et al. Levels of 
antibodies against C1q and 60 kDa family of heat shock proteins in the sera of patients 
with various autoimmune diseases. Immunol Lett 2001; 75(2):103-109 
20 Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC et 
al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic 
citrullinated peptide. Arthritis Rheum 2000; 43(1):155-163 
21  Kwak BR, Mulhaupt F, Mach F. Atherosclerosis: anti-inflammatory and 
immunomodulatory activities of statins. Autoimmun Rev 2003; 2(6):332-338 
22  Werner N, Nickenig G, Laufs U. Pleiotropic effects of HMG-CoA reductase inhibitors. 
Basic Res Cardiol 2002; 97(2):105-116 
23 Mahdi OS, Horne BD, Mullen K, Muhlestein JB, Byrne GI. Serum immunoglobulin G 
antibodies to chlamydial heat shock protein 60 but not to human and bacterial homologs 
are associated with coronary artery disease. Circulation 2002; 106(13):1659-1663 
 
  67
 
 
 
 
Chapter 7 
 
______________________________________________________________________________ 
 
 
 
Cardiovascular risk profile of  
antirheumatic agents in patients with 
osteoarthritis and rheumatoid arthritis 
 
 
 
______________________________________________________________________________ 
 
 
 
 
M.T. Nurmohamed, V.P. van Halm, B.A.C. Dijkmans 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drugs. 2002;62(11):1599-609 
 
Chapter 7 
 68 
ABSTRACT 
 
Several new drugs have become available for the treatment of patients with osteoarthritis and 
rheumatoid arthritis (RA). These agents include selective cyclooxygenase-2 (COX-2) inhibitors, 
leflunomide and anti-tumor necrosis factor-α (anti-TNF α) blocking agents.  
COX-2 inhibitors have a more favorable gastrointestinal side effect profile as compared with 
conventional non steroidal antiinflammatory agents (NSAIDs).  
However, the COX-2 inhibitors (coxibs) are also associated with hypertension, edema and 
congestive heart failure, the well known side effects of  conventional NSAIDs. Patients with 
treated hypertension should be monitored regularly when conventional NSAIDs or coxibs are 
given. At present, there is a considerable debate regarding the risk of cardiovascular events with 
the coxibs. The available literature gives no unequivocal answers. This matter can only be solved 
by an appropriate trial assessing the cardiovascular risk of these agents. 
Patients with RA appear to have an enhanced cardiovascular risk which might be related to an 
unfavorable lipid profile. Corticosteroids induce hypercholesterolemia in other patients than RA. 
It was recently shown that total and HDL-cholesterol were low in RA patients with a high disease 
activity. Contrary to the expectation, combination therapy with prednisolone rapidly improved 
the atherogenic index (total/HDL-cholesterol). Ongoing studies investigating  this topic are 
underway. 
It not known to which extent corticosteroids induce hypertension in RA. Hence, we advocate 
blood pressure control for these patients 
Leflunomide is associated with a small percentage of hypertension, and no other serious 
cardiovascular side effects have been reported in the literature. Blood pressure monitoring is 
recommended especially in the first months of treatment. 
TNF blocking agents are contraindicated in RA patients with congestive heart failure. No specific 
cardiovascular side effects have been reported with the use of these agents, in the non-
cardiovascular compromised RA patient.  TNF blocking agents are the most powerful anti-
inflammatory drugs presently available. As inflammation plays an important role in RA as well 
as in cardiovascular disease and, in view of the increased cardiovascular risk in RA, it is tempting 
to expect that suppression of inflammation ultimately will lower the cardiovascular morbidity and 
mortality in RA. 
 
 
 
1. Introduction 
In the last decade several new drugs have become available for the treatment of patients with 
osteoarthritis (OA) and rheumatoid arthritis (RA). These drugs have powerful anti-inflammatory 
and/or disease modifying properties. However, some of them are accompanied with 
cardiovascular side effects. In this review we will discuss cardiovascular risk profile of  these 
new agents and their application in patients with cardiovascular disorders. The focus of this 
review will be on the selective cyclooxygenase-2 (COX2) inhibitors, leflunomide and anti tumor 
necrosis factor α (anti-TNFα) blocking agents. As corticosteroids are also frequently used we will 
discuss recent data regarding the effects of corticosteroids on lipid metabolism.  
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2. Osteoarthritis 
OA is a chronic disorder characterized by disintegration of articular cartilage, with reactive 
phenomena and formation of osteophytes. It is not an inflammatory disorder, albeit that there are 
sometimes signs of inflammation. The incidence increases with age from about 1 percent in 
people younger than 30 to almost 10 percent of those 40 years old and to more than 50 percent in 
individuals older than 60 years. A large-scale incidence study of symptomatic hand, hip, and knee 
OA showed that OA occurred more frequently in women than in men, especially after the age of 
50 years.[1] The incidence of knee OA was twice that of hand or hip OA and women suffered 
twice as often from OA as compared with men.  
Patients with OA of hip or knee have pain that worsens with weight bearing and improves with 
rest. Inflammation, if present, is mostly mild and localized in the affected joint. The 
recommended management of hip or knee OA includes modalities as patient education, weight 
loss and physical therapy as well as drug therapy.[2]  
Acetaminophen, a simple analgesic, is comparably effective as non-steroidal anti-inflammatory 
drugs (NSAIDs) in patients with mild-to-moderate pain, whereas for severe pain NSAIDs are 
superior to acetaminophen.[3,4] 
COX-2 specific inhibitors might have a place in patients who are at an increased risk of serious 
gastrointestinal adverse events such as bleeding, perforation and obstruction. These risk factors 
are age above 65 years, use of oral corticosteroids, prolonged use of maximum dose NSAIDs , 
serious co-morbidity, history of peptic ulcer and of upper gastrointestinal bleeding or use of 
anticoagulants.[2,5] Alternatively, the use of a nonselective NSAID and misoprostol or a proton 
pump inhibitor could be considered.[6] 
Tramadol, a centrally acting oral analgesic, is a synthetic opioid agonist that also inhibits re-
uptake of norepinephrine and serotonin with an efficacy comparable to that of NSAIDs. 
Tramadol is another option for patients who have contraindications to NSAIDs or to COX-2 
specific inhibitors as well as those patients who have not responded to previous drug 
treatment.[7] 
 
 
 
3. Rheumatoid arthritis 
RA is a systemic disease with chronic joint inflammation and characterized by symmetrical pain 
and swelling of the joints and affects approximately 1 percent of the population. The chronic 
synovitis may lead to destruction of cartilage and bone. RA has a wide clinical spectrum which 
varies from mild joint symptoms to severe joint destruction,  accompanied by extra-articular 
symptoms such as pericarditis, pulmonary involvement, vasculitis and mononeuritis multiplex.[8] 
The management of RA consists of co-ordinated multidisciplinary care, e.g. with physical and 
occupational therapy and drug treatment. Successful treatment to limit joint damage and 
functional loss requires early diagnosis and timely initiation of disease-modifying agents.  
The pain in RA is caused by joint inflammation and therefore NSAIDs are preferred over 
analgesics for pain management, in view of their anti-inflammatory effects.9 Analgesics may  be 
added when NSAIDs alone are not enough for pain relief. However, these agents do not change 
the course of the disease nor do they prevent joint damage. Therefore, patients with persisting 
disease activity require (early) treatment with disease modifying antirheumatic drugs  
(DMARDs).[9] Evidence is accumulating that DMARDs can reduce or prevent joint 
destruction.[10] Active RA may cause irreversible joint destruction in the first months of the 
disease and therefore DMARDs should be initiated early in those patients with disease activity, 
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i.e. persisting joint pain, morning stiffness or fatigue, active arthritis or persisting elevation of the 
CRP or ESR.[9] In general, early application of DMARDs means within several weeks after the 
first visit to the rheumatologist. 
Conventional DMARDs include methotrexate, sulphasalazine,  hydroxychloroquine, gold salts, 
ciclosporin, azathioprine and penicillamine. Methotrexate is considered the drug of choice with a 
better long-term efficacy than the other conventional DMARDs.[11] Several investigations have 
demonstrated that combination DMARD therapy might be more effective than mono-DMARD 
therapy in patients with early disease.[12] 
The place of corticosteroids is a continuing matter of debate in view of the side effects 
particularly with long-term use. There is no doubt that corticosteroids rapidly and effectively 
suppress the inflammation in RA and their use might be justified for short-term therapy, e.g. for 
“bridging therapy” between the initiation of DMARD therapy and its actual efficacy.[13] 
Recently, leflunomide and TNFα antagonists have become available for RA treatment. 
Leflunomide is a pyrimidine antagonists that blocks the enzyme dihydroorotate dehydrogenase, 
thereby inhibiting DNA synthesis has an efficacy similar to that of methotrexate.[14] 
TNFα is a pivotal cytokine in the pathogenesis in RA and TNFα blockade was shown to be very 
effective are rapid in controlling disease activity. Although TNFα antagonists appear to be the 
most effective antirheumatic drugs presently available long-term safety data are not yet 
available.[14] 
Presently two anti-TNFα blockers are available for clinical use. Infliximab (RemicadeR) is a 
chimeric mouse/human anti-TNFα monoclonal antibody and binds to soluble as well as 
membrane-bound TNFα. Infliximab is intravenously administered and after the initial infusion it 
is given at two, six and then every 8 weeks thereafter. Etanercept (EnbrelR) consists of two 
human TNFα receptors linked to each other and binds to circulating as well as cell-bound TNFα 
molecules. Etanercept is given subcutaneously twice weekly. 
 
 
 
4. Conventional NSAIDs and selective COX-2 inhibitors.  
The isoenzymes cyclooxygenase (COX)-1 and 2 catalyse the conversion of arachidonic acid to 
thromboxanes and prostaglandins. Thromboxane causes irreversible platelet aggregation and, 
vasoconstriction, and smooth muscle proliferation and it is the major COX-1 product in platelets. 
Aspirin irreversibly inhibits platelet cyclooxygenase-1 and this activity is responsible for its 
efficacy in the prevention of cardiovascular disease. 
Prostacyclin is a potent platelet aggregation inhibitor, a vasodilator and inhibits smooth muscle 
cell proliferation and it is the major COX-2 product in vascular endothelium. 
At low doses, i.e. up to 100 mg/day, aspirin does not interfere with prostacyclin biosynthesis. 
Other NSAIDs inhibit both thromboxane and prostacyclin formation, albeit that the degree of 
inhibition differs between the individual NSAIDs,[15] whereas COX-2 specific inhibitors 
suppress prostacyclin synthesis without a concomitant inhibition of thromboxane 
formation.[16,17] Cyclooxygenase is upregulated in foam cells and smooth muscle cells of 
atherosclerotic plaques,[18] and laminar shear forces may increase COX-2 expression in 
endothelial cells.[19] The resulting increased production of prostacyclin limits the platelet 
activation thereby counterbalancing the effects of thromboxane, as part of a homeostatic 
mechanism. Elderly patients using NSAIDs are at the highest risk for developing cardiovascular 
disease. Hence, the use of specific COX-2 inhibitors might pose them to an additional increased 
thrombotic risk due to a lower prostacyclin synthesis.[20-22] 
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There is accumulating evidence that the use of the coxibs, celecoxib and rofecoxib, results in a 
significant decrease of  gastrointestinal complications as compared with non-selective NSAIDs. 
Recently, two very large trials investigating this topic were published, i.e. the Vioxx 
Gastrointestinal Outcomes Research (VIGOR) trial and the Celecoxib Long-term Arthritis Safety 
Study (CLASSS) investigation. In the VIGOR trial,[23] rofecoxib in a once daily dose of 50 mg 
was compared with a twice daily of 500 mg naproxen in more than 8000 RA patients. Patients 
requiring or who had been treated with aspirin were excluded. The primary end point was 
confirmed clinical gastrointestinal events. Cardiovascular events were also monitored for a future 
meta-analysis. However, a separate analysis was not specified in the study protocol. 
The median treatment duration was nine months and the incidence of clinically important upper 
gastrointestinal side effects was 2.1 per 100 patient years in the rofecoxib group and 4.5 per 100 
patient-years in the naproxen group, (relative risk 0.5; 95 percent confidence interval 0.3 – 0.6; p 
< 0.001). The rate of cardiovascular diseases was 0.8 percent in the rofecoxib patients and 0.4 in 
the naproxen treated patients. This difference was mainly caused by a difference in myocardial 
infarction and occurred mainly in patients with a high risk of myocardial infarction, for whom 
low-dose aspirin was indicated (but not given).23 The relative risk among these patients between 
the rofecoxib group and naproxen group was 4.89 (95% CI 1.41-16.88, p =0.01) and in the group 
of patients not requiring aspirin the risk was 1.89 (95% CI: 1.03 – 3.45, p = 0.04).[20] 
In the CLASS trial celecoxib, 400 mg twice daily was compared to either ibuprofen, 800 mg 
thrice daily or diclofenac twice daily 75 mg.[24] More than 8000 patients with either RA or 
osteoarthritis with an intended treatment period of at least 6 months were studied. The patients 
were allowed to take aspirin and 21 percent of patients actually used aspirin.  
No statistical difference was observed in the primary endpoint of ulcer complications with an 
annualized incidence rate of 0.8 percent in the celecoxib group vs. 1.5 percent in either NSAID 
group (p = 0.09). Combined with symptomatic ulcers these rates were 2.1 and 3.5, respectively 
(p= 0.02). No significant differences were observed between the cardiovascular events between 
the two treatment groups. 
The rumour about a possible increase of cardiovascular events by rofecoxib has led to a 
continuous debate whether or not coxibs are associated with an increased cardiovascular risk. 
From a theoretical point of view formation of thromboxane without the simultaneous production 
of prostacyclin, due to the COX-2 suppression could lead to a prothrombotic state. An increased 
rate of cardiovascular events was not observed in the CLASS trial. There are several reasons for 
this discrepancy. An indeed true difference, i.e. induction of cardiovascular events by coxibs, 
might be masked by the aspirin use in the CLASS trial. Moreover, naproxen in contrast to 
diclofenac and ibuprofen, the comparator drugs in the CLASS trial, might be 
cardioprotective,[23] although direct evidence for this interesting hypothesis is lacking. In 
addition, there is no epidemiological evidence for a cardioprotective effect of NSAIDs (including 
naproxen).[25] Actually, none of the nonaspirin NSAIDs has been adequately investigated in 
terms of their potential (preventive) cardiovascular effects.[26] Finally, there is accumulating 
evidence for an increased cardiovascular risk in patients with RA as compared to the normal 
population. The patients studied in the VIGOR trial were RA patients whereas predominantly OA 
patients were studied in the CLASS trial. OA patients are considered to have a cardiovascular 
risk comparable with the general population and this lower background incidence of 
cardiovascular events might be another explanation for the observed difference between the two 
trials. In summary, there is no convincing evidence for an increased cardiovascular risk when 
coxibs are used instead of conventional NSAIDs. Obviously, there is a need for powered trials 
that address these topics. Until the results of such studies are available this issue, i.e. whether 
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there is an increased risk with coxibs when compared to placebo or were the results of the 
VIGOR trial attributable to antiplatelet effects of naproxen, remains a continuing matter of 
debate.[27,28] 
Apart from the arterial side the venous side deserves attention, particularly in patients undergoing 
major orthopedic surgery. Theoretically, COX-2 inhibitors could lead to a higher incidence of 
postoperative venous thromboembolic complications in these patients when coxibs are used 
instead of conventional NSAIDs which might offset the lower rate of gastrointestinal 
complications.[29] 
 
4.1 Hypertension and congestive heart failure 
NSAIDs cause little or no elevation in blood pressure in normotensive subjects.[30] The risk for 
interaction between NSAIDs and antihypertensive medication, with a resulting inadequate blood 
pressure control, is high and there is evidence for a positive correlation between the use of  
NSAIDs and blood pressure, especially in those already receiving antihypertensive 
medication.[31,32] The CLASS study revealed that patients receiving celecoxib experienced less 
hypertension than patients on other NSAIDs, 1.7 percent versus 2.3 percent, respectively 
(p<0.05). Data regarding hypertension were not provided in the VIGOR publication but a review 
about the cardiovascular risk of COX-2 inhibitors indicated that more rofecoxib treated patients 
than naproxen treated patients developed hypertension in the VIGOR trial; for rofecoxib the 
mean increase in systolic blood pressure was 4.6 mmHg and a diastolic increase of 1.7 mmHg, 
for naproxen these values were 1.0 mmHg and 0.1 mmHg, respectively.[20] 
Rofecoxib and celecoxib were recently compared in a six-week double-blind investigation of 810 
elderly OA patients using antihypertensive agents. Patients were treated with either 25 mg 
rofecoxib (n = 399) or 200 mg celecoxib (n = 411). The primary endpoints were changes in 
systolic or diastolic blood pressure and the occurrence of edema. Systolic blood pressure 
increased significantly in 17% and 11% of the patients randomised to rofecoxib and celecoxib, 
respectively (p=0.03). Diastolic blood pressure increased in 2.3% in the rofecoxib treated patients 
and 1.5% in those receiving celecoxib. Edema was experienced in 9.5% of the rofecoxib group 
treated patients and 4.9% of  the celecoxib treated patients. The clinical relevance of the observed 
edema is unclear as another study indicated clearing of edema in many of the patients treated 
with rofecoxib when the drug was continued.[33] Moreover, one could argue whether or not the 
applied dosages were equipotent regarding efficacy as there are some suggestions for a lower 
efficacy of the investigated dose of celecoxib as compared to rofecoxib.[34] Altogether, data 
regarding coxibs,  hypertension and edema are not yet conclusive. It unclear whether these side 
effects occur less frequently with coxibs in comparison with conventional NSAIDs and whether 
or not there are true differences between celecoxib and rofecoxib.  
The kidney produces both COX-1 and COX-2. In healthy individuals renal prostaglandins play a 
minor role in maintaining electrolyte balance and renal hemodynamic function and NSAIDs have 
no significant effect on renal blood flow. However, when renal  perfusion, e.g. in congestive 
heart failure patients, is reduced renal prostaglandins become important for maintaining renal 
blood flow and for the maintenance of compensated heart failure in these patients with a 
compromised left ventricular function. NSAIDs reduce renal perfusion in these susceptible 
patients and recently, it was shown that conventional NSAIDs doubles the risk of congestive 
heart failure in elderly patients, particularly in those with a history of cardiac disease.[35] The 
NSAIDs, sulindac, meloxicam and nabemutone were introduced for their so-called renal-sparing 
effects.[36-39] However, convincing clinical evidence regarding the effects of these agents on 
cardiovascular homeostasis in patients with an impaired left ventricular function is not yet 
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available. COX-2 specific inhibitors probably have the same risk[40] and recently, both sodium 
and potassium retention,[41,42] and a decreased glomerular filtration rate were observed in salt-
depleted subjects, by several investigators.[43] 
 
 
 
5. Corticosteroids 
Corticosteroids can be of value in the management of rheumatoid arthritis are used between 15 % 
and 40%  at any give time by RA patients.13 Several double-blind trials indicate some 
advantages of corticosteroid treatment, which is confirmed in meta-analyses.[44,45] However, 
these studies are limited by a relatively short time treatment and the toxicities of corticosteroids 
may be cumulative over time. Several large retrospective investigations found corticosteroids to 
be an independent predictor of adverse outcomes. In addition, corticosteroids induce 
unfavourable lipid profiles in patient categories other than RA.[46,47] Moreover, corticosteroids 
can cause hyperglycemia with subsequent detrimental effects on atherogenesis. Therefore, it is 
commonly stated that corticosteroids should be used minimally, if at all, in RA. The major 
cardiovascular adverse events include hypertension and dyslipidemia. The occurrence of 
hypertension has not been assessed adequately but has been estimated to be 20%.[48] However, a 
retrospective investigation in 195 patients with asthma or rheumatoid arthritis indicated that low 
dose corticosteroid treatment (prednison or prednisolone less than 7.5 mg/day) for more than one 
year failed to show any relation between blood pressure and dose or duration of therapy.[49] 
Another, prospective, investigation in 155 early RA patients showed no influence of 
corticosteroids in the 76 patients randomised to combination therapy with prednisolone (tapered 
and stopped after 28 weeks), methotrexate and sulphasalazine (COBRA Study).[50] Altogether, 
if and to which extent corticosteroids induce hypertension in RA, need to be investigated in 
appropriate trials. 
The enhanced cardiovascular morbidity and mortality RA might be due to an increased 
prevalence of risk factors for cardiovascular disease, such as dyslipidemia The available literature 
regarding RA patients is contradictory and there have been a few reports about lipid levels in RA 
and their relation with disease activity. One cross-sectional study in 28 RA patients, with a mean 
disease duration of 7 years, demonstrated an inverse relationship between disease activity and 
lipid levels.[51] A subsequent 9 month follow-up study in 11 RA patients demonstrated 
normalisation of the lipid levels during antirheumatic treatment after 9 months.[52] 
So far no randomized investigations have been reported in early RA patients. Therefore, we 
recently studied the effects of prednisolone on total and HDL-cholesterol levels in RA patients 
and the relation of lipid levels with disease activity.[53] Total and HDL-cholesterol levels were 
determined in stored samples from a previously conducted, 56-week multicenter trial among 
early RA patients investigating the value of intensive combination therapy (COBRA): the 
combination of sulphasalazine, methotrexate (stopped at 40 weeks) and prednisolone (initially 60 
mg/day, tapered in 6 weekly steps to 7.5 mg/day and stopped after 28 weeks) was compared to 
sulphasalazine alone. Contrary to expectation, both total and HDL-cholesterol were depressed in 
these active RA patients at baseline, and increased on antirheumatic therapy. Although a storage 
problem of the serum samples can not be totally excluded in the COBRA trial this will not 
influence the observed changes of lipid levels. 
Combination therapy with prednisolone rapidly improved the atherogenic index (total/HDL-
cholesterol), an important prognostic cardiovascular risk factor. Early antirheumatic and 
especially corticosteroid (combination) treatment may improve the cardiovascular risk in RA, and 
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it appears that the use of corticosteroids is not a risk factor for cardiovascular disease in RA 
which is also  suggested  by other investigators.[54,55] 
Presently, additional investigations are performed to confirm these findings. 
 
 
 
6. Leflunomide 
In clinical trials leflunomide efficacy was similar to that of methotrexate with a relatively rapid 
onset of benefit within 1 – 3 months and in 2000 leflunomide was approved in the Netherlands 
for treatment of RA. Leflunomide is associated with an incidence of hypertension of 
approximately 6 - 10% as compared to approximately 4% for placebo or other comparators, i.e. 
sulfasalazine or methotrexate treated patients. Drug related hypertension occurred in 
approximately 2 - 4% of the leflunomide treated patients as compared to 2% for the comparator 
drugs. New onset hypertension is reported in 2% of the leflunomide treated patients.[56-60] 
A retrospective investigation in 99 consecutive outpatients in whom leflunomide was started, 
revealed a total discontinuation rate of more than 60% (41% due to inefficacy) probably caused 
by patient selection.[61] Hypertension was observed in 8% of the patients which is significantly 
higher than expected from the literature. As this retrospective “clinical practice” investigation has 
several methodological limitations, we have initiated a prospective study of the side effect profile 
of leflunomide in patients in whom leflunomide treatment is initiated, with a special focus on 
cardiovascular risk factors, i.e. hypertension, lipid and homocysteine metabolism. 
 
 
 
7. Anti-TNFα agents 
Presently, two anti-TNFα preparations are available for clinical use in patients with RA. No 
specific cardiovascular problems have been reported with the use of these agents except for 
incidental allergic reactions. 
An interesting potential indication for these agents was recently investigated following the 
findings that that the development of symptomatic heart failure is associated  with  increased 
levels of TNFα. Several experimental studies have shown that elevated levels of TNF are capable 
of inducing heart failure with concomitant left ventricular dilatation and dysfunction.[62] Hence, 
theoretically, inhibition of TNF expression or bioavailability might be beneficial for patients with 
symptomatic heart failure. Indeed, a double-blind placebo-controlled pilot study in 18 NYHA 
class III heart failure patients with an initial ejection fraction < 35% revealed an increase in 
quality-of-life scores, 6-minute walk distance and ejection fraction in those treated with single 
dose etanercept  as compared with no changes of  these parameters in the placebo treated 
patients.[63] No significant side effects were encountered in the etanercept patients. Similar 
findings were found in a larger randomised placebo-controlled study where 47 patients were 
treated with biweekly with doses etanercept or placebo for three months.[64] These promising 
results initiated two large randomised trials in  heart failure patients; one in the US 
(RENAISSANCE) and the other one in Europe, Australia and New Zealand (RECOVER). The 
studies had randomised 1500 patients when an interim analysis revealed  no likelihood of a 
difference between etanercept and placebo and  consequently, these trials of etanercept were 
stopped because of lack of evidence.[65] Safety data of these two large trials have not yet been 
published. 
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The failure to find a benefit of etanercept in these patients challenge the role of TNF for the 
remodelling process in hear failure. Alternatively, (the dose of) etanercept was not sufficiently 
effective or other cytokines are more important for the remodelling process.[65] 
Very recently, a phase 2 trial with infliximab in patients with moderate to severe congestive heart 
failure, demonstrated higher incidence of mortality and worsened heart failure in patients treated 
with infliximab as compared to placebo. Seven of the 101 infliximab treated patients died 
compared to no deaths among the 49 placebo treated patients. Hence, it was advised that  
congestive heart failure patients should not be given infliximab and a clinical alert and warning 
was issued by the US Food and Drug administration.[66] 
 
 
 
8. Practical guidelines for cardiovascular patients 
Commonly applied drugs for osteoarthritis include acetaminophen and NSAIDs whereas in 
rheumatoid arthritis besides NSAIDs, second-line antirheumatic drugs are indicated. 
 
8.1 Oral anticoagulants treated patients 
Acetaminophen is often the preferred analgesic in patients with osteoarthritis who need 
anticoagulants. However, administering this drug in high doses and continuous doses may 
increase the half-life of oral anticoagulants. Therefore, the international normalized ratio (INR) 
should be monitored in these patients.[67] The statement that selective COX-2 inhibitors could be 
considered for these patients in view of their absent antiplatelet effects, appears to be not correct 
as also for the coxibs increased INR values have been described. 
 
8.2 Aspirin treated patients  
When NSAIDs are required in aspirin treated patients there is at present no convincing evidence 
that the COX-2 selective agents, as compared with conventional NSAIDs, offer significant 
benefit for this category. In patients with risk factors for the development for gastrointestinal side 
effects co-medication with misoprostol or proton pump inhibitors should be considered.[28] 
Formal cost-effectiveness investigations are required to compare the possible treatment 
modalities in the aspirin treated patient. 
 
8.3 Patients with hypertension and/or congestive heart failure 
Both conventional NSAIDs and the coxibs are associated with the development of hypertension , 
edema and congestive heart failure. The observed differences between the various drugs appear 
to have a limited clinical significance. Patients with treated hypertension should be monitored 
regularly when conventional NSAIDs or coxibs are used. 
High doses of corticosteroids necessitate blood pressure control. We also recommend monitoring 
with lower doses corticosteroids (up to 20 mg prednisone/day) as the literature is not conclusive 
regarding its hypertensive effects.  
Leflunomide requires also regular control of the blood pressure, especially in the first months of 
treatment. Hypertension in leflunomide treated patients can sometimes be managed by omitting 
the NSAIDs.  
Conventional NSAIDs and the coxibs should be applied with great caution in patients with 
congestive heart failure in view of their potential to provoke cardiac decompensation in these 
patients. It has been suggested that corticosteroids with a high mineralocorticoid activity should 
be avoided in patients with congestive heart failure.[48] 
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Infliximab should not be used in congestive heart failure RA patients. Presently, there are not 
enough safety data of etanercept in patients with congestive heart failure. The infliximab data 
suggest a detrimental effect of TNF blocking in congestive heart failure patients. Hence, also 
etanercept should be considered contraindicated, at least until there are convincing (favourable) 
safety data available for application of etanercept in this category of patients. 
 
8.4 Remaining issues 
There is some indirect evidence that naproxen might be cardioprotective as compared to 
rofecoxib or other NSAIDs which is confirmed by a recent meta-analysis. This meta-analysis of 
23 investigations conducted with rofecoxib, encompassing a total of 28,000 patients, showed 
relative risks of 0.84, 0.79 and 1.69 when comparing rofecoxib with placebo, non-naprosyne 
NSAIDs and naprosyne for the cardiovascular composite endpoint.[68] Obviously, this 
investigation is hampered by its retrospective design and it goes without saying that prospective 
studies with pre-defined cardiovascular endpoints investigating this issue are required for 
confirmation. Particularly, as another retrospective observational cohort investigation failed to 
indicate a cardioprotective effect for naproxen.[69] 
Hopefully, the results will answer the question whether or not aspirin therapy, when indicated, 
can be omitted in patients treated with naprosyne. 
 
 
 
9. Conclusions 
The new NSAIDs, i.e. the coxibs, offer little advantages over the conventional NSAIDs in the 
arthritis patient with cardiovascular comorbidity. Coxibs can be preferred over conventional 
NSAIDs in patients not requiring aspirin as they are associated with less gastrointestinal side 
effects. It is not known whether coxibs can also be preferred over conventional NSAIDs in 
combination with a gastroprotective agent (misoprostol or a proton pump inhibitor) in patients 
with risk factors for the development of a NSAID related gastrointestinal side effects. However, 
when equally effective coxibs are to be preferred in view of the administration convenience  and, 
at least in the Netherlands, substantially lower costs. 
Hypertension is the only reported cardiovascular side effect for leflunomide, and so far no 
significant cardiovascular side have been reported for the use of anti TNF agents. 
Ongoing studies will address the effects of leflunomide and corticosteroids on lipid metabolism 
and other risk factors for cardiovascular disease in RA patients. As inflammation plays a pivotal 
role in RA as well as in cardiovascular disease and the cardiovascular risk appears to be enhanced 
in RA, it can be expected that effective suppression of inflammation, ultimately will lead to a 
decreased cardiovascular risk in RA. Ongoing investigations are presently investigating these 
issues. 
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ABSTRACT 
 
Rheumatoid arthritis (RA) is characterized by inflammation and an increased risk for 
cardiovascular disease (CVD). This study investigates possible associations between CVD and 
the use of conventional disease-modifying antirheumatic drugs (DMARDs) in RA. 
Using a case control design 613 RA-patients (5649 patient-years) were studied, 72 with CVD and 
541 without CVD. Data on RA, CVD and drug treatment were evaluated from time of RA-
diagnosis up to the first cardiovascular event or the end of the follow-up period. 
The dataset was categorized according to DMARD-use, sulfasalazine (SSZ), hydroxychloroquine 
(HCQ) or methotrexate (MTX). Odds ratios (ORs) for CVD, corrected for age, gender, smoking 
and RA-duration, were calculated per DMARD-group. Patients who never used SSZ, HCQ or 
MTX were used as reference group. 
MTX-treatment was associated with a significant CVD-risk reduction, ORs (95% CI): 'MTX 
only' 0.16 (0.04-0.66), 'MTX and SSZ ever' 0.20 (0.08-0.51) and 'MTX, SSZ and HCQ ever' 0.20 
(0.08-0.54). The risk reductions remained significant after additional correction for the presence 
of rheumatoid factor and erosions. After correction for hypertension, diabetes and 
hypercholesterolemia 'MTX or SSZ ever' and 'MTX, SSZ and HCQ ever' showed significant 
CVD-risk reduction. Rheumatoid factor positivity and erosions both increased CVD-risk, ORs: 
2.04 (1.02-4.07) and 2.36 (0.92-6.08). 
MTX and, to lesser extent SSZ, were associated with significantly lower CVD-risk compared to 
RA-patients who never used SSZ, HCQ or MTX. We hypothesize that DMARD-use, in particular 
MTX-use, results in powerful suppression of inflammation, thereby reducing the development of 
atherosclerosis and subsequently clinically overt CVD. 
 
INTRODUCTION 
 
Cardiovascular diseases (CVD) are the most important cause of death in patients with rheumatoid 
arthritis (RA). RA is associated with a significant increase of cardiovascular morbidity and 
mortality, compared to the general population.[1-7] A clear explanation for this excess in 
cardiovascular risk is lacking, although several causes have been postulated. Firstly, an increased 
prevalence of established cardiovascular risk factors, as hypertension, diabetes and 
hypercholesterolemia. A second possibility is undertreatment of cardiovascular co-
morbidity.[8,9] Thirdly, RA itself could be responsible for the excess in cardiovascular morbidity 
and mortality, either by a decreased functional capacity[10], or by the underlying inflammatory 
process. There is growing evidence that atherosclerosis is an inflammatory disease.[11,12] 
Moreover, inflammation might cause deterioration of fatty streaks into (unstable) plaques[13] and 
can lead to plaque ruptures[14], as well as to complement activation[15] or facilitate deterioration 
of the lipid profile[16], all important aspects in the pathogenesis of atherosclerosis. 
A complex element in the association between RA and cardiovascular risk is the use of anti-
rheumatic medication. Patients with persisting disease activity require treatment with disease-
modifying antirheumatic drugs (DMARDs).[17] There are some indications that DMARDs can 
alter cardiovascular risk either by influencing atherosclerotic processes directly through 
inflammation or indirectly by influencing cardiovascular risk factors.[18,19] However, reports on 
the relationship between DMARDs and CVD are limited, focused on mortality, predominantly on 
methotrexate (MTX) and the results were contradictory.[20,21] Therefore, the present study 
investigates associations between cardiovascular morbidity and the use of several conventional 
DMARDs. 
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METHODS 
 
Patients 
Demographic, RA and CVD related data, of 613 RA-patients, were collected by chart review. 
This sample of RA-patients was randomly taken from the entire RA-population registered in the 
Jan van Breemen Institute, a large rheumatology outpatient clinic in Amsterdam, the Netherlands. 
All patients fulfilled the ACR criteria of RA. Patients were recruited from time of diagnosis, 
between 1953 and 2002, onwards till the end of the follow up period, i.e. March 2004. 
 
Study design 
A case-control study of incident CVD was performed, comparing 72 patients with RA and CVD 
to 541 RA-patients without CVD. CVD was evaluated from the time of diagnosis of the RA up to 
the time of the first cardiovascular event or till the end of the follow up period. 
 
CVD and risk factors for CVD 
CVD was defined as a verified medical history of coronary, cerebral or peripheral arterial 
disease. Coronary artery disease included a history of myocardial infarction, a coronary artery by-
pass graft procedure, a percutaneous transluminal coronary angioplasty or ischemic abnormalities 
on ECG. Cerebral arterial disease was defined as a history of cerebral vascular accident 
(confirmed by a neurologist), a transient ischemic attack or a carotid endarterectomy. Peripheral 
arterial disease included an aneurysm of the thoracic and / or abdominalis aorta, a peripheral 
arterial by-pass operation and amputation of the (lower) leg. Assessed risk factors for CVD were 
age, male sex, hypertension, diabetes, hypercholesterolemia, and smoking habits. Hypertension, 
diabetes and hypercholesterolemia were considered to be present if patients received treatment 
for these conditions. Smoking habits were recorded as use ever versus never. All these variables 
were monitored throughout the entire disease duration. 
 
Statistical analyses 
Comparison, between the various DMARD-groups and between the RA-patients with CVD and 
without CVD, was done using Students’ t-tests and Mann Whitney U-tests for the continues 
variables and Pearson’s Chi-square tests for the dichotomic variables. 
The dataset was categorized into groups according to the use ever of sulfasalazine (SSZ), 
hydroxychloroquine (HCQ) or MTX, either as monotherapy or as combinations of these drugs 
(both sequentially and concurrently in time). The final group consisted of patients who never 
used any of the three major DMARDs, this resulted in a total of eight groups. These groups were 
chosen because SSZ, HCQ and MTX are the most commonly used drugs and well represented in 
our random sample of RA-patients. 
Logistic regression modelling was used to calculate the odds ratios (ORs) and 95% confidence 
intervals (95% CIs) of CVD for the various DMARD-groups simultaneously. In the regression 
analysis the group of RA-patients who never used SSZ, HCQ or MTX was used as the reference 
group with a preset OR of 1.00. 
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The first regression model corrected for age, gender, smoking ever and RA-duration. Correcting 
for age, gender and smoking was done because these variables are known to be associated with 
CVD but not with the use of certain DMARDs. Correcting for RA-duration was done because the 
chance for a patient to be treated with more than one DMARD increases with a longer of the 
disease duration. As an additional analysis prednisone use ever was added to this first model. 
In the second regression analysis we added the presence of hypertension, diabetes and 
hypercholesterolemia to the first model. Adding these known risk factors for CVD was done for 
two reasons. Firstly, because these risk factors could be over- or underrepresented in certain 
DMARD-groups and therefore falsely influencing the cardiovascular risk for these groups. 
Secondly, correction for known cardiovascular risk factors was done to explore possible 
pathways by which the investigated DMARDs can influence cardiovascular risk. As illustration 
of this latter, a DMARD could increase the cardiovascular risk by causing hypertension, this 
increased risk would disappear after correcting for hypertension. 
A third analysis was done using the first model and adding the presence or absence of a positive 
rheumatoid factor test and erosions on radiographs. This enabled us to calculate the ORs for CVD 
associated with these two RA related variables. 
The three above described models were also used to explore if there was any dose dependency in 
the possible associations between the DMARD-groups and CV-risk. Therefore, we determined 
the presence of interactions between any of the DMARD-groups and the maximum used dosages, 
days of DMARD-use and a cumulative variable. Because the maximum dosages of the different 
DMARD are of different quantities (e.g. for MTX 30 mg and for SSZ 3000 mg) we calculated the 
percentage of the maximum dosages allowed by the Dutch and European medication agencies to 
be prescribed. For example, 30 mg is the maximum dosage for MTX allowed to be prescribed, 
therefore if a patient only used 15 mg at the most, we used 50% as the maximum dosage in the 
calculations. This way we were able to compare the various DMARD-dosages. As a cumulative 
variable we calculated the maximum percentage of the highest prescribable dosage multiplied by 
the years this DMARD was used. 
A p-value of 0.05 or smaller was considered statically significant and all tests were performed 
using the SPSS 12.0 software package for windows. 
 
 
RESULTS 
 
RA-patients with and without CVD 
The baseline characteristics of the RA-patients with and without CVD in our study population are 
shown in table 1. The RA-patients with CVD were significantly older (p < 0.001) and more often 
male (p = 0.02). Furthermore, they had a longer RA-duration (p < 0.001) and were more likely 
have a positive IgM rheumatoid factor test (p = 0.05) and erosion on radiographs (p = 0.02). The 
use of DMARDs was also different between the two groups of RA-patients. Patients with CVD 
had a higher median number of used DMARDs (p = 0.01). However, the number of DMARD 
naive patients and patients who never used SSZ, HCQ or MTX was also higher in the groups of 
patients with CVD (p = 0.002 and p < 0.001, respectively). Finally, the RA-patients with CVD 
showed more often to have hypertension and hypercholesterolemia (p < 0.001). 
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DMARD-groups 
Various RA and CVD related variables of the entire study population and the different DMARD-
groups are shown in table 2. This table also shows the comparison of these variables between a 
DMARD-group and the remainder of the study population. The 'only MTX ever'-group had a 
significantly shorter RA-duration (p < 0.001), lower percentage of patients with erosions (p < 
0.001) and a higher percentage of diabetics (p = 0.002). The 'only SSZ ever'-group showed 
significantly less erosive patients compared to the remainder of patients (p = 0.03). The RA-
Table 1   Characteristics of RA-patients with and without cardiovascular disease (CVD) 
 
 
RA without CVD 
(n = 541) 
RA with CVD 
(n = 72) 
p-value 
   Demographic variables    
mean age, years (SD) 62 (11) 67 (10) <0.001* 
% females 72 58 0.02* 
   RA related variables    
median disease duration, years (IQ-range) 7.7 (5-11) 10.6 (8-13) <0.001* 
% IgM-RF positive 70 82 0.05* 
% erosive patients 80 92 0.02* 
median number of used DMARDs, (IQ-range) 2 (2-3) 3 (1-3) 0.01* 
% DMARD naive patients 3 10 0.002* 
% never SSZ, HCQ or MTX 5 17 <0.001* 
% SSZ ever 78 65 0.02* 
% HCQ ever 40 38 0.67 
% MTX ever 72 44 <0.001* 
% Prednisone ever 31 25 0.32 
   CVD related variables    
% smoking ever 64 65 0.83 
% hypertension 19 49 <0.001* 
% diabetes 5 10 0.14 
% hypercholesterolemia  2 21 <0.001* 
Comparison made using Students’ t-tests or Mann-Whitney U tests for the continues variables 
and Pearson’s Chi-square tests for dichotomic variables. 
n = number, SD = standard deviation, % = percentage, IQ-range = inter-quartile-range, 
DMARD = disease modifying anti-rheumatic drug, * = significant 
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duration of the 'only HCQ ever'-group was longer than the rest (p = 0.01). The percentage of 
patients receiving treatment for hypertension was higher in 'SSZ and HCQ ever'-group (p < 
0.001). In the 'MTX, SSZ and HCQ ever'-group the RA-duration was longer (p = 0.04) and the 
percentage erosive patients was higher (p < 0.001). 
 
 
Table 2   Comparison calculated using a Students’ t-tests or Pearson’s Chi-square tests, 
relative to the remainder of the population 
 
RA related variables       (p-value) Groups n (%) 
RA-duration % RF  % erosive 
Entire group 613 (100) 9 72 82 
Never MTX, SSZ or HCQ 37 (6) 12 (0.25) 68 (0.58) 70 (0.06) 
Only MTX ever 51 (8) 5 (<0.001)* 61 (0.09) 57 (<0.001)* 
Only SSZ ever 82 (13) 8 (0.29) 70 (0.65) 73 (0.03)* 
Only HCQ ever 36 (6) 12 (0.01)* 70 (0.77) 81 (0.85) 
MTX and SSZ ever 199 (33) 9 (0.10) 75 (0.18) 85 (0.12) 
MTX and HCQ ever 20 (3) 10 (0.83) 75 (0.73) 80 (0.12) 
SSZ and HCQ ever 39 (7) 10 (0.39) 69 (0.74) 90 (0.20) 
MTX, SSZ and HCQ ever 149 (24) 10 (0.04)* 73 (0.63) 91 (<0.001)* 
CVD related risk factors       (p-value) Groups n (%) 
% hypertension % diabetes % hypercholesterolemia
Entire group 613 (100) 22 6 4 
Never MTX, SSZ or HCQ 37 (6) 24 (0.74) 11 (0.19) 10 (0.11) 
Only MTX ever 51 (8) 12 (0.06) 16 (0.002)* 6 (0.77) 
Only SSZ ever 82 (13) 26 (0.38) 2 (0.16) 9 (0.14) 
Only HCQ ever 36 (6) 17 (0.46) 3 (0.42) 4 (0.96) 
MTX and SSZ ever 199 (33) 22 (0.97) 6 (0.80) 1 (0.11) 
MTX and HCQ ever 20 (3) 22 (0.97) 6 (0.80) 1 (0.11) 
SSZ and HCQ ever 39 (7) 39 (<0.001)* 3 (0.36) 0 (0.35) 
MTX, SSZ and HCQ ever 149 (24) 20 (0.56) 5 (0.48) 5 (0.90) 
n = number, % = percentage, RA-duration in years, RF = positive test for IgM rheumatoid 
factor, erosive = erosions on radiographs of hands and / or feet, CVD = cardiovascular 
disease, * = significant 
 
 
ORs for CVD 
ORs for CVD calculated in three models comparing the various DMARD-groups to the RA-
patients who never used SSZ, HCQ or MTX are presented in Table 3. The first model, correcting 
for age, gender, smoking ever and RA-duration, yielded significant risk reductions for CVD for 
the 'only MTX ever', the 'MTX and SSZ ever' and 'MTX, SSZ and HCQ ever'-groups.  
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The second model added additional correction for hypertension, diabetes and 
hypercholesterolemia to the corrections of the first model. This model revealed significant 
reductions in risk for CVD for the 'MTX and SSZ ever' and 'MTX, SSZ and HCQ ever'-group.  
The third model, correcting for the same variables as model one plus rheumatoid factor positivity 
and erosions, showed significant CVD-risk reduction for the 'only MTX ever', 'only SSZ ever', 
'MTX and SSZ ever' and 'MTX, SSZ and HCQ ever'-groups. This third model quantified the ORs 
for having positive rheumatoid factor test and erosions on radiographs, namely OR 2.04 (95% CI 
1.02-4.07) and OR 2.36 (95% CI 0.92-6.08), respectively, showing RA patients with pore 
prognostic signs to have an elevated risk for CVD. 
As an additional analysis we added the use ever of prednisone to the first model, giving an OR 
for CVD 0.89 (95% CI 0.48-1.65), showing no significant association between corticosteroid use 
and the development of CVD. 
 
Dose dependency 
None of the calculated interactions between the DMARD-groups and maximum dosages or the 
days of DMARD-use reached statistical significance (data not shown). Moreover, several 
interactions between the DMARD-groups and the cumulative variable did reach statistical 
significance. In model 1 and 3 we found significant interactions for the 'MTX, SSZ and HCQ 
ever'-, the 'MTX and SSZ ever'- and the 'SSZ-only'-group. In model 2 just the 'MTX, SSZ and 
HCQ ever'-group showed a significant interaction with the cumulative variable. All the observed 
interactions showed that the cardiovascular risk for these DMARD-groups decreased when the 
cumulative DMARD-exposure increased (data not shown). 
Table 3   Odds Ratios for cardiovascular disease 
 
Groups Model 1 OR (95%-CI) 
Model 2 
OR (95%-CI) 
Model 3 
OR (95%-CI) 
Never MTX, SSZ or HCQ (reference) 1.0 1.0 1.0 
Only MTX ever 0.16 (0.04 - 0.66)* 0.47 (0.07 - 3.23) 0.11 (0.02 - 0.56)* 
Only SSZ ever 0.42 (0.16 - 1.10) 0.31 (0.07 - 1.33) 0.37 (0.14 - 0.99)* 
Only HCQ ever 0.55 (0.18 - 1.67) 0.45 (0.10 - 2.04) 0.47 (0.15 - 1.46) 
MTX and SSZ ever 0.20 (0.08 - 0.51)* 0.24 (0.07 - 0.85)* 0.16 (0.06 - 0.42)* 
MTX and HCQ ever 0.22 (0.04 - 1.19) 0.54 (0.08 - 3.66) 0.19 (0.04 - 1.02) 
SSZ and HCQ ever 0.44 (0.14 - 1.41) 0.34 (0.05 - 2.16) 0.37 (0.11 - 1.24) 
MTX, SSZ and HCQ ever 0.20 (0.08 - 0.54)* 0.27 (0.07 - 0.99)* 0.16 (0.06 - 0.43)* 
Model 1: Correcting for age, gender, smoking and RA-duration. 
Model 2: Identical to ‘Model 1’ plus correction for hypertension, diabetes and hypercholesterolemia. 
Model 3: Identical to ‘Model 1’ plus correction for a positive rheumatoid factor test and erosions. 
OR = odds ratio, CI = confidence interval, * = significant
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DISCUSSION 
 
The present study is the first showing a protective role of DMARD-use for the risk of 
cardiovascular morbidity in RA patients. Furthermore, it demonstrates that rheumatoid factor 
positivity and joint destruction on radiographs both approximately double the risk for CVD. 
Earlier studies report on associations between DMARDs and cardiovascular mortality [20,21], 
the tip of the iceberg, and not on cardiovascular morbidity as the present paper does. Previous 
literature predominantly focused on MTX and thereby ignores the other major conventional 
DMARDs, such as SSZ and HCQ. Because a substantial number of RA-patients use other 
DMARDs than MTX we choose to include these drugs in our evaluation. Another advantage of 
the present study is the fact that several CVD but also RA related variables were evaluated for 
their association with cardiovascular disease.  
Mechanisms by which DMARD-use could influence the risk for CVD are poorly investigated. 
HCQ is reported to influence cardiovascular risk by lowering total cholesterol levels.[19,22] 
Corticosteroids are known to cause insulin resistance, hyperglycaemia, weight gain, fluid 
retention and hypertension, all effects which are associated with an increased cardiovascular 
risk.[23] The use of MTX can cause a folic acid deficiency with subsequently higher 
homocysteine levels and thereby increasing the risk of CVD.[20,24] On the other hand Choi and 
colleagues reported a lower cardiovascular mortality in RA patients using MTX, which was 
ascribed to the anti-inflammatory quality of MTX.[22] 
The reduction of CVD related morbidity in MTX treated patients is in line with the reduced CVD 
related mortality in these patients results as found by Choi et al. The results of the present study 
suggests that the use of other conventional DMARDs, such as SSZ (but not significantly HCQ) is 
also associated with a reduction of the risk of developing CVD, which strengthens the hypothesis 
that reducing inflammation is of importance to reduce the risk of CVD. The relationship between 
inflammation and cardiovascular risk is furthermore underlined by the observation that 
rheumatoid factor positivity and joint destruction are associated with CVD. These findings stress 
the importance of aggressive pro-active treatment of RA, as this would not only be beneficial for 
the outcome of the patients' mobility but could also prevent co-morbidity such as CVD. 
There are some limitations to the present study. First, data was obtained by chart review, 
however, this was done systematically by one observer and classification of CVD was verified in 
source documents. Second, there is the possibility of 'confounding by indication', i.e. more severe 
disease, in this case indicated by the presence of rheumatoid factor and erosions on radiographs, 
was associated with a higher risk of CVD, however patients with these characteristics are also 
likely to receive more aggressive treatment with DMARDs which were found to be associated 
with a cardiovascular protective effect. Therefore, confounding by indication may have biased 
the results towards null. We can not exclude entirely such a phenomenon, however, the reported 
associations between DMARDs and CVD risk remained present when variables of severity were 
included in the analyses. 
In summary, RA-patients who are being treated with DMARDs, especially MTX, have a reduced 
risk for CVD in comparison with RA-patients who do not use SSZ, HCQ or MTX. We 
hypothesize that treatment with MTX, and other conventional DMARDs to a smaller extend, is 
associated with less severe atherosclerosis through suppression of inflammation, which results in 
a decreased risk for CVD. 
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ABSTRACT 
 
Objectives 
To evaluate the effects of powerful immunosuppressive treatment, i.e. infliximab, on the lipid 
profile in patient with rheumatoid arthritis (RA). 
 
Methods 
Infusions with infliximab were given at 0, 2, 6 and 14 weeks and from thereon every 8 weeks in 
patients with active RA. Disease activity parameters (DAS-28 score, C-reactive protein, 
erythrocyte sedimentation rate) and lipid levels (total-, high-density lipoprotein (HDL) 
cholesterol, triglycerides, apolipoprotein A-1 (Apo A-1) and apolipoprotein B) were measured in 
80 consecutive RA patients prior to each infusion. Longitudinal analyses were used to investigate 
[1] the course of lipid levels over time [2] the longitudinal relationship between lipids, indicators 
of disease activity and prednisone doses. 
 
Results 
Infliximab treatment causes a significant reduction in disease activity which leads to a 
concomitant decrease of prednisone doses. Initially, lipid levels improved significantly during 
infliximab therapy, however, at the end of the study period all lipid changes, except for Apo A-1 
levels, were normalized. Longitudinal analyses revealed a significant association between lipid 
levels and disease activity and a significant inverse association between lipid levels and 
prednisone doses. Improvement according to the DAS-28 score of 1 point was associated with an 
increase of 0.016 mmol/l (0.618 mg/dl) total- and 0.045 mmol/l (1.737 mg/dl) HDL cholesterol. 
In addition, 10 mg reduction of prednisone dose was associated with a decrease of 0.04 mmol/l 
(1.544 mg/dl) total- and 0.16 mmol/l (6.177 mg/dl) HDL cholesterol.  
 
Conclusion 
No changes in serum lipid levels were observed after 48 weeks of immunosuppressive treatment, 
which may be the result of opposing effects of changes in disease activity and prednisone dose on 
the lipid profile.  
 
 
 
INTRODUCTION 
 
Rheumatoid arthritis (RA) is a chronic, inflammatory disorder of the joints. Patients with RA 
have an increased morbidity and mortality compared to the general population. Mortality due to 
cardiovascular disease (CVD) is the leading cause of death observed in patients with RA.[1] This 
excess cardiovascular mortality in patients with RA is predominantly due to accelerated 
atherosclerosis.[2] 
A well-known cause of atherosclerosis is an atherogenic lipid profile. In particular, low levels of 
high-density lipoprotein (HDL) cholesterol, and high levels of total cholesterol, low-density 
lipoprotein (LDL) cholesterol, and triglycerides are associated with an increased prevalence of 
CVD in the general population.[3] An important prognostic indicator for future CVD is the 
atherogenic index, i.e. the ratio between total- and HDL cholesterol.[4] New data indicate that 
apolipoproteins, which are protein parts of the lipoprotein complex, are possibly better predictors 
for CVD. High levels of apolipoprotein B (apo B) and an increased apolipoprotein B / 
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apolipoprotein A-1 ratio (apo B / apo A-1) are associated with an increased cardiovascular risk, 
whereas higher levels of apolipoprotein A-1 (apo A-1) are protective for developing CVD.[5,6] 
Several studies reported that RA is associated with an unfavorable lipid profile, particularly, in 
patients with active disease.[7-9] These studies show that active RA is associated with lower 
levels of HDL cholesterol compared to healthy controls leading to a higher, i.e. unfavorable, 
atherogenic index. Hence, an atherogenic lipid profile may be part of the cause of the increased 
cardiovascular risk in patients with RA. 
There is growing evidence that inflammation in RA is associated with a worsening of the lipid 
profile[10,11], which improves upon effective anti-rheumatic treatment.[12,13] We previously 
reported that normalization of the lipid profile in patients with RA occurred more rapidly in 
combination treatment with methotrexate (MTX), sulfasalazine, and prednisone than in treatment 
with sulfasalazine alone, thereby demonstrating the temporal relationship between decreasing 
disease activity and improvement of the atherogenic index.[14] However, due to the limited 
duration of the study we were unable to answer the question whether this difference was due to 
improved disease suppression or changes in prednisone dose.  
In another study, we found that treatment with anti-tumour necrosis factor (aTNF) therapy leads 
to a significant increase of both total- and HDL cholesterol levels, which was inversely related 
with disease activity. The atherogenic index, however, remained constant during the six weeks 
study period.[15] 
Thus far, data regarding lipid changes during immunosuppressive treatment are contradictory 
[16,17] and studies observing lipid changes during long-term immunosuppressive treatment are 
lacking. In the present study longitudinal analyses are performed to investigate 1) the longitudinal 
course of lipid levels, including apolipoproteins, over time during immunosuppressive treatment, 
i.e. infliximab and 2) the longitudinal relationship between lipids and indicators of disease 
activity and between lipids and prednisone doses.  
 
 
 
METHODS 
 
Patients 
Consecutive patients with active RA (defined as a Disease Activity Index 28 Joint Score (DAS-
28) of at least 3.2) who were referred to the Slotervaart Hospital for treatment with infliximab 
were included. All RA patients fulfilled the American College of Rheumatology criteria.[18] 
Infusions with infliximab were given at weeks 0, 2, 6 and 14 weeks and from thereon every 8 
weeks. Generally, infliximab was given in combination with stable doses of methotrexate. 
Infliximab was administered intravenously in a starting dose of 3 mg/kg. In patients with 
inadequate response as judged by the patients’ rheumatologist the dose of infliximab could be 
increased to 7.5 mg/kg. Blood samples (nonfasting) were collected in the morning, prior to each 
infusion on week 0, 6, 22 and 48 and were stored at –70°C until analyses. Total cholesterol, HDL 
cholesterol, triglycerides, apo A-1 and apo B concentrations were measured and the total / HDL 
cholesterol and apo B / apo A-1 ratios were calculated. At each visit disease activity, defined as 
DAS-28 [19] and drug treatment was assessed. In total, 108 patients were included in the cohort, 
but 28 patients dropped out in the first year of treatment: 22 because of non-response (78,5%), 5 
because of side effects (18%) and 1 patient (3,5%) who died owing to infliximab-unrelated 
events. Thus, the data from 108 patients were eligible for analyses . The baseline characteristics 
of the dropout patients were comparable to those of the patients included in the study (data not 
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shown). Thus, all included patients completed the study period of 48 weeks and the patients who 
dropped out (n =28) were not included for the analysis. There were no (additional) exclusion 
criteria.  
 
Lipids 
Total serum cholesterol (N < 5.0 mmol/l (193 mg/dl)) and triglycerides (N < 2.2 mmol/l, 196 
mg/dl)) were measured by an enzymatic method using Roche clinical chemistry analyzers. HDL 
cholesterol (N men > 0.9 mmol/l (35 mg/dl), women > 1.1 mmol/l (42 mg/dl)) was determined 
enzymatically with PEG-modified enzymes. The atherogenic index was calculated using the 
following formula: atherogenic index = total / HDL cholesterol. Apo A-1 (N men 1.04-2.02 g/l, 
women 1.08-2.25 g/l) and apo B (N men 0.66-1.33 g/l, women 0.60-1.17 g/l) were analyzed by 
an immunoturbidimetric method, using assays supplied by Roche Diagnostics. 
 
Statistical analyses 
As some patients were treated with prednisone, differences in lipid profiles between prednisone 
users (yes/no) were analyzed by using independent t-tests for normally distributed variables (i.e. 
HDL cholesterol, apo A-1, apo B, and the apo B / apo A-1 ratio), and Mann Whitney U tests were 
used for not normally distributed variables (i.e. total cholesterol, atherogenic index and 
triglycerides).  
The time course of lipid levels during treatment with infliximab was investigated by using 
general estimation equations (GEEs). This regression technique is used as it adjusts for 
dependency of several variables within one subject. For this each lipid value was included 
separately as an independent variable and time was included as categorical, dependent variable.  
GEE analysis were also used to investigate the influence of 1) indicators of disease activity (i.e. 
DAS-28 score and CRP) and 2) prednisone dose on all lipid levels. This regression technique 
quantifies the association between the included variables and tests it for statistical significance. 
Separate analysis were done for each lipid value; for example total cholesterol as dependent 
variable and DAS-28 as independent variable, total cholesterol as dependent variable and CRP as 
independent variable and total cholesterol as dependent variable and prednisone as independent 
variable. GEE analysis were chosen as it combines the within subject relationships with the 
between-subjects relationships resulting in one regression coefficient and has the advantage of 
handling longitudinal data on subjects with varying number and different time intervals.[20] All 
analyses were adjusted for age and gender. As the distribution of total cholesterol, atherogenic 
index and triglycerides were not normal, a log transformation was performed before the GEE 
analyses. All analyses were performed with STATA (version 7) and p-values of less than 0.05 
were considered statistically significant.[21] 
 
 
 
RESULTS 
 
Patients 
The study population consisted of 80 (62 women and 18 men) consecutively included RA 
patients with a mean age of 56 years (SD 14 years). The median disease duration was 10 years 
(range: 0-59 years), 55 patients (69%) were IgM-Rheumatoid factor positive and 67 patients 
(82%) had erosions. At baseline statins were used by 4 patients and 2 patients (2%) reported 
diabetes mellitus. During the study period none of the included patients started statins or glucose 
Changes in lipid profile in RA during IFX treatment 
 95
lowering therapy. Seventy-seven patients (96%) used concomitant methotrexate in a stable dose, 
i.e. 15 mg/wk at all time points and 35 patients (44%) used prednisone at the start of the study 
(mean prednisone dose 8.3 mg/day). As expected treatment with infliximab leads to a 
significantly better DAS-28-score at 48 weeks compared to baseline: 5.7 vs. 3.9 (p < 0.01).  
 
Lipids 
The course of lipid levels over time during treatment with infliximab is shown in table 1. Patients 
who used prednisone had higher total- and HDL cholesterol levels and a lower atherogenic index 
at baseline, but these differences did not reach statistical significance.  
After six weeks infliximab treatment total cholesterol levels increased by 6.1% (p < 0.01) and 
HDL cholesterol levels increased by 10.3% (p < 0.01), resulting in a 6.4% decrease of the 
atherogenic index (p < 0.01). In the next period (6 to 22 weeks) both total- and HDL cholesterol 
levels decreased, but remained significantly elevated compared to baseline. At 48 weeks, total- 
and HDL cholesterol levels approached baseline levels. As total- and HDL cholesterol levels 
moved towards baseline levels the atherogenic index revealed no significant difference compared 
to the baseline index at 22 and 48 weeks. Triglycerides levels did not change during the whole 
treatment period.  
Compared to baseline apo A-1 levels increased 4.5% at 48 weeks (p < 0.01), whereas apo B 
levels and the apo B / apo A-1 ratio did not change significantly at 48 weeks compared to 
baseline.  
 
Lipids and disease activity (table 2). The course of lipids over time was compared to the course 
of disease activity after adjustment for age and gender. GEE analyses yielded a significant 
inverse association between disease activity and lipid levels. Changes in disease activity (DAS-
28) were significantly related with changes in HDL- as well as total cholesterol levels. This 
 
Table 1. Progression over time of lipid levels and ratios in RA patients during treatment with 
infliximab. 
 
Variable Baseline 6 Weeks 22 Weeks 48 Weeks 
median TC (range) 4.79 (2.70-8.10) 5.08 (2.79-9.18)* 4.94 (2.90-10.42)* 4.81 (3.21-7.29) 
mean HDLc (SD) 1.46 (0.50) 1.61 (0.54)* 1.55 (0.53)* 1.53 (0.51) 
median Atherogenic Index (range) 3.42 (1.74-7.78) 3.20 (1.59-8.63)* 3.43 (1.67-8.08) 3.38 (1.62-10.70) 
median Triglycerides (range) 1.26 (0.62-4.40) 1.39 (0.52-3.80)* 1.32 (0.46-3.36) 1.26 (0.62-3.48) 
mean Apo A-1 (SD) 1.58 (0.35) 1.70 (0.33)* 1.65 (0.33)* 1.65 (0.33)* 
mean Apo B (SD) 0.93 (0.23) 0.95 (0.24) 0.94 (0.24) 0.93 (0.19) 
Apo B / Apo A-1 ratio (SD) 0.62 (0.20) 0.58 (0.20)* 0.59 (0.18) 0.59 (0.16) 
* p < 0.05 Compared to baseline (performed by GEE analysis).  
TC=total cholesterol (mmol/L), HDLc=high density lipoprotein cholesterol (mmol/L),  
triglycerides (mmol/l), Apo A-1= apolipoprotein A-1 (g/L), Apo B=apolipoprotein B (g/L) 
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means that if disease activity according to DAS-28 decreases one point, total cholesterol will 
raise 0.016 mmol/l (0.618 mg/dl) and HDL cholesterol will raise 0.045 mmol/l (1.737 mg/dl), 
resulting in a more favorable i.e. lower, atherogenic index. Similarly, individual inflammation 
parameters, ESR and CRP, were significantly inversely associated with both HDL- and total 
cholesterol levels. Moreover, the analyses showed that disease activity was inversely related with 
apo A-1, resulting in a lower, i.e. more favorable, apo B / apoA-1 ratio. 
 
Lipids and prednisone (table 2). During treatment with infliximab lipid levels were compared to 
changes in prednisone dose at different time points after adjustment for age and gender. Changes 
in prednisone dose were related to changes in HDL- and total cholesterol. Prednisone changes, 
however, had a greater influence on HDL- than on total cholesterol levels resulting in an inverse 
association between prednisone dose and the atherogenic index. In other words, a higher 
prednisone dose is associated with a lower, i.e. more favorable atherogenic index. Furthermore, 
the prednisone dose appeared to have a significant positive relation with apo A-1, leading to a 
significant inverse association with the apo B to apo A-1 ratio. Due to the favourable effect of 
infliximab on the DAS-28 score, the prednisone dose was gradually decreased from a median 
dose of 8.3 to 4.6 mg/day. Subgroup analysis revealed no significant differences with regard to 
cholesterol levels between RA patients with prednisone and without prednisone at all time points.  
The reported associations did not change when prednisone and disease activity parameters were 
both included as independent variables in the same regression analysis (data not shown). 
 
Table 2  Relationship between lipid items, indicators of disease activity and prednisone. 
Variable 
Atherogenic 
index 
Coefficient (S.E.)
Total cholesterol 
Coefficient (S.E.) 
HDL cholesterol 
Coefficient (S.E.)
Indicators of disease activity    
1-point decrease of DAS-28 -0.016 (0.008) * 0.016 (0.005) * 0.045 (0.013) * 
10-points decrease of CRP -0.030 (0.001) * 0.020 (0.001) * 0.070 (0.001) * 
Reduction of 1mg prednisone 0.009 (0.004) * -0.004 (0.002) * -0.016 (0.006) * 
Variable Apo B / Apo A-1 Coefficient (S.E.)
Apo B 
Coefficient (S.E.) 
Apo A-1 
Coefficient (S.E.)
Indicators of disease activity    
1-point decrease of DAS-28 -0.013 (0.005)* 0.005 (0.004) 0.036 (0.009)* 
10-points decrease of CRP -0.010 (0.001)* 0.010 (0.001) 0.050 (0.001)* 
Reduction of 1mg prednisone 0.005 (0.002)* 0.001 (0.002) -0.009 (0.004)* 
 
Regression coefficients and standard errors estimated by GEE analysis for each lipid item as a 
continuous outcome variable. Atherogenic index, Total cholesterol (mmol/l), HDL cholesterol 
(mmol/l), Apo B / Apo A-1 ratio, Apo A-1 (g/l) and Apo B (g/l). All analysis were adjusted for 
age and gender.  
* p < 0.05 
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DISCUSSION 
 
In this study we observed a significant increase of total- and HDL cholesterol levels after 6 weeks 
of infliximab treatment, which gradually returned to baseline after 48 weeks. As a result 
improvement of the atherogenic index at six weeks was not observed anymore from 22 weeks 
onwards. Longitudinal data analyses, i.e. GEE analyses, revealed that lowering the prednisone 
dose attenuated the effects of infliximab on total cholesterol and HDL cholesterol levels and its 
main protein part apo A-1, thereby abolishing the improvement of the atherogenic index as well 
as the apo B to apo A-1 ratio. Nevertheless, apo A-1 levels remained significantly elevated after 
48 weeks of treatment. This latter might be important as there is accumulating epidemiological 
evidence indicating that high levels of apo A-1 are strongly related with a lower risk for future 
CVD.[5-6] 
Recent research has shown that systemic inflammation plays a pivotal role in the development of 
atherosclerosis. Immune cells dominate early atherosclerotic lesions, their effector molecules 
accelerate progression of the lesions and inflammation elicits CVD.[22] Hence, inflammation 
might be the key explaining the enhanced cardiovascular risk in RA patients.[23] Moreover, 
inflammation induces the acute phase response leading to lipid changes and alterations in 
lipoprotein metabolism. Most of these changes, i.e. decreased levels of HDL cholesterol and apo 
A-1, are pro-atherogenic and ultimately they may contribute to the increased cardiovascular risk 
in RA. In this study, a decreasing disease activity resulted in a lower, atherogenic index as a 
result of higher total cholesterol levels and even more pronounced higher HDL-levels. In 
addition, a decrease of disease activity led to a better apo B to apo A-1 ratio, due to significantly 
increased apo A-1 levels. These findings are in line with other studies reporting an inverse 
association between inflammatory markers (ESR and CRP) and HDL cholesterol or its apo A-1. 
[12-13] 
Differences reported in this study are small and may therefore question their clinical relevance. 
Several studies, however, illuminate the importance of lipid changes even though the observed 
differences are small. The Lipid Research Clinics Coronary Primary Prevention Trial (LRC-
CPPT) as well as the Framingham Study for example show that a 1 mg/dl (0.026 mmol/l) 
increment of baseline HDL cholesterol is associated with an approximately 3.5% risk reduction 
for coronary heart disease. Another study performed by Rubins et al. revealed that a 6% increase 
in HDL cholesterol is associated with an absolute risk reduction of 4.4% of death from coronary 
heart disease or non-fatal infarction. Although these findings cannot be directly extrapolated to 
our study, they demonstrate the clinical importance of only small lipid changes. Moreover several 
recent observations indicate that apo-B and apo A-1 may in fact be more powerful predictors of 
risk for CVD than the conventional lipid values.[22,5,6] This is important and might be clinically 
relevant as this study indicates that apo-A1 remains significantly elevated during the whole 
treatment period.  
Mechanisms underlying the decrease of HDL cholesterol during inflammation are not firmly 
established. Our findings, however, suggest that alterations in prednisone dose are relevant. We 
showed that lowering the prednisone dose results in a decrease of total cholesterol levels, that is 
predominantly due to a decrease in HDL cholesterol leading to a higher atherogenic index (as the 
effect on total cholesterol was less pronounced). Vice versa, increasing the prednisone dose might 
have favorable effects on the lipid profile. Nevertheless, it is highly uncertain whether or not this 
postulated beneficial effect is ultimately offset by other cardiovascular side effects of long-term 
prednisone use, as insulin resistance and hypertension.  
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In addition to a previous study performed by our study group [14], the present study reveals 
additional insights into the influence of prednisone and disease activity on the lipid profile as 
both have a significant, but opposing, and more pronounced influence on HDL cholesterol than 
on total cholesterol.  
There might be (additional) explanations for the observed longitudinal lipid changes. First, 
exercise increases HDL cholesterol in healthy individuals [24] and immunosuppressive therapy is 
associated with a substantial clinical improvement whereby RA patients will increase their 
physical activity. Second, RA patients with a high disease activity have higher levels of tumour 
necrosis factor, which is associated with rheumatoid cachexia.[25] Treatment with infliximab 
obviously leads to lower levels of the tumour necrosis factor, therefore possibly leading to a 
better dietary intake resulting in increased lipid levels. Finally, we have to consider the possibility 
that the observed lipid changes are due to a direct effect of biologicals through blocking TNF-
alpha.  
In conclusion, the present investigation shows that immunosuppressive therapy, with infliximab, 
might have beneficial effects on the increased cardiovascular risk in RA patients through several 
pathways: 1) due to its anti-inflammatory effects, 2) indirectly as a cause of lower prednisone 
doses and 3) through, albeit small, anti-atherogenic effect on the lipid profile. Prospective 
cardiovascular outcome studies are needed to establish whether or not immune-suppressive 
therapy indeed results in a lower cardiovascular risk. 
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To the editor: 
 
Therapeutic options for patients with the chronic inflammatory disease ankylosing spondylitis 
(AS) are limited. Treatment was, until recently, mainly based on non-steroidal anti-inflammatory 
drugs and physical therapy. The efficacy of disease modifying antirheumatic drugs, as 
sulfasalazine and methotrexate, is less beneficial in AS compared with other rheumatic diseases 
as rheumatoid arthritis (RA).[1] Recently, tumour necrosis factor (TNF)-α blocking agents, have 
been proven to be very effective in a high proportion of patients with AS. However, these agents 
are expensive and are sometimes accompanied by severe adverse events, as opportunistic 
infections. Moreover, TNF-α blocking agents fail to reach efficacy in approximately 30% of the 
patients.[2] Hence, there is an ongoing need for alternative therapeutic options. There is growing 
evidence that statins possess anti-inflammatory properties, as indicated by lowering C-reactive 
protein levels, and recently a clinically beneficial effect on disease activity of the statin 
atorvastatin was demonstrated in RA.[3,4] Therefore, we conducted an open pilot study to 
investigate the effect of rosuvastatin on disease activity in patients with AS.  
Fifteen unselected consecutive outpatients with AS, according to the modified New York criteria, 
were treated with rosuvastatin (20 mg/day) for twelve weeks, followed by an observational phase 
of twelve weeks. Patients were eligible for inclusion if they had active disease defined as at least 
4 points at the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI, 0-10) and a pain 
score of at least 4 on the Visual Analogue Scale (VAS, 0-10). The local ethics committee 
approved the study protocol and all patients gave written informed consent. Main exclusion 
criteria included cardiovascular events within the previous 3 months, current lipid lowering 
therapy and current use of biologicals. No patients were entered who would otherwise have 
qualified for statins on the basis of calculated risk. Plasma concentrations of C-reactive protein 
(CRP), erythrocyte sedimentation rate (ESR), total cholesterol, low density lipoprotein (LDL)-
cholesterol, high density lipoprotein (HDL)-cholesterol, triglycerides and the following clinical 
parameters: BASDAI, Bath Ankylosing Spondylitis Functional Index (BASFI, 0-10), Bath 
Ankylosing Spondylitis Metrology Index (BASMI, 0-10), general well being according to the 
doctor/patient (GWBD/P) and pain score were determined. Statistical analysis was performed 
with the Wilcoxon signed rank test. P-values below 0.05 were considered significant.  
The patients’ mean age was 46 years (range 29-61), 9 were men and 14 were HLA-B27-positive. 
The mean disease duration was 11.5 years (range 2-22). All patients completed the trial. 
However, the dose of rosuvastatin was reduced in two patients to 10 mg/day after 6 weeks due to 
side effects. Clinical parameters, as BASDAI, BASMI, pain score and GWBD/P, tended to 
improve during the treatment period. The first three parameters sustained, with further 
improvement, during the observational phase. In addition, treatment with rosuvastatin resulted in 
significant laboratory improvements of CRP and ESR after 12 weeks. Total- and LDL-cholesterol 
were significantly reduced after 6 and 12 weeks and increased during the observational phase 
(table 1).  
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The main conclusion is that rosuvastatin therapy leads to an improvement of disease activity in 
patients with active AS and is accompanied by significant reduction of acute-phase-reactants. 
Moreover, several clinical parameters continued to improve during the follow-up phase 
suggesting that rosuvastatin has long lasting beneficial effects. There is accumulating evidence 
that statins exert anti-inflammatory properties through modulation of the immune-response. The 
immune-response is up regulated in the inflammatory disorder AS and we hypothesized that 
suppression of the immune-response by statins would lead to clinical improvement accompanied 
with lower levels of inflammation markers, such as ESR and CRP. The results of our 
investigation are in line with this hypothesis but clearly confirmatory randomized studies are 
required.  
Finally, as AS is associated with an increased cardiovascular risk[5], the use of statins might 
ultimately lead to reduction of this risk by two pathways: one through the lipoprotein metabolism 
and the other by beneficial effects on the underlying inflammatory process in AS.  
 
 
 
Table 1   Clinical and biological variables (median) in 15 patients at baseline and at weeks 6, 12 
(with rosuvastatin) and at weeks 18, 24 (without rosuvastatin) 
 
  With rosuvastatin After stopping rosuvastatin 
Variable 
T = 0 
weeks 
T = 6 
weeks 
T = 12 
weeks 
T = 18 
weeks 
T = 24 
weeks 
ESR (mm/hr) 22.0 20.0 15.0* 18.0 15.0 
CRP (log mg/L) 15.0 10.0 10.0* 12.5 12.0 
Total cholesterol (mmol/l) 4.8 3.5* 3.6* 5.0** 5.0** 
HDL-cholesterol (mmol/l) 1.3 1.3 1.5 1.3 1.2 
LDL-cholesterol (mmol/l) 2.8 1.1* 1.8* 3.3** 3.2** 
Triglycerides (mmol/l) 1.4 1.2 1.3 1.5 1.8 
BASDAI 6.3 5.6 5.8 5.2 5.6 
BASFI 4.7 5.4 4.9 5.0 4.9 
BASMI 4.4 4.0 3.8 3.6 4.2 
General well being 
according to the doctor 4.4 4.5 3.9 4.2 4.0 
General well being 
according to the patient 6.4 5.7 5.3 5.6 5.7 
Pain score 6.5 6.8 6.2 5.7 5.2 
 
*significant changes compared to T = 0 (Wilcoxon signed ranks test): P = 0.05.  
**significant changes compared to T= 12 weeks (Wilcoxon signed rank test): P = 0.05.  
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Scope of this thesis 
 
In this thesis the cardiovascular risk in rheumatic diseases is investigated against the background 
of mounting evidence revealing the pivotal role of inflammation in the development of 
cardiovascular disease (CVD). The chronic inflammatory nature of rheumatic diseases, such as 
rheumatoid arthritis (RA) and ankylosing spondylitis (AS), raises the question whether the 
increase in inflammatory burden causes a higher prevalence of CVD. 
Moreover, in this thesis epidemiological associations between inflammation and CVD are 
studied, trying to elucidate possible causal pathways. The focus of this thesis is on established 
cardiovascular risk factors such as dyslipidemia and thyroid dysfunction in rheumatic diseases. 
Furthermore, disease associated variables such as antibody formation and anti-rheumatic 
treatment, that might be responsible for an increase in cardiovascular risk in rheumatic diseases 
are investigated. 
In the final paragraphs of this thesis the generalisability of the main findings are addressed and 
recommendations for future research of CVD in rheumatic diseases are given. 
 
 
 
Main findings 
 
In chapter 2 results of the CARRÉ study, an ongoing study into CVD in RA, are presented. The 
prevalence of CVD and its risk factors in RA-patients is studied and compared to healthy 
individuals and individuals with impaired glucose metabolism. In total 755 participants were 
included, 353 RA-patients, 258 healthy individuals and 194 diabetes mellitus type 2 (DM2) 
patients, respectively. The prevalence of CVD and its risk factors were compared per group and 
the odds ratios for CVD were calculated. 
Hypertension and smoking, were observed more frequently in RA-patients compared to healthy 
individuals. On the other hand other cardiovascular risk factors, such as dyslipidemia, were found 
less often in RA-patients. The prevalence for CVD in RA-patients was approximately 13 %, 
which is two to three fold that of healthy individuals. Furthermore, the observed cardiovascular 
risk in RA at least equals the risk found in DM2-patients, which does not change after adjusting 
for age, gender, hypertension, dyslipidemia and smoking, indicating that RA is an independent 
risk factor for CVD. 
 
An important well established risk factor for CVD is dyslipidemia. Some authors have suggested 
that inflammation can cause a deterioration of the lipid profile. Whether this association between 
inflammation and dyslipidemia exists and if so to what extent, is investigated in chapters 3 and 
4.  
In chapter 3 the relationship between inflammation parameters and lipid levels in 45 AS-patients 
participating in a phase 2 trial into the safety and efficacy of leflunomide, is assessed. It was 
shown that increases in disease activity are associated with decreases in lipid levels. Moreover, 
the decrease in the anti-atherogenic high density lipoprotein cholesterol (HDLc) tends to be 
almost twice as large as the decrease in total cholesterol (TC), resulting in a more atherogenic 
lipid profile. The magnitude in which disease activity influences lipid levels is limited.  
Although the observed influence of inflammation of lipid levels is small, this limited worsening 
of the lipid profile may have a clinically important impact on the cardiovascular risk in view of 
the chronic nature of rheumatic diseases. 
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In chapter 4 the effect of powerful immunosuppression on the lipid profile is studied in 80 
consecutive RA-patients. These patients received anti-tumor necrosis factor-α treatment in the 
form of periodic infliximab (IFX) infusions for a total period of one year. During this year the 
course over time of the lipid levels and their relationship with inflammatory parameters and 
prednisone dosages were studied.  
It was shown that IFX treatment causes reduction in disease activity, with concomitant decrease 
in prednisone dosages. Furthermore, lipid levels initially improved, however, at the end of the 
study the lipid changes normalised. Longitudinal analyses revealed a significant association 
between lipid levels and inflammation parameters which is in line with chapter 3 of this thesis. 
Furthermore, a significant inverse association was found between lipid levels and prednisone 
dosages. No changes in lipid levels were observed after 48 weeks of immunosuppressive 
treatment which is thought to be caused to the opposing effects of inflammation and prednisone 
dosage on the lipid profile. 
The worsening effect of inflammation on the lipid profile, as demonstrated in chapters 3 and 4, is 
a possible pathway between inflammation and CVD in patients with rheumatic diseases. 
 
Chapter 5 is a study of the lipid profile in the pre-clinical phase of RA, before the start of the 
symptoms. Earlier studies in this pre-clinical phase had shown that future RA-patients formed 
more antibodies and had elevated inflammation parameters. This combined with the studies 
described in chapters 3 and 4 showing that inflammation deteriorates the lipid profile, the study 
in chapter 5 was done to investigate when the worsening of the lipids, compared to healthy 
controls, starts. 
The lipid levels of 1078 deep frozen, serial samples of 79 non-related RA-patients were 
compared to 1071 control sera, which were matched for age, gender and storage time and 
condition. A median of 13 samples per RA-patient was recovered with the first sample taken at a 
median of 7.5 years before the onset of symptoms. 
Comparison of the future-RA and non-RA sera revealed that up to at least 10 years before the 
symptoms onset, future-RA patients displayed, on average, 4% higher TC, 9% lower HDLc, 17% 
higher triglyceride and 6% higher apolipoprotein B levels compared to matched controls 
(p≤0.05). In line with the results found in chapters 3 and 4, only a small part of the differences in 
lipid levels between future-RA and non-RA could be explained by inflammation parameters. For 
example, only 3.6% of difference between groups in HDLc levels was explained by C-reactive 
protein (CRP) levels.  
Chapter 5 supports the impression that inflammation enhances cardiovascular risk through 
altering the lipid profile. However, because the deterioration and the differences between future-
RA and non-RA were small the results of this study leaves room for various other ways by which 
inflammation could alter cardiovascular risk. 
 
In addition to dyslipidemia thyroid disorders, particularly hypothyroidism, are well established 
risk factors for CVD. In chapter 6 the prevalence of thyroid disorders and its relation with 
cardiovascular risk in RA is investigated. The study in this chapter uses the dataset from the 
CARRÉ study described in chapter 2. Of all the participants the thyroid status is established and 
subsequently compared to the population at large. Furthermore, an assessment of the 
cardiovascular risk per group was done, correcting for other conventional cardiovascular risk 
factors as diabetes, hypertension and dyslipidemia. 
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It is shown that clinical hypothyroidism is found three times more often in female RA-patients 
than in the general population. Furthermore, these women have a fourfold higher risk for CVD in 
comparison with euthyroid RA-patients. 
This study shows that in addition to dyslipidemia, thyroid disorders also play an important role in 
the enhanced cardiovascular risk of patients with rheumatic diseases, such as RA. 
 
A subset of 192 RA-patients from the CARRÉ database was used for chapter 7. In this chapter a 
non-conventional risk factor for CVD, antibody formation against human 60-kDa heat shock 
protein (HSP60), is investigated. Heat shock proteins protect endothelial cells against 
denaturation caused by harmful influences such as oxidising agents, dyslipidemia, hypertension 
and certain agents in cigarette smoke. Patients with rheumatic disorders are known to form more 
antibodies than healthy individuals, for example against citrinullated peptides. Therefore, in 
theory RA-patients could form more antibodies against HSP60, counteracting or even eliminating 
HSP60 and subsequently develop more CVD. Chapter 7 shows that although RA-patients have 
higher titres of HSP60-antibodies than healthy controls, nor the height, nor presence of these 
antibodies was associated with prevalent CVD. Therefore, in this study the increased 
cardiovascular risk in RA can not be explained through formation of antibodies against HSP60. 
 
In addition to naturally occurring influences on established and newer risk factors for CVD, 
influences on the cardiovascular risk in rheumatic diseases caused by treatment, should be 
considered. That is why chapters 8 to 10 address the influence of anti-rheumatic treatment on the 
risk for CVD. The first of these chapters provides an overview of the literature on the risk for 
CVD associated with agents prescribed in osteoarthritis and rheumatoid arthritis (chapter 8). 
 
Chapter 9 reports the findings of a case control study of 5649 patient-years in 613 RA-patients, 
72 with CVD and 541 without CVD. Data on RA, CVD and drug treatment were evaluated from 
time of RA-diagnosis up to the first cardiovascular event or the end of the follow-up period. The 
dataset was categorised according to use of disease modifying anti-rheumatic drug (DMARD), 
sulfasalazine (SSZ), hydroxychloroquine (HCQ), methotrexate (MTX) or combinations of time. 
Subsequently, per DMARD-group odds ratios for CVD in comparison with RA-patients who 
never used SSZ, HCQ or MTX, corrected for age, gender, smoking and RA-duration, were 
calculated.  
A significant reduction in the risk for CVD in the treatment groups that included treatment with 
MTX and to a lesser extent SSZ, was observed. This reduction remained after additional 
adjustment for hypertension, diabetes, hypercholesterolemia, the presence of rheumatoid factor 
positivity and erosion(s) on radiographs. It is hypothesised that treatment with conventional 
DMARDs, particularly MTX, slows down atherosclerosis through suppression of inflammation, 
which results in a decreased risk for CVD. 
 
Chapter 10 describes an open pilot study in which 15 consecutive AS-patients were followed for 
6 months, starting with 3 months of rosuvastatin therapy followed by a 3 months observational 
period. Assessing various disease activity parameters in these patients showed improvement 
during statin therapy illustrated by a significant reduction of acute-phase-reactants such as CRP 
and ESR. 
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This study enforces the pleiotropic effects of statins by showing a decrease in disease activity in 
patients receiving the active compound compared to patients who do not. These results 
demonstrate that administering statins to patients with rheumatic diseases because of their 
increased cardiovascular risk, could also have a beneficial effect on the rheumatic disease itself. 
 
 
 
Generalisability 
 
In this thesis a significantly increased cardiovascular risk in patients with chronic inflammatory 
rheumatic diseases such as RA and AS is shown. Furthermore, this thesis advocates that this 
increase is caused partially by worsening of the cardiovascular risk profile and partially by a 
direct pro-atherogenic effect of inflammation, the distinctive feature of rheumatic diseases. 
The worsening effect on the cardiovascular risk profile is supported in this thesis by 
demonstrating that inflammation deteriorates lipid levels, thus increasing the risk for CVD. 
Moreover, the heightened immune response in RA seems to be related to a higher prevalence of 
clinically overt hypothyroidism with a subsequently increased cardiovascular risk. 
This thesis also addresses the possibility of direct pro-atherogenic effect of inflammation, the 
most prominent characteristic of rheumatic diseases. The inflammatory character of rheumatic 
diseases is thought to cause accelerated atherosclerosis with more and less stable plaque 
formation in arteries. This thesis supports this harmful effect of inflammation by showing that 
suppression of inflammation lowers the cardiovascular risk, which remains even after correcting 
for conventional cardiovascular risk factors. 
 
One should see a rheumatic, inflammatory disease as an independent risk factor for CVD, as 
diabetes mellitus is known to be. When this is more widely accepted this will have consequences 
on the management of patients at risk for CVD. Furthermore, this increased risk should 
encourage active treatment of the rheumatic disease itself. Lowering inflammation appears to, at 
least, slow down the build up of atherosclerosis in arteries and could subsequently decrease the 
prevalent CVD. 
 
This thesis points to inflammation as the major cause of the enhanced cardiovascular risk in 
rheumatic diseases. One could generalise this to all inflammatory diseases and events. In support 
of such a generalisation are several studies demonstrating that people with chronic inflammatory 
periodontal diseases, such as gingivitis, suffer greater risk for getting CVD. However, the fact 
that the inflammatory processes in rheumatic diseases are autoimmune driven may make it 
impossible to extrapolate the findings of this thesis to all inflammatory events. Furthermore, RA 
and AS are diseases with high-grade inflammation and it is not sure whether low-grade 
inflammation has similar associations with CVD and its risk factors. 
 
 
Future perspectives  
 
Future research has to be done to further elucidate the pathway, or many pathways by which 
inflammation causes an enhanced risk for CVD. This should be done by a combination of both 
laboratory research and epidemiological studies. Meanwhile, one feels that it would be prudent 
for any clinician to be aware of the association between inflammation and CVD.  
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With awareness comes planning for the future. The next logical step for future research, would be 
to start mapping the cardiovascular risk profile of patients with chronic inflammatory diseases 
such as RA and AS. Besides registration of events and risk factors it should be investigated 
whether or not the elevated risk can be diminished by therapeutic interventions. 
This raises the question how this research should be done. The most feasible setup would be a 
large outpatient setting. All patients with a rheumatic disease would be followed at regular 
intervals to record variables related to cardiovascular risk and related to the rheumatic disease. 
Within this setting it would be possible to investigate whether (intensive) treatment of 
cardiovascular risk factors reduces cardiovascular risk. Ideally this would be done in a double 
blind placebo controlled fashion, whether this is feasible is questionable. A fortunate finding, 
shown in this thesis, for when interventions are being explored, is that treatment with statins to 
lower cholesterol levels, could also have a beneficial effect on the rheumatic disease itself.  
 
 
 
Conclusions 
 
In conclusion, since in 1999 the author Russel Ross stated in a leading journal that atherosclerosis 
should be seen as an inflammatory disease, there have been many articles published on this topic. 
However, several important questions regarding the relationship between CVD and 
inflammation, remain to be answered. Nevertheless, one could speculate and make an addition to 
the statement by Ross and state:  
“Atherosclerosis is an inflammatory disease and inflammatory diseases are atherogenic.” 
 
After reading this thesis three messages should stand out. Firstly, rheumatologists should be 
aware of the increased risk for CVD in their patients and so they should easily be convinced to 
actively screen their patients for CVD and cardiovascular risk factors. Secondly, cardiologists 
should be able to see that rheumatic inflammatory diseases are important independent risk factors 
for CVD. Thirdly, besides awareness of clinicians, patients should be made aware of the 
increased cardiovascular risk associated with rheumatic diseases, so they can take the appropriate 
measures to try to minimise their cardiovascular risk for the future. 
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De strekking van dit proefschrift 
 
Er is steeds meer bewijs dat ontsteking een belangrijke rol speelt bij de ontwikkeling van hart- en 
vaatziekten (HVZ). Omdat reuma gepaard gaat met chronische ontsteking, onderzoekt dit 
proefschrift het risico op HVZ bij reumapatiënten. Of patiënten met reumatische ziekten, zoals 
reumatoïde artritis (RA) en spondylitis ankylopoëtica (SA), vanwege hun grotere 'ontstekings-
last' ook werkelijk meer HVZ hebben is de vraag. 
In dit proefschrift worden epidemiologische verbanden onderzocht tussen ontsteking en HVZ met 
als doel licht te werpen op mogelijke verbanden en werkingsmechanismen. Dit proefschrift 
onderzoekt klassieke risicofactoren voor HVZ, zoals dyslipidemie en afwijkingen van de 
schildklier, bij reumapatiënten. Tevens worden potentiële risicofactoren die nauw verbonden zijn 
met reumatisch aandoeningen, zoals antilichaamvorming en het gebruik van antireumatica, 
onderzocht op hun mogelijke invloed op het risico op HVZ. 
De laatste alinea's van dit proefschrift zijn gewijd aan de vraag of de bevindingen 
generaliseerbaar zijn en hoe toekomstig onderzoek er uit zou kunnen zien. 
 
 
 
Bevindingen 
 
In hoofdstuk 2 worden de resultaten van de CARRÉ-studie, een doorlopend onderzoek naar 
HVZ bij RA-patiënten, gepresenteerd. De prevalentie van HVZ en risicofactoren voor HVZ bij 
RA-patiënten wordt bestudeerd en vergeleken met die van gezonde mensen en mensen met een 
afwijkende glucose stofwisseling. In het totaal namen deel aan deze studie 353 RA-patiënten, 258 
mensen met een normaal glucose metabolisme en 194 mensen met diabetes mellitus type 2 
(DM2).  
Er werd gevonden dat hypertensie en roken meer voorkwam bij RA-patiënten dan bij de 
gezonden, doch hadden de RA-patiënten gemiddeld een beter lipidenprofiel. De prevalentie van 
HVZ bij RA-patiënten was ongeveer 13 %, hetgeen twee tot drie keer hoger is dan bij de 
gezonden. Het verhoogde risico op HVZ dat bij RA-patiënten gevonden werd was tenminste even 
hoog als dat van mensen met DM2, ook na statistische correctie voor leeftijd, geslacht, 
hypertensie, lipidenprofiel en roken. Het lijkt er dan ook op dat RA gezien moet worden als een 
onafhankelijke risicofactor voor HVZ. 
 
Een reeds bewezen risicofactor voor HVZ is dyslipidemie. Eerdere onderzoeken suggereerden 
dat een lipidenprofiel kan verslechteren onder invloed van ontsteking. In de hoofdstukken 3 en 4 
wordt onderzocht of er bij reumapatiënten inderdaad een relatie bestaat tussen ontsteking en het 
lipidenprofiel en als deze er is hoe groot de invloed van de één op de ander is. 
In hoofdstuk 3 wordt de relatie onderzocht tussen ontstekingsparameters en lipidengehaltes bij 
45 SA-patiënten, die deelnamen aan een fase 2 studie naar de effectiviteit en veiligheid van 
leflunomide. Er werd aangetoond dat met het stijgen van de ontstekingsparameters de 
lipidengehaltes in het bloed daalden, echter daalde het high density lipoprotein cholesterol 
(HDLc) tweemaal zoveel als het totaal cholesterol (TC), hetgeen resulteerde in een meer 
atherogeen lipidenprofiel.  
De invloed van ontsteking op de lipidengehaltes was slechts beperkt, echter kan deze kleine 
beïnvloeding toch klinisch relevant zijn vanwege het chronische karakter van SA. 
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Hoofdstuk 4 beschrijft een studie naar het effect van krachtige onderdrukking van het 
immuunsysteem op het lipidenprofiel. Dit werd onderzocht bij 80 opéénvolgende RA-patiënten 
die een jaar lang anti-tumor necrosis factor-α therapie kregen voorgeschreven. In dat jaar kregen 
deze patiënten periodiek infliximab (IFX) intraveneus toegediend en werd er onderzoek gedaan 
naar een mogelijke relatie tussen lipidengehaltes in het bloed, ontstekingsparameters en de 
prednison dosis die patiënten eventueel gebruikten. 
Tijdens behandeling met IFX bleken de ontstekingsparameters af te nemen en daarmede ook de 
eventueel gebruikte prednison dosis. Aanvankelijk verbeterde het lipidenprofiel zich echter aan 
het einde van de studieperiode waren te lipidengehaltes weer terug op het beginniveau. 
Longitudinale data-analyse liet een gelijksoortige associatie zien tussen de ontstekingsparameters 
en de lipidengehaltes als beschreven in hoofdstuk 3 van dit proefschrift. Tevens werd er een 
omgekeerde associatie gevonden tussen de hoogte van de gebruikte prednison dosis en de 
lipidengehaltes. Het feit dat er aan het einde van de studieperiode geen veranderde 
lipidengehaltes gevonden werden bleek veroorzaakt te worden door de tegenovergestelde 
effecten van de afgenomen ontstekingsactiviteit en de afgenomen prednison dosis. 
Het verslechterende effect dat ontsteking heeft op het lipidenprofiel, zoals beschreven in 
hoofdstuk 3 en 4, kan een verklaring zijn voor de relatie tussen ontsteking en HVZ. bij 
reumapatiënten. 
 
Eerdere studies van onze onderzoeksgroep lieten zien dat toekomstige RA-patiënten reeds in de 
pré-klinische fase van RA, voor het begin van de klachten, meer antilichamen vormen en tevens 
hogere ontstekingsparameters hebben dan controles die later geen RA ontwikkelen. Dit 
gecombineerd met het verslechterende effect van ontsteking op het lipidenprofiel zoals besproken 
in hoofdstuk 3 en 4, leidde ertoe dat het lipidenprofiel van 79 RA-patiënten in de pré-klinische 
fase van de ziekte onderzocht werd (hoofdstuk 5). In het totaal werden de lipidengehaltes van 
1078 diepgevroren bloedmonsters van toekomstige RA-patiënten vergeleken met 1071 controle 
bloedmonsters die werden gematcht op leeftijd, geslacht, bewaarduur en bewaarconditie. Per RA-
patiënt werden gemiddeld 13 bloedmonsters teruggevonden met het eerste monsters gemiddeld 
afgenomen 7,5 jaar voor het begin van de klachten van de RA. 
De bloedmonsters van de toekomstige RA-patiënten hadden een 4% hoger TC, 9% lager HDLc, 
17% hoger triglyceride en 6% hoger apolipoprotein B gehalte in vergelijking met de gematchte 
controle monsters (p≤0.05). In lijn met de resultaten van hoofdstuk 3 en 4 bleek slechts een klein 
deel van het verschil tussen toekomstige RA-patiënten en controles in lipidengehaltes veroorzaakt 
door verschillen in ontstekingswaarden. Zo werd van het verschil in HDLc gehalte tussen de twee 
groepen slechts 3.6% veroorzaakt door het C-reactive protein (CRP) gehalte.  
Dit hoofdstuk steunt de bevinding dat ontsteking het lipidenprofiel verslechterd hetgeen 
vervolgens kan leiden tot meer HVZ. Het blijkt echter ook dat er slechts een klein deel van de 
gevonden verschillen in lipidengehaltes verklaard wordt door ontsteking. Er lijkt dan ook 
voldoende ruimte te zijn voor alternatieve verklaringen voor het verhoogde risico op HVZ bij 
RA-patiënten. 
 
Naast dyslipidemie is het ook evident dat een schildklierafwijking, in het bijzonder 
hypothyreoidie, een risicofactor is voor het ontwikkelen van HVZ. Daarom wordt in hoofdstuk 6 
onderzoek gedaan naar schildklierafwijkingen en het hiermee geassocieerde risico op HVZ. Voor 
dit onderzoek werd de CARRÉ-populatie gebruikt zoals deze reeds beschreven werd in hoofdstuk 
2. Per deelnemer werd de schildklierstatus bepaald en de op deze manier gevonden 
prevalentiecijfers voor schildklierafwijkingen werd vergeleken met die van de algemene 
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bevolking. Tevens werd per groep het risico op HVZ berekend, gecorrigeerd voor conventionele 
risicofactoren voor HVZ zoals diabetes, hypertensie en dyslipidemie.  
Hypothyreoidie bleek 3 keer meer voor te komen bij vrouwelijke RA-patiënten dan bij de 
algemene bevolking. Tevens bleek dat deze vrouwen 4 keer meer kans hadden HVZ te 
ontwikkelen in vergelijking met vrouwelijke, euthyreote RA-patiënten. 
Hoofdstuk 6 laat zien dat naast dyslipidemie ook schildklierafwijkingen een belangrijke rol 
kunnen spelen in het verhoogde risico op HVZ bij reumapatiënten. 
 
In hoofdstuk 7 wordt een onconventionele risicofactor voor HVZ onderzocht in 192 deelnemers 
van de CARRÉ-populatie. Onderzocht wordt of antilichaamvorming tegen humaan 60-kDa heat 
shock protein (HSP60) geassocieerd is met HVZ in RA-patiënten. HSP60 beschermt 
endotheelcellen tegen denaturatie veroorzaakt door de kwalijke invloed van zuurstofradicalen, 
dyslipidemie, hypertensie en bepaalde stoffen in sigarettenrook. Van reumapatiënten weten we 
dat ze vaker antilichamen vormen dan gezonde controles, bijvoorbeeld tegen gecitrinuleerde 
peptiden. Het zou dan ook kunnen dat RA-patiënten antilichamen vormen tegen HSP60 waardoor 
deze zijn beschermende werking niet kan uitoefenen met als mogelijk gevolg, meer HVZ.  
Ondanks dat de gevonden hoogte van de antilichaamtiter tegen HSP60 bij RA-patiënten hoger 
was dan bij gezonde controles, bleek noch de aanwezig, noch de hoogte van de titer geassocieerd 
met prevalente HVZ. In deze studie kan dan ook niet het verhoogde risico op HVZ bij RA-
patiënten verklaard worden dat de formatie van antilichamen tegen HSP60. 
 
Naast beïnvloeding van het risico op HVZ door natuurlijke, biologische mechanismen in 
reumapatiënten kan dit risico ook beïnvloed worden door de behandeling. Daarom wordt in 
hoofdstuk 8 tot 10 het effect van antireumatische behandeling op het HVZ-risicoprofiel onder de 
loep genomen. Om te beginnen wordt er in hoofdstuk 8 een overzicht gegeven van de literatuur 
over het risico op HVZ geassocieerd met geneesmiddelen die worden voorgeschreven bij de 
behandeling van arthrose en RA. 
 
In hoofdstuk 9 worden de resultaten gepresenteerd van een case-control studie betreffende 5649 
patiëntjaren van 613 RA-patiënten, 72 met HVZ en 541 zonder HVZ. Er werden gegevens 
verzameld met betrekking tot RA, HVZ en medicatiegebruik vanaf het ontstaan van de RA tot het 
eerste cardiovasculaire incident of tot het einde van de studieperiode. De gegevens werden 
onderverdeeld aan de hand van gebruikte antireumatica, zogenaamde 'disease modifying anti-
rheumatic drug' (DMARD), zoals sulfasalazine (SSZ), hydroxychloroquine (HCQ), methotrexaat 
(MTX) of combinaties hiervan tijdens de gehele onderzoeksperiode. Per DMARD-groep werd 
het relatief risico op HVZ berekend, ten opzichte van RA-patiënten die nooit SSZ, HCQ of MTX 
gebruikten en gecorrigeerd voor leeftijd, geslacht, roken en RA-duur. 
In vergelijking met de controle groep bleek er een afname van het risico op HVZ te zijn in de 
behandelgroepen die MTX bevatte, in mindere mate gold dit ook voor SSZ. Deze afname in 
risico bleef aanwezig na aanvullende correctie voor diabetes, hypertensie, hypercholesterolemie, 
positieve reumafactor test en erosies op röntgenfoto's. Als verklaring voor de gevonden resultaten 
werd geopperd dat de behandeling met conventionele DMARDs en in het bijzonder MTX, het 
atherosclerotisch proces afremt door de onderdrukking van ontsteking hetgeen weer leidt tot 
minder HVZ. 
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In hoofdstuk 10 wordt een open studie beschreven bij 15 opéénvolgende SA-patiënten die een 
half jaar gevolgd werden. Tijdens deze periode werden ze de eerste 3 maanden behandeld met 
rosuvastatine waarna een observatieperiode volgde van nog eens 3 maanden. De verschillende 
bestudeerde ziekteactiviteitsparameters verbeterden tijdens de statine behandeling, hetgeen zich 
uiten in een daling van de ontstekingswaarden CRP en erytrocyten bezinkingssnelheid. 
Dit onderzoek bekrachtigd de pleiotrope effecten van statines door te laten zien dat het 
ziekteactiviteit kan verminderen. De gevonden resultaten laten zien dat statine behandeling bij 
reumapatiënten, die toch al een verhoogd risico op HVZ hebben, een gunstig effect kan hebben 
op de reuma zelf. 
 
 
 
Generaliseerbaarheid 
 
Dit proefschrift laat een significant verhoogd cardiovasculair risico zien bij patiënten met 
chronische inflammatoire reumatische ziekten zoals RA en SA. Het bepleit dat dit verhoogde 
risico wordt veroorzaakt door een verslechterend effect op HVZ-risicofactoren maar ook door 
een direct atherogeen effect van ontsteking op het atherosclerotisch proces. 
Het verslechterend effect op risicofactoren voor HVZ wordt in dit proefschrift ondersteund 
doordat het laat zien dat ontsteking lipidenprofielen doet verslechteren. Tevens wordt aangetoond 
dat RA-patiënten, met hun verhoogde immuun respons, vaker klinische hypothyreoidie hebben. 
Zowel een verstoord lipidenprofiel als hypothyreoidie zijn op hun beurt weer geassocieerd met 
een verhoogde kans op HVZ. 
Dit proefschrift steunt tevens de bevinding dat ontsteking, de meest prominente eigenschap van 
reumatische ziekten, een direct atherogeen effect heeft. Aangenomen wordt dat ontsteking het 
atherosclerotisch proces versneld door de formatie van meer en onstabielere plaques in arteriën. 
De ondersteuning van dit directe atherogene effect in dit proefschrift is de bevinding dat 
onderdrukking van ontsteking het risico op HVZ verlaagd, onafhankelijk van conventionele 
risicofactoren voor HVZ. 
 
Men dient een reumatische ontstekingsziekte te zien als een onafhankelijke risicofactor voor 
HVZ, zoals dat reeds voor diabetes algemeen geaccepteerd is. Zodra dit meer erkend wordt zal 
dit consequenties hebben voor het algeheel inschatten van het risico op HVZ.  
Tevens is het van belang om de ontstekingsziekte actief te onderdrukken om zo het risico op 
HVZ zoveel mogelijk te verkleinen. Want naar het zich laat aanzien kan onderdrukking van 
ontsteking ten minste de ontwikkeling van atherosclerose remmen waardoor ook een afname van 
prevalente HVZ verwacht mag worden. 
 
Dit proefschrift wijst naar ontsteking als de belangrijkste oorzaak voor het verhoogde risico op 
HVZ bij reumapatiënten. Men zou de generalisatie kunnen maken dat dit geldt voor iedere 
ontstekingsziekte en zelfs ieder moment van ontsteking. Deze gedachtegang wordt ondersteund 
door de reeds lang bestaande observatie dat het risico op HVZ verhoogd is bij mensen met 
chronische tandvleesontsteking. Het feit dat de ontsteking bij reuma auto-immuun gedreven is 
maakt het echter dat de bevindingen van dit proefschrift niet direct te extrapoleren zijn naar alle 
ontstekingen. Verder maakt het feit dat RA en SA ziekten zijn met hoog-gradige ontsteking, 
extrapolatie van de huidige bevindingen naar alle, dus ook laag-gradige ontstekingen, onzeker. 
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Toekomstperspectieven 
 
Toekomstig onderzoek zal de verbanden en werkingsmechanismen tussen ontsteking en HVZ 
verder moeten ontrafelen. Dit onderzoek zal een combinatie moeten zijn van laboratorium en 
epidemiologisch onderzoek. Tussentijds is het van belang dat elke clinicus op de hoogte is van de 
relatie tussen ontsteking en HVZ.  
De volgende logisch stap lijkt het registreren van het cardiovasculaire risicoprofiel van patiënten 
met chronische ontstekingsziekten, zoals RA en SA. Echter zal naast registratie ook onderzocht 
moeten worden of het verhoogde risico op HVZ bij deze patiënten verkleind kan worden door 
therapeutische interventies. 
Dit werpt de vraag op hoe registratie en behandeling, kortom toekomstig onderzoek, het beste 
plaats kan vinden. Het best haalbaar lijkt een grote poliklinisch setting te zijn waarbij 
reumapatiënten gevolgd worden tijdens hun reguliere behandeling echter met de toevoeging van 
screening naar HVZ en risicofactoren voor HVZ. Binnen deze setting kan vervolgens in sub-
populaties uitgezocht worden of intensive behandeling van ontsteking en / of conventionele HVZ 
risicofactoren tot vermindering van HVZ leidt. Idealiter wordt een desbetreffend onderzoek 
gerandomiseerd, dubbel blind gedaan, of dit haalbaar is, is echter onwaarschijnlijk. 
Met oog op toekomstige behandelstrategieën is het een gunstige bevinding dat het gebruik van 
statines bij reumapatiënten, om zo hun cholesterolgehaltes en dus ook hun risico op HVZ te 
verlagen, ook een positief effect kan hebben op de reumatische ziekte zelf. 
 
 
Conclusie 
 
Sinds de auteur Russel Ross in 1999 in één van de toonaangevende vakbladen schreef dat 
atherosclerose gezien diende te worden als een ontstekingsziekte zijn er veel artikelen over dit 
onderwerp verschenen. Echter dienen er nog diverse belangrijke vragen over de relatie tussen 
ontsteking en HVZ beantwoord te worden. Toch zou men de bewering van Ross inmiddels wel 
kunnen aanvullen tot het volgende: 
"Atherosclerose is een ontstekingsziekte en ontstekingsziekten gaan gepaard met atherosclerose" 
 
Na het lezen van dit proefschrift moeten er drie boodschappen duidelijk zijn geworden. Ten 
eerste, de reumatoloog dient bewust te zijn van het verhoogde cardiovasculaire risico van hun 
patiënten en zou dan ook positief tegenover actief screenen van hun patiënten op HVZ en HVZ 
risicofactoren moeten staan. Ten tweede, zouden cardiologen overtuigd moeten zijn dat 
chronische reumatische ontstekingsziekten gezien dienen te worden als onafhankelijke 
risicofactoren voor HVZ. Ten derde, dienen naast de artsen de patiënten met chronische 
reumatische ontstekingsziekten bewust te zijn van het verhoogd cardiovasculair risico, zodat zij 
de nodige maatregelen kunnen treffen om het gevaar HVZ te krijgen in de toekomst zo klein 
mogelijk te maken. 
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